

The NCCN logo is located in the top left corner. It consists of the letters "NCCN" in white, sans-serif font inside a rounded square frame with a thin white border.

NCCN

National Comprehensive  
Cancer Network®

**NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)**

# Gastric Cancer

Version 3.2025 — August 22, 2025

**NCCN.org**

**NCCN recognizes the importance of clinical trials and encourages participation when applicable and available. Trials should be designed to maximize inclusiveness and broad representative enrollment.**

**NCCN Guidelines for Patients® available at [www.nccn.org/patients](http://www.nccn.org/patients)**

**Continue**



# NCCN Guidelines Version 3.2025

## Gastric Cancer

\***Jaffer A. Ajani, MD/Chair †**  
The University of Texas  
MD Anderson Cancer Center

\***Thomas A. D'Amico, MD/Vice Chair ¶**  
Duke Cancer Institute

**David J. Bentrem, MD, MS ¶**  
Robert H. Lurie Comprehensive  
Cancer Center of Northwestern  
University

**Sakti Chakrabarti, MD †**  
Case Comprehensive Cancer  
Center/University Hospitals  
Seidman Cancer Center and  
Cleveland Clinic Taussig Cancer  
Institute

**Carlos U. Corvera, MD ¶**  
UCSF Helen Diller Family  
Comprehensive Cancer Center

**Prajnan Das, MD, MS, MPH §**  
The University of Texas  
MD Anderson Cancer Center

**Peter C. Enzinger, MD †**  
Dana-Farber/Brigham and  
Women's Cancer Center

**Thomas Enzler, MD, PhD † ‡**  
University of Michigan  
Rogel Cancer Center

**Hans Gerdes, MD □ ¶**  
Memorial Sloan Kettering  
Cancer Center

**Michael K. Gibson, MD, PhD † ‡ ¶**  
Vanderbilt-Ingram Cancer Center

**Patrick Grierson, MD, PhD †**  
Siteman Cancer Center at Barnes-  
Jewish Hospital and Washington  
University School of Medicine

**Garima Gupta, MD †**  
O'Neal Comprehensive  
Cancer Center at UAB

**Wayne L. Hofstetter, MD ¶**  
The University of Texas  
MD Anderson Cancer Center

**David H. Ilson, MD, PhD † ¶**  
Memorial Sloan Kettering  
Cancer Center

**Shadia Jalal, MD †**  
Indiana University  
Melvin and Bren Simon  
Comprehensive Cancer Center

**Sunnie Kim, MD †**  
University of Colorado  
Cancer Center

**Lawrence R. Kleinberg, MD §**  
Johns Hopkins Kimmel Cancer  
Center

**Samuel Klempner, MD †**  
Mass General Cancer Center

**Moshim Kukar, MD ¶**  
Roswell Park Comprehensive  
Cancer Center

**Jill Lacy, MD †**  
Yale Cancer Center/  
Smilow Cancer Hospital

**Vincent Lam, MD †**  
Johns Hopkins Kimmel Cancer  
Center

**Byrne Lee, MD ¶**  
Stanford Cancer Institute

**Frank Licciardi ¶**  
Patient Advocate

**Shane Lloyd, MD §**  
Huntsman Cancer Institute  
at the University of Utah

**Quan P. Ly, MD ¶**  
Fred & Pamela Buffett  
Cancer Center

**Karen Matsukuma MD, PhD ≠**  
UC Davis  
Comprehensive Cancer Center

**Michael McNamara, MD †**  
Case Comprehensive Cancer  
Center/University Hospitals  
Seidman Cancer Center and  
Cleveland Clinic Taussig Cancer  
Institute

**Ryan P. Merkow, MD, MS ¶**  
The UChicago Medicine  
Comprehensive Cancer Center

**Aaron M. Miller, MD, PhD †**  
UC San Diego  
Moores Cancer Center

**Sarbjit Mukherjee, MD, MS † ¶**  
Roswell Park Comprehensive  
Cancer Center

**Mary F. Mulcahy, MD ‡ †**  
Robert H. Lurie Comprehensive  
Cancer Center of Northwestern  
University

**Kyle A. Perry, MD ¶**  
The Ohio State University  
Comprehensive Cancer Center -  
James Cancer Hospital and  
Solove Research Institute

**Jose M. Pimiento, MD ¶**  
Moffitt Cancer Center

**Deepti M. Reddi, MD ≠**  
Fred Hutchinson Cancer Center

**Scott Reznik, MD ¶**  
UT Southwestern Simmons  
Comprehensive Cancer Center

**Robert E. Roses, MD ¶**  
Abramson Cancer Center  
at the University of Pennsylvania

**Vivian E. Strong, MD ¶**  
Memorial Sloan Kettering  
Cancer Center

**Stacey Su, MD ¶**  
Fox Chase Cancer Center

\***Nataliya Uboha, MD, PhD †**  
University of Wisconsin  
Carbone Cancer Center

**Zev A. Wainberg, MD †**  
UCLA Jonsson  
Comprehensive Cancer Center

**Christopher G. Willett, MD §**  
Duke Cancer Institute

**Yanghee Woo, MD ¶**  
City of Hope National Medical  
Center

**Harry H. Yoon, MD †**  
Mayo Clinic  
Comprehensive Cancer Center

**NCCN**  
Nicole R. McMillian, MS  
MaryElizabeth Stein, PhD

**Continue**

- Gastroenterology
- △ Genetics
- ‡ Hematology/Hematology oncology
- ¶ Internal medicine
- † Medical oncology
- ≠ Pathology

- ¥ Patient advocacy
- § Radiotherapy/Radiation oncology
- ¶ Surgery/Surgical oncology
- \* Discussion Writing Committee Member



# NCCN Guidelines Version 3.2025

## Gastric Cancer

[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)

[NCCN Gastric Cancer Guidelines Panel Members](#)

[Summary of the Guidelines Updates](#)

[Workup and Additional Evaluation \(GAST-1\)](#)

[Conclusions of Multidisciplinary Review, Primary Treatment \(GAST-2\)](#)

[Response Assessment, Additional Management \(GAST-3\)](#)

[Surgical Outcomes/Clinical Pathologic Findings for Patients Who Have Not Received Systemic Therapy \(GAST-4\)](#)

[Surgical Outcomes/Clinical Pathologic Findings for Patients Who Have Received Systemic Therapy \(GAST-5\)](#)

[Post-Treatment Assessment/Additional Management \(GAST-6\)](#)

[Follow-up/Surveillance \(GAST-7\)](#)

[Recurrence \(GAST-8\)](#)

[Palliative Management \(GAST-9\)](#)

[Peritoneal Carcinoma As Only Disease \(GAST-10\)](#)

[Principles of Endoscopic Staging and Therapy \(GAST-A\)](#)

[Principles of Pathologic Review and Biomarker Testing \(GAST-B\)](#)

[Principles of Surgery \(GAST-C\)](#)

[Principles of Genetic Risk Assessment for Gastric Cancer \(GAST-D\)](#)

[Principles of Multidisciplinary Team Approach for Esophagogastric Cancers \(GAST-E\)](#)

[Principles of Systemic Therapy \(GAST-F\)](#)

[Principles of Radiation Therapy \(GAST-G\)](#)

[Principles of Surveillance \(GAST-H\)](#)

[Principles of Survivorship \(GAST-I\)](#)

[Principles of Palliative Care/Best Supportive Care \(GAST-J\)](#)

[Staging \(ST-1\)](#)

[Abbreviations \(ABBR-1\)](#)

Find an NCCN Member Institution:  
<https://www.nccn.org/home/member-institutions>.

**NCCN Categories of Evidence and Consensus:** All recommendations are category 2A unless otherwise indicated.

See [NCCN Categories of Evidence and Consensus](#).

**NCCN Categories of Preference:** All recommendations are considered appropriate.

See [NCCN Categories of Preference](#).

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2025.

**Updates in Version 3.2025 of the NCCN Guidelines for Gastric Cancer from Version 2.2025 include:**

**GAST-1**

• Workup

- ▶ Bullet added: Universal testing for programmed death ligand 1 (PD-L1) is recommended in all newly diagnosed patients
- ▶ 11th bullet revised: HER2 and PD-L1 testing if advanced/metastatic disease is documented/suspected

**GAST-2**

- Primary Treatment, cT2 or higher, Any N pathway revised: Perioperative chemotherapy systemic therapy (category 1) (Also for GAST-3)

**Principles of Pathologic Review and Biomarker Testing**

**GAST-B 1 of 7**

- Analysis/Interpretation/Reporting column revised for rows 1-3: Universal testing for MSI by PCR/NGS or MMR by IHC and PD-L1 testing by IHC is recommended in all newly diagnosed patients

**GAST-B 5 of 7**

- PD-L1 Testing, 1st bullet revised: *Universal testing for PD-L1 by IHC should be performed for all newly diagnosed patients with gastric cancer who are candidates for treatment with programmed cell death protein 1 (PD-1) or PD-L1 inhibitors. PD-L1 testing may be considered on locally advanced, recurrent, or metastatic gastric carcinomas in patients who are candidates for treatment with programmed cell death protein 1 (PD-1) inhibitors. A companion diagnostic test should be used on FFPE tissue as an aid in identifying patients for treatment with PD-1/PD-L1 inhibitors. PD-L1 testing should be performed only in CLIA-approved laboratories.*
- 2nd bullet, 2nd sub-bullet added: CPS and tumor area positivity (TAP) score have high concordance and may be interchangeable.

**GAST-B 7 of 7**

- Reference added: Qiu MZ, Oh DY, Kato K, et al. RATIONALE-305 Investigators. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ 2024;385:e078876. (Also for GAST-F 1)
- Reference added: Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol 2023;24:483-495. (Also for GAST-F 1)

**Principles of Systemic Therapy**

**GAST-F 1 of 20**

- 11th bullet, 1st sub-bullet added: CPS and TAP score have high concordance and may be interchangeable.



**Updates in Version 3.2025 of the NCCN Guidelines for Gastric Cancer from Version 2.2025 include:**

Principles of Systemic Therapy

GAST-F 3 of 20

- Table heading revised: Perioperative *Chemotherapy Systemic Therapy*
  - ▶ Perioperative Systemic Therapy, Preferred Regimens, bullet added: FLOT + durvalumab for PD-L1 CPS  $\geq 1$  or TAP  $\geq 1\%$  (category 1)
- Footnote \* added: Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. *N Engl J Med* 2025;393:217-230. (Also for GAST-F 6 and GAST-F 17)
- Footnote d added: In the MATTERHORN trial, diffuse type gastric or EGJ adenocarcinoma showed no EFS advantage when durvalumab was added to FLOT. (Also for GAST-F 6)

Principles of Systemic Therapy-Regimens and Dosing Schedules

GAST-F 6 of 20

- Heading revised: Perioperative *Chemotherapy Systemic Therapy*
- Perioperative Systemic Therapy; Preferred Regimens; The following dosing schedule was added:
  - ▶ FLOT + durvalumab
    - ◊ Durvalumab 1500 mg IV on Day 1
    - Fluorouracil 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours on Day 1 and 15
    - Leucovorin 200 mg/m<sup>2</sup> IV on Day 1 and 15
    - Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1 and 15
    - Docetaxel 50 mg/m<sup>2</sup> IV on Day 1 and 15
    - Cycled every 28 days
    - (2 cycles preoperative and 2 cycles postoperative, 4 cycles total)
    - followed by Durvalumab 1500 mg IV on Day 1
    - every 4 weeks for 10 additional cycles

MS-1

- The Discussion has been updated to reflect the changes in the algorithm.



**Updates in Version 2.2025 of the NCCN Guidelines for Gastric Cancer from Version 1.2025 include:**

**MS-1**

- The Discussion has been updated to reflect the changes in the algorithm.

**Updates in Version 1.2025 of the NCCN Guidelines for Gastric Cancer from Version 5.2024 include:**

**General**

- Upper GI gastrointestinal (GI) endoscopy changed to Esophagogastroduodenoscopy (EGD) throughout the algorithm.

**GAST-1**

- Workup; Last bullet revised: ~~Assess H. pylori status and conduct genetic testing as needed Test for H. pylori infection and eradicate in all patients with early gastric cancer if positive. Conduct genetic testing as needed and recommend H. pylori testing of close family members~~

**GAST-1A**

- Footnote i revised: Added link to Principles of Surveillance (GAST-H).
- Footnote m revised: "...performed to evaluate for peritoneal spread when considering ~~chemoradiation or surgery local therapy~~. Laparoscopy..."

**GAST-2**

- Locoregional disease: Medically fit potentially resectable, cT2 or higher, Any N: Preoperative chemoradiation (category 2B) removed as a primary treatment option. (Also for first column; top pathway on GAST-3)

**GAST-2A**

- Footnote q revised: "...perioperative immunotherapy ~~or surgery alone~~ should be considered in consultation with a multidisciplinary team. *The role of surgery after biopsy proven and radiologic/metabolic complete response on neoadjuvant immunotherapy is unclear.*" (Also for GAST-3)
- Footnote removed: The role of surgery after biopsy proven and radiologic/metabolic complete response on neoadjuvant immunotherapy is unclear. The role for surgery in the setting of favorable neoadjuvant response should be carefully discussed. (Also for GAST-3)

**GAST-3**

- Primary Treatment for Patients who are medically fit
  - ▶ Top pathway revised: Perioperative chemotherapy (category 1) ~~or Preoperative chemoradiation (category 2B)~~
  - ▶ Neoadjuvant or perioperative ICI if tumor is microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR)
    - ◊ Outcome clarified: No evidence of disease
    - ◊ Additional Management for patients with no evidence of disease; Revised: Observation or Surgery
- Footnote removed: Principles of Radiation Therapy (GAST-C)
- Footnote removed: If surgery is not being considered for management, upper GI endoscopy and biopsy should be done.

**GAST-4**

- Column header revised: Surgical Outcomes/Clinical Pathologic Findings (Patients Have Not Received ~~Preoperative Chemoradiation or Systemic Therapy~~)

**Continued**  
**UPDATES**



**Updates in Version 1.2025 of the NCCN Guidelines for Gastric Cancer from Version 5.2024 include:**

**GAST-5**

- Column header Revised: Surgical Outcomes/Clinical Pathologic Findings (Patients Have Received Preoperative Chemoradiation or Systemic Therapy)
- Postoperative Management:
  - ▶ R0 resection:
    - ◊ Observation (if received preoperative chemoradiation) removed as an option
    - ◊ Revised: Systemic therapy, if received preoperatively (category 1)
  - ▶ R1 resection revised: Chemoradiation (fluoropyrimidine-based), only if not received preoperatively. Also for R2 resection.

**GAST-7**

- Footnote bb revised: For patients undergoing total gastrectomy for curative intent, surveillance should follow these recommendations except for endoscopy. Endoscopy has no role in as clinically indicated for routine surveillance for total gastrectomy unless patients are symptomatic.

**GAST-9**

- 3rd column; Bullet revised: NGS may should be considered via a validated assay

**GAST-A 3 of 4**

- Treatment
  - ▶ New bullet and sub-bullets added
    - ◊ Several Japanese and American guidelines have expanded the indications for ESD to include:
      - Well to moderately differentiated cancer of any size, without ulceration
      - Well or moderately differentiated with submucosal (sm) layer invasion <500 micrometers
      - Well or moderately differentiated <3 cm with ulceration
      - Poorly differentiated <2 cm without ulceration
  - ▶ New bullet added: This may potentially be considered curative resection if the margins are negative, there is no LVI, and curative resection is limited to sm1. However, there is still a very small risk of lymph node involvement, so such decisions should be made following multidisciplinary discussions and careful explanation to the patient.

**GAST-B 1 of 7**

- Pathologic review; Specimen type
  - ▶ 3rd row revised: Gastrectomy, without prior chemoradiation
  - ▶ 4th row
    - ◊ Revised: Gastrectomy, with prior chemoradiation *in unresectable gastric cancer treated with chemoradiation followed by surgery*
    - ◊ Analysis/Interpretation/Reporting revised
      - 1st bullet revised: Tumor site should be thoroughly sampled for specimens s/p neoadjuvant therapy chemoradiation without grossly obvious residual tumor
      - 2nd bullet revised: For pathology report, include all elements as for of resection without prior chemoradiation plus and assessment of treatment effect
- New footnote d added: For patients with surgically managed cancer, ≥16 regional lymph nodes are removed and pathologically examined during resection for curative intent therapy.

**Continued**  
**UPDATES**



**Updates in Version 1.2025 of the NCCN Guidelines for Gastric Cancer from Version 5.2024 include:**

**GAST-B 2 of 7**

- Assessment of Treatment Response revised: "Response of the primary tumor and lymph node metastases to previous chemotherapy and/or RT should be reported..."

**GAST-B 3 of 7**

- Assessment of Overexpression or Amplification of HER2 in Gastric Cancer revised: "...and MSI status. ~~NGS can be considered instead of sequential testing for single biomarkers when limited diagnostic tissue is available or when the patient is unable to undergo a traditional biopsy. The use of IHC/ISH should be considered first, followed by additional NGS testing as appropriate. IHC/ISH/targeted PCR is the preferred approach to assess biomarkers initially. However, NGS testing through a CLIA-approved laboratory may be considered later in the clinical course of patients with sufficient tumor tissue available for testing.~~ Repeat biomarker testing may be considered..."
- Footnote f revised: ~~An FDA-approved biosimilar is an appropriate substitute for trastuzumab. An FDA-approved biosimilar is an appropriate substitute for any recommended systemic biologic therapy in the NCCN Guidelines.~~

**GAST-B 5 of 7**

- Microsatellite Instability (MSI) or Mismatch Repair (MMR) Testing; 1st bullet revised: "...Patients with MSI-H or dMMR tumors ~~may~~ should be referred to a genetics counselor for further assessment in the appropriate clinical context."

**GAST-B 6 of 7**

- Next-Generation Sequencing revised
  - "...by the FDA for use in gastric cancer. ~~Immunohistochemistry/in situ hybridization/targeted PCR should be considered first for the identification of biomarkers, followed by NGS testing. If limited tissue is available, or the patient is unable to undergo a traditional biopsy, sequential testing of single biomarkers/limited molecular diagnostic panels will exhaust the sample. In these scenarios, or at the discretion of the treating physician, comprehensive genomic profiling via a validated NGS assay performed in a CLIA-approved laboratory should be considered.~~ *IHC/ISH/targeted PCR is the preferred approach to assess biomarkers, initially. However, NGS testing through a CLIA-approved laboratory may be considered later in the clinical course of patients with sufficient tumor tissue available for testing.*
  - PD-L1 expression by immunohistochemistry
- Liquid Biopsy revised: The genomic alterations of solid cancers may be identified by evaluating circulating tumor DNA (ctDNA) in the blood, hence a form of "liquid biopsy." ~~Liquid biopsy is being used more frequently in patients with advanced disease, particularly those who are unable to have a clinical biopsy for disease surveillance and management. The detection of mutations/alterations or fusions in DNA shed from gastric carcinomas can identify targetable alterations or the evolution of clones with altered treatment response profiles. Therefore, when limited tissue is available or for patients who have metastatic or advanced gastric cancer who ~~may be unable~~ are not able to undergo a traditional biopsy, or for disease progression monitoring, testing using a validated NGS-based comprehensive genomic profiling assay performed in a CLIA-approved laboratory may be considered.~~ A negative result should be interpreted with caution, as this does not exclude the presence of tumor mutations or amplifications.

**GAST-C 4 of 5**

- Palliative Procedures: Gastric resections should be reserved for the palliation of symptoms (eg, obstruction or uncontrollable bleeding) in patients with incurable disease ~~when non-surgical options are not feasible such as endoscopic or interventional radiology procedures (ie, endoscopic stenting).~~

**Continued**  
**UPDATES**



**Updates in Version 1.2025 of the NCCN Guidelines for Gastric Cancer from Version 5.2024 include:**

Principles of Systemic Therapy for Unresectable Locally Advanced, Recurrent, or Metastatic Disease

GAST-F 1 of 20

- New bullets added
  - ▶ An FDA-approved biosimilar is an appropriate substitute for any recommended systemic biologic therapy in the NCCN Guidelines.
  - ▶ A checkpoint inhibitor should be added to first-line chemotherapy for patients with advanced disease with PD-L1 CPS  $\geq 1$ .
  - ▶ Nivolumab and hyaluronidase-nvhy is not approved for concurrent use with IV ipilimumab; however, for nivolumab monotherapy, nivolumab and hyaluronidase-nvhy subcutaneous injection may be substituted for IV nivolumab. Nivolumab and hyaluronidase-nvhy has different dosing and administration instructions compared to IV nivolumab.
  - ▶ Footnote removed: An FDA-approved biosimilar is an appropriate substitute for trastuzumab. (Also for all GAST-F pages)

GAST-F 3 of 20

- The regimens for preoperative chemoradiation were removed. The corresponding dosing schedules were also removed.
  - ▶ Paclitaxel and carboplatin (category 2B)
  - ▶ Fluorouracil and oxaliplatin (category 2B)
  - ▶ Fluorouracil and cisplatin (category 2B)
  - ▶ Fluoropyrimidine (fluorouracil or capecitabine) (category 2B)
- Footnote removed: Cisplatin may not be used interchangeably with oxaliplatin in this setting.

GAST-F 4 of 20

- First-line Therapy revised
  - ▶ Preferred Regimens; HER2 overexpression negative
    - ◊ Fluoropyrimidine (fluorouracil or capecitabine), oxaliplatin, and nivolumab (~~PD-L1 CPS  $\geq 5$~~ ) (category 1) for PD-L1 CPS  $\geq 1$  (category 1 for PD-L1 CPS  $\geq 5$ )
    - ◊ Fluoropyrimidine (fluorouracil or capecitabine), oxaliplatin, and pembrolizumab for PD-L1 CPS  $\geq 1$  (category 1 for PD-L1 CPS  $\geq 10$ ; ~~category 2B for PD-L1 CPS 1 to <10~~)
    - ◊ New regimen added: Fluoropyrimidine (fluorouracil or capecitabine), oxaliplatin, and tislelizumab-jsg for PD-L1 CPS  $\geq 1$  (category 1 for PD-L1 CPS  $\geq 5$ )
    - ◊ Fluoropyrimidine (fluorouracil or capecitabine), cisplatin, and pembrolizumab for PD-L1 CPS  $\geq 1$  (category 1 for PD-L1 CPS  $\geq 10$ ; ~~category 2B for PD-L1 CPS 1 to <10~~)
    - ◊ New regimen added: Fluoropyrimidine (fluorouracil or capecitabine), cisplatin, and tislelizumab-jsg for PD-L1 CPS  $\geq 1$  (category 1 for PD-L1 CPS  $\geq 5$ )
  - ▶ Useful in Certain Circumstances
    - ◊ New systemic therapy options added: Entrectinib, larotrectinib, or repotrectinib for NTRK gene fusion-positive tumors (category 2B)
    - ◊ Removed: Fluoropyrimidine (fluorouracil or capecitabine), oxaliplatin, and nivolumab (PD-L1 CPS  $< 5$ ) (category 2B).



**Updates in Version 1.2025 of the NCCN Guidelines for Gastric Cancer from Version 5.2024 include:**

**GAST-F 4A of 20**

- Footnote e revised: If no prior checkpoint inhibitor therapy or no tumor progression while on therapy with a checkpoint inhibitor. (Applies to all GAST-F pages)
- Footnote h revised: Trastuzumab should be added to first-line chemotherapy for HER2 overexpression-positive adenocarcinoma. An FDA-approved biosimilar is an appropriate substitute for trastuzumab.

**Principles of Systemic Therapy-Regimens and Dosing Schedules**

**GAST-F 11 of 20**

- First-line therapy; Preferred Regimens; Dosing revised:

► HER2 Overexpression Negative, CLDN18.2 Positive

◊ Fluoropyrimidine (fluorouracil or capecitabine), oxaliplatin, and zolbetuximab-clzb

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1 (per study maximum of 12 doses)

Leucovorin 400 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1

Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion

over 24 hours daily on Days 1 and 2

Zolbetuximab-clzb 800 mg/m<sup>2</sup> IV (first-dose only)

on Day 1 (subsequent doses 400 mg/m<sup>2</sup>)

Cycled every 14 days

Capecitabine 850–1000 mg/m<sup>2</sup> PO BID on Days 1–14

Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1

Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1 (per study maximum of 8 doses)

Zolbetuximab-clzb 800 mg/m<sup>2</sup> IV (first-dose only)

on Day 1 (subsequent doses 600 mg/m<sup>2</sup>)

Cycled every 21 days

**Continued**  
**UPDATES**



**Updates in Version 1.2025 of the NCCN Guidelines for Gastric Cancer from Version 5.2024 include:**

Principles of Systemic Therapy-Regimens and Dosing Schedules

GAST-F 12 of 20

- First-line Therapy; Preferred Regimens; New dose schedule added:

► Tislelizumab-jsgv with fluoropyrimidine and oxaliplatin or cisplatin

Tislelizumab 200 mg IV on Day 1 every 21 days

in combination with:

Fluoropyrimidine and oxaliplatin

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1

Leucovorin 200 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1 and 2

Cycled every 14 days for 12 cycles

Capecitabine 850–1000 mg/m<sup>2</sup> PO BID on Days 1–14

Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1

Cycled every 21 days (per study maximum of 6 doses)

Fluoropyrimidine and cisplatin

Cisplatin 60–80 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 750–800 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1–5

Cycled every 21 days for 6 cycles

Cisplatin 60–80 mg/m<sup>2</sup> IV on Day 1 (per study maximum of 6 doses)

Capecitabine 850–1000 mg/m<sup>2</sup> PO BID on Days 1–14

Cycled every 21 days

GAST-F 14 of 20

- First-line therapy; Useful in Certain Circumstances, new dosing added:

► Entrectinib, larotrectinib, or repotrectinib (for NTRK gene fusion-positive tumors)

Entrectinib 600 mg PO once daily

Larotrectinib 100 mg PO twice daily

Repotrectinib

160 mg PO daily Days 1–14 of cycle 1

160 mg PO BID Days 15–28 of cycle 1

160 mg PO BID Days 1–28 of cycle 2 and beyond

Cycled every 28 days

**Continued  
UPDATES**



## Updates in Version 1.2025 of the NCCN Guidelines for Gastric Cancer from Version 5.2024 include:

### Principles of Systemic Therapy-References

#### GAST-F 17 of 20 through GAST-F 20 of 20

- The reference pages were updated to reflect the changes in the algorithm.

### GAST-G 2 of 5

#### • Target Volume (General Guidelines)

- ▶ Preoperative chemoradiation section along with sub-bullets below removed
  - ◊ Pretreatment diagnostic studies (EUS, EGD, FDG-PET, and CT scans) should be used to identify the tumor and pertinent nodal groups.
  - ◊ The relative risk of nodal metastases at a specific nodal location is dependent on both the site of origin of the primary tumor and other factors including width and depth of invasion of the gastric wall. Coverage of nodal areas may be modified based on clinical circumstances and the risks of toxicity.

### GAST-G 5 of 5

- Reference removed: Ajani AJ, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): Quality of combined modality therapy and pathologic response. J Clin Oncol 2006;24:3953-3958.

### GAST-H 1 of 2

- New bullet added: All patients with H. pylori infection who underwent curative ER or gastric subtotal resection must receive an H. pylori eradication regimen. The choice and duration of the eradication regimen should follow the recommendations of the latest American (American College of Gastroenterology) or international (Maastricht consensus report) H. pylori guidelines.

### GAST-H 2 of 2

- Reference 1 is new: Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med 2018;378:1085-1095.

### GAST-I 3 of 4

- Survivorship Care Planning and Coordination of Care; 4th bullet; 3rd sub-bullet revised: "...NCCN Disease-Specific Guidelines: *Treatment by Cancer Type*"

### GAST-J 2 of 3

- Pain; 3rd bullet, New sub-bullet added: Severe uncontrolled pain following gastric stent placement should be treated with endoscopic removal of the stent once the uncontrollable nature of the pain is established.

### ABBR-1


- The abbreviations page was updated as appropriate.

# NCCN Guidelines Version 3.2025

## Gastric Cancer

### WORKUP

- History and physical (H&P)
- Esophagogastroduodenoscopy (EGD) and biopsy<sup>a</sup>
- Chest/abdomen/pelvis CT with oral and IV contrast
- FDG-PET/CT evaluation (skull base to mid-thigh) for locally advanced or metastatic disease<sup>b</sup> or if clinically indicated
- CBC and comprehensive chemistry profile
- Endoscopic ultrasound (EUS) is recommended if early-stage disease suspected or if early versus locally advanced disease needs to be determined (preferred)
- Endoscopic resection (ER) is essential for the accurate staging of early-stage cancers (T1a or T1b).<sup>c</sup> Early-stage cancers can best be diagnosed by ER.
- Biopsy of metastatic disease as clinically indicated
- Universal testing for microsatellite instability (MSI) by PCR/next-generation sequencing (NGS) or MMR by IHC is recommended in all newly diagnosed patients<sup>d</sup>
- Universal testing for programmed death ligand 1 (PD-L1) is recommended in all newly diagnosed patients<sup>d</sup>
- HER2 testing if advanced/metastatic disease is documented/suspected<sup>d,e</sup>
- CLDN18.2 testing if advanced/metastatic disease is documented/suspected<sup>d</sup>
- NGS should be considered<sup>d</sup>
- Assess Siewert category<sup>f</sup>
- Nutritional assessment and counseling
- Smoking cessation advice, counseling, and pharmacotherapy as indicated<sup>g</sup>
- Screen for family history<sup>h</sup>
- Test for *H. pylori* infection and eradicate in all patients with early gastric cancer if positive. Conduct genetic testing as needed and recommend *H. pylori* testing of close family members<sup>i</sup>



Note: All recommendations are category 2A unless otherwise indicated.

[Footnotes on GAST-1A](#)

## FOOTNOTES FOR **GAST-1**

<sup>a</sup> [Principles of Endoscopic Staging and Therapy \(GAST-A\)](#).

<sup>b</sup> May not be appropriate for T1.

<sup>c</sup> ER may also be therapeutic for early-stage disease/lesions.

<sup>d</sup> [Principles of Pathologic Review and Biomarker Testing \(GAST-B\)](#).

<sup>e</sup> Tumor Epstein-Barr virus status is emerging as a potential biomarker for personalized treatment strategies for gastric cancer, but is not currently recommended for clinical care. EBV testing should be performed if the morphology of the tumor contains prominent lymphoid stroma.

<sup>f</sup> [Principles of Surgery \(GAST-C\)](#).

<sup>g</sup> [NCCN Guidelines for Smoking Cessation](#).

<sup>h</sup> See [Principles of Genetic Risk Assessment for Gastric Cancer \(GAST-D\)](#). Also see [NCCN Guidelines for Colorectal Cancer Screening](#) and [Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate](#).

<sup>i</sup> If H. pylori testing is positive, discuss recommendations with family members as appropriate. [See Principles of Surveillance \(GAST-H\)](#).

<sup>j</sup> See [Staging \(ST-1\)](#) for tumor classification.


<sup>k</sup> Medically able to tolerate major surgery.

<sup>l</sup> Patients who are medically unable to tolerate major surgery or patients who are medically fit, but decline surgery.

<sup>m</sup> Laparoscopy with cytology is performed to evaluate for peritoneal spread when considering local therapy. Laparoscopy with cytology is not indicated if a palliative resection is planned. Laparoscopy with cytology is indicated for clinical stage T1b or higher.

<sup>n</sup> [Principles of Multidisciplinary Team Approach \(GAST-E\)](#).

**Note:** All recommendations are category 2A unless otherwise indicated.



Note: All recommendations are category 2A unless otherwise indicated.

# NCCN Guidelines Version 3.2025

## Gastric Cancer

[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)

### Footnotes for GAST-2

<sup>a</sup> [Principles of Endoscopic Staging and Therapy \(GAST-A\)](#).

<sup>d</sup> [Principles of Pathologic Review and Biomarker Testing \(GAST-B\)](#).

<sup>f</sup> [Principles of Surgery \(GAST-C\)](#).

<sup>j</sup> See [Staging \(ST-1\)](#) for tumor classification.

<sup>k</sup> Medically able to tolerate major surgery.

<sup>l</sup> Patients who are medically unable to tolerate major surgery or patients who are medically fit, but decline surgery.


<sup>o</sup> Surgery as primary therapy is appropriate for  $\geq T1b$  cancer or actively bleeding cancer, or when postoperative therapy is preferred.

<sup>p</sup> [Principles of Systemic Therapy \(GAST-F\)](#).

<sup>q</sup> In patients with a microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) tumor, perioperative immunotherapy should be considered in consultation with a multidisciplinary team. The role of surgery after biopsy proven and radiologic/metabolic complete response on neoadjuvant immunotherapy is unclear.

<sup>r</sup> [Principles of Radiation Therapy \(GAST-G\)](#).

**Note:** All recommendations are category 2A unless otherwise indicated.



<sup>d</sup> [Principles of Pathologic Review and Biomarker Testing \(GAST-B\)](#).

<sup>f</sup> [Principles of Surgery \(GAST-C\)](#).

<sup>o</sup> Surgery as primary therapy is appropriate for ≥T1b cancer or actively bleeding cancer, or when postoperative therapy is preferred.

<sup>p</sup> [Principles of Systemic Therapy \(GAST-F\)](#).

<sup>q</sup> In patients with an MSI-H/dMMR tumor, perioperative immunotherapy should be considered in consultation with a multidisciplinary team. The role of surgery after biopsy proven and radiologic/metabolic complete response on neoadjuvant immunotherapy is unclear.

<sup>s</sup> Assessment ≥5 to 8 weeks after completion of preoperative therapy.

<sup>t</sup> Pelvis CT if clinically indicated.

<sup>u</sup> See Post-Treatment Surveillance in [Principles of Endoscopic Staging and Therapy \(GAST-A 3 of 4\)](#).


<sup>v</sup> Feeding jejunostomy for postoperative nutritional support, generally preferred.

**Note:** All recommendations are category 2A unless otherwise indicated.

## **SURGICAL OUTCOMES/CLINICAL PATHOLOGIC FINDINGS (Patients Have Not Received Systemic Therapy)**

## TUMOR CLASSIFICATION

## **POSTOPERATIVE MANAGEMENT**



## f Principles of Surgery (GAST-C).

j See Staging (ST-1) for tumor classification.

## p Principles of Systemic Therapy (GAST-F).

## Principles of Radiation Therapy (GAST-G)

w R0 = No cancer at resection margins, R1 =

\* Smalley SR, et al. J Clin Oncol 2012;30:2327-2333. See [Principles of Systemic Therapy \(GAST-F\)](#).

High-risk features include poorly differentiated or higher grade cancer, lymphovascular invasion (LV

undergo D2 lymph node dissection.


**Note:** All recommendations are category 2A unless otherwise indicated.



**SURGICAL OUTCOMES/CLINICAL PATHOLOGIC FINDINGS**  
(Patients Have Received Systemic Therapy)

**TUMOR CLASSIFICATION<sup>j</sup>**

**POSTOPERATIVE MANAGEMENT**



<sup>j</sup> See [Staging \(ST-1\)](#) for tumor classification.


<sup>p</sup> [Principles of Systemic Therapy \(GAST-F\)](#).

<sup>r</sup> [Principles of Radiation Therapy \(GAST-G\)](#).

<sup>w</sup> R0 = No cancer at resection margins, R1 = Microscopic residual cancer, R2 = Macroscopic residual cancer or M1.

<sup>z</sup> The yp prefix is used to indicate cases in which staging is performed following preoperative therapy.

**Note: All recommendations are category 2A unless otherwise indicated.**



<sup>d</sup> [Principles of Pathologic Review and Biomarker Testing \(GAST-B\)](#).

<sup>f</sup> [Principles of Surgery \(GAST-C\)](#).

<sup>l</sup> Patients who are medically unable to tolerate major surgery or patients who are medically fit, but decline surgery.

<sup>aa</sup> In cases of renal insufficiency or allergy to CT contrast.

**Note:** All recommendations are category 2A unless otherwise indicated.



**FOLLOW-UP/SURVEILLANCE<sup>cc</sup>**

Tis  
(successfully  
treated by  
ER)<sup>bb</sup>

- H&P every 3–6 months for 1–2 years, then every 6–12 months for 3–5 years
- CBC and chemistry profile as clinically indicated
- Upper gastrointestinal (GI) endoscopy (EGD) every 6 months for 1 year, then annually for 3 years
- Routine imaging (CT chest/abdomen/pelvis with oral and IV contrast) as clinically indicated based on symptoms and concern for recurrence

p stage I  
(T1a,T1b,  
N0 treated  
by surgical  
resection or  
T1a treated  
by ER)<sup>bb</sup>

- H&P every 3–6 months for 1–2 years, then every 6–12 months for 3–5 years
- CBC and chemistry profile as clinically indicated
- For patients treated by ER, EGD every 6 months for 1 year, then annually for up to 5 years
  - Thereafter, as needed based on symptoms and/or radiographic findings
- For patients treated by surgical resection, EGD as clinically indicated
- CT chest/abdomen/pelvis with oral and IV contrast as clinically indicated<sup>dd,ee</sup>
- Monitor for nutritional deficiency in patients who have undergone surgical resection (especially after total gastrectomy) and treat as indicated<sup>ff</sup>

p stage II/III or  
yp stage I–III  
(treated with  
neoadjuvant  
± adjuvant  
therapy)<sup>bb</sup>

- H&P every 3–6 months for 1–2 years, then every 6–12 months for 3–5 years
- CBC and chemistry profile as clinically indicated
- For patients who had partial or subtotal gastrectomy, EGD as clinically indicated
- CT chest/abdomen/pelvis with oral and IV contrast every 6 months for first 2 years, then annually for up to 5 years<sup>dd,ee</sup>
- Monitor for nutritional deficiency in patients who have undergone surgical resection (especially after total gastrectomy) and treat as indicated<sup>ff</sup>

→ Recurrence  
([GAST-8](#))  
or  
Survivorship<sup>gg</sup>

<sup>bb</sup> For patients undergoing total gastrectomy for curative intent, surveillance should follow these recommendations except for endoscopy. Endoscopy as clinically indicated for routine surveillance for total gastrectomy unless patients are symptomatic.

<sup>cc</sup> [Principles of Surveillance \(GAST-H\)](#).

<sup>dd</sup> After 5 years, additional follow-up may be considered based on risk factors and comorbidities.


<sup>ee</sup> CT scan preferred. For patients who cannot undergo CT scan, alternative imaging such as PET/CT or MRI as clinically indicated.

<sup>ff</sup> Follow-up with appropriate practitioners or specialists should be established for lifelong monitoring and management of potential nutritional sequelae of gastrectomy, which may include, but are not limited to, vitamin B<sub>12</sub>, iron, zinc, calcium, and vitamin D deficiencies. Consider routine supplementation with a daily multivitamin/mineral complex, vitamin B<sub>12</sub>, calcium, and vitamin D. See [Principles of Survivorship \(GAST-I 2 of 4\)](#).

<sup>gg</sup> [Principles of Survivorship \(GAST-I\)](#).

**Note:** All recommendations are category 2A unless otherwise indicated.

**RECURRENCE**



<sup>d</sup> [Principles of Pathologic Review and Biomarker Testing \(GAST-B\)](#).


<sup>f</sup> [Principles of Surgery \(GAST-C\)](#).

<sup>hh</sup> Review if surgery is appropriate for patients with isolated local recurrences. Surgery should be considered as an option for locoregional recurrence in patients who are medically fit.

**Note:** All recommendations are category 2A unless otherwise indicated.

**PERFORMANCE STATUS**

**PALLIATIVE MANAGEMENT**



<sup>d</sup> [Principles of Pathologic Review and Biomarker Testing \(GAST-B\)](#).


<sup>p</sup> [Principles of Systemic Therapy \(GAST-F\)](#).

<sup>r</sup> [Principles of Radiation Therapy \(GAST-G\)](#).

<sup>ii</sup> [Principles of Palliative Care/Best Supportive Care \(GAST-J\)](#).

**Note:** All recommendations are category 2A unless otherwise indicated.

PERITONEAL CARCINOMA AS ONLY DISEASE<sup>jj</sup>



<sup>d</sup> [Principles of Pathologic Review and Biomarker Testing \(GAST-B\)](#).

<sup>n</sup> [Principles of Multidisciplinary Team Approach \(GAST-E\)](#).

<sup>p</sup> [Principles of Systemic Therapy \(GAST-F\)](#).

<sup>ii</sup> [Principles of Palliative Care/Best Supportive Care \(GAST-J\)](#).

<sup>jj</sup> Chicago Consensus Working Group. Ann Surg Oncol 2020;27:1768-1773.

<sup>kk</sup> [Principles of Surgery \(GAST-C 3 of 5\)](#).

Note: All recommendations are category 2A unless otherwise indicated.

## PRINCIPLES OF ENDOSCOPIC STAGING AND THERAPY

Endoscopy has become an important tool in the diagnosis, staging, treatment, and palliation of patients with gastric cancer.

### Diagnosis

- Diagnostic and surveillance endoscopies are performed with the goal of determining the presence and location of neoplastic disease and to biopsy any suspicious lesion. Thus, an adequate endoscopic exam addresses both of these components. The location of the tumor in the stomach (cardia, fundus, body, antrum, and pylorus) and relative to the esophagogastric junction (EGJ) for proximal tumors should be carefully recorded to assist with treatment planning and follow-up examinations.
- Multiple (6–8) biopsies using standard size endoscopy forceps should be performed to provide adequately sized material for histologic and molecular interpretation, especially in the setting of an ulcerated lesion.<sup>1,2</sup> Larger forceps may improve the yield.
- Endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) can be performed in the evaluation of small lesions. EMR or ESD of focal nodules ≤2 cm can be safely performed to provide a larger specimen that can be better assessed by the pathologist, providing greater information on degree of differentiation, the presence of lymphovascular invasion (LVI), and the depth of infiltration, thereby providing accurate T-staging.<sup>3</sup> Such excisional biopsies have the potential of being therapeutic.<sup>4</sup>

### Staging

- EUS performed prior to any treatment is important in the initial clinical staging of gastric cancer.<sup>5</sup> Careful attention to ultrasound images provides evidence of depth of tumor invasion (T-category), presence of abnormal or enlarged lymph nodes likely to harbor cancer (N-assessment), and occasionally signs of distant spread, such as lesions in surrounding organs (M-category) or the presence of ascites.<sup>6</sup> This is especially important in patients who are being considered for ER (EMR or ESD).<sup>7</sup>
- Hypoechoic (dark) expansion of the gastric wall layers identifies the location of tumor, with gradual loss of the layered pattern of the normal stomach wall corresponding with greater depths of tumor penetration, correlating with higher T-categories. A dark expansion of layers 1–3 corresponds with infiltration of the superficial and deep mucosa plus the submucosal, T1 disease. A dark expansion of layers 1–4 correlates with penetration into the muscularis propria, T2 disease, and expansion beyond the muscularis propria resulting in an irregular outer border that correlates with invasion of the subserosa, T3 disease. Loss of the bright line recognized as the serosa is now staged as pT4a, and extension of the mass into surrounding organs such as the liver, pancreas, and spleen is staged as pT4b disease.
- Perigastric lymph nodes are readily seen by EUS, and the identification of enlarged, hypoechoic (dark), homogeneous, well-circumscribed, rounded structures around the stomach correlates with the presence of malignant or inflammatory lymph nodes. The accuracy of this diagnosis is significantly increased with the combination of features, but also may be confirmed with the use of fine-needle aspiration (FNA) biopsy for cytology assessment.<sup>8</sup> FNA of suspicious lymph nodes should be performed if it can be achieved without traversing an area of primary tumor or major blood vessels, and if it will impact treatment decisions. Furthermore, an attempt should be made to identify the presence of ascites and FNA should be considered to rule out peritoneal spread of disease.


[Continued](#)  
[References](#)

Note: All recommendations are category 2A unless otherwise indicated.

**GAST-A**  
**1 OF 4**

## PRINCIPLES OF ENDOSCOPIC STAGING AND THERAPY

### Endoscopic Therapy for Early-Stage Gastric Adenocarcinoma<sup>a,9,10</sup>



<sup>a</sup> Endoscopic features suggestive of deep submucosal invasion include converging folds, irregular surface pattern, and ulceration in a large gastric mass.

<sup>b</sup> Unfavorable histologic features include: poorly differentiated or diffuse type (compared to intestinal) histology.

<sup>c</sup> [Principles of Surgery \(GAST-C\)](#).

<sup>d</sup> The resected endoscopy specimen should be evaluated by a pathologist with expertise in GI pathology. Curative ER features include: submucosal invasion <500 µm, but without poorly or undifferentiated pathology, and without LVI.

<sup>e</sup> See Postoperative Chemotherapy in [Principles of Systemic Therapy \(GAST-F 3 of 20\)](#).

[Continued](#)  
[References](#)

**Note:** All recommendations are category 2A unless otherwise indicated.



## PRINCIPLES OF ENDOSCOPIC STAGING AND THERAPY

### Treatment

- EMR or ESD of early-stage gastric cancer can be considered adequate therapy when the lesion is  $\leq 2$  cm in diameter, is shown on histopathology to be well or moderately well differentiated, does not penetrate beyond the superficial submucosa, does not exhibit LVI, and has clear lateral and deep margins. En-bloc excision of small gastric lesions by ESD has been shown to be more effective than EMR in curing small early-stage gastric cancer, but requires greater skills and instrumentation to perform and has a significant risk of complications including perforation.<sup>11</sup>
- Japanese Gastric Cancer guidelines recommend that EMR or ESD should be considered for early-stage gastric cancer lesions  $\leq 2$  cm in diameter without associated ulcer formation.<sup>3</sup>
- Several Japanese and American guidelines have expanded the indications for ESD to include:
  - Well to moderately differentiated cancer of any size, without ulceration
  - Well or moderately differentiated with submucosal (sm) layer invasion  $<500$  micrometers
  - Well or moderately differentiated  $<3$  cm with ulceration
  - Poorly differentiated  $<2$  cm without ulceration
- This may potentially be considered curative resection if the margins are negative, there is no LVI, and curative resection is limited to sm1. However, there is still a very small risk of lymph node involvement, so such decisions should be made following multidisciplinary discussions and careful explanation to the patient.
- EMR or ESD of gastric cancers that are poorly differentiated, harbor evidence of LVI, invade into the deep submucosa, or have positive lateral or deep margins or lymph node metastases should be considered to be incomplete. Additional therapy by gastrectomy with lymphadenectomy should be considered.<sup>12</sup>
- EUS performed after chemotherapy or radiation therapy (RT) has a reduced ability to accurately determine the post-treatment stage of disease.<sup>13</sup> Similarly, biopsies performed after chemotherapy or RT may not accurately diagnose the presence of residual disease but still provide useful information.<sup>14</sup>
- Endoscopic tumor ablation can be performed for the short-term control of bleeding. Endoscopic insertion of expandable metal stents is effective in long-term relief of tumor obstruction at the EGJ or the gastric outlet, although surgical gastrojejunostomy may be more efficacious for those with longer-term survival ([Principles of Palliative Care/Best Supportive Care \[GAST-J\]](#)).<sup>15,16</sup>
- Long-term palliation of anorexia, dysphagia, or malnutrition may be achieved with endoscopic- or radiographic-assisted placement of a feeding gastrostomy tube in carefully selected cases where the distal stomach is uninvolved by tumor, or the placement of a feeding jejunostomy tube (J-tube).<sup>17</sup>

### Post-Treatment Surveillance

- Endoscopic surveillance following definitive treatment of gastric cancer requires careful attention to detail for mucosal surface changes, and multiple (4–6) biopsies of any visualized abnormalities. Strictures should be biopsied to rule out neoplastic cause. EUS performed in conjunction with endoscopy exams has a high sensitivity for detecting recurrent disease.<sup>18</sup> EUS-guided FNA should be performed if suspicious lymph nodes or areas of wall thickening are seen.

### References

Note: All recommendations are category 2A unless otherwise indicated.

**GAST-A**  
**3 OF 4**



## PRINCIPLES OF ENDOSCOPIC STAGING AND THERAPY REFERENCES

- <sup>1</sup> Hatfield AR, Slavin G, Segal AW, Levi AJ. Importance of the site of endoscopic gastric biopsy in ulcerating lesions of the stomach. Gut 1975;16:884-886.
- <sup>2</sup> Graham DY, Schwartz JT, Cain GD, Gyorkay F. Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. Gastroenterology 1982;82:228-231.
- <sup>3</sup> Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011;14:113-123.
- <sup>4</sup> Akiyama M, Ota M, Nakajima H, et al. Endoscopic mucosal resection of gastric neoplasms using a ligating device. Gastrointest Endosc 1997;45:182-186.
- <sup>5</sup> Botet JF, Lightdale CJ, Zauber AG, et al. Endoscopic ultrasound in the pre-operative staging of gastric cancer: A comparative study with dynamic CT. Radiology 1991;181:426-432.
- <sup>6</sup> Bentrem D, Gerdes H, Tang L, et al. Clinical correlation of endoscopic ultrasonography with pathologic stage and outcome in patients undergoing curative resection for gastric cancer. Ann Surg Oncol 2007;14:1853-1859.
- <sup>7</sup> Okada K, Fujisaki J, Kasuga A, et al. Endoscopic ultrasonography is valuable for identifying early gastric cancers meeting expanded-indication criteria for endoscopic submucosal dissection. Surg Endosc 2011;25:841-848.
- <sup>8</sup> Keswani RN, Early DS, Edmundowicz SA, et al. Routine positron emission tomography does not alter nodal staging in patients undergoing EUS-guided FNA for esophageal cancer. Gastrointest Endosc 2009;69:1210-1217.
- <sup>9</sup> Forbes N, Elhanafi SE, et al. American Society for Gastrointestinal Endoscopy guideline on endoscopic submucosal dissection for the management of early esophageal and gastric cancers: summary and recommendations. Gastrointest Endosc 2023;98:271-284.
- <sup>10</sup> Pimentel-Nunes P, Libânia D, Bastiaansen BAJ, et al. Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2022. Endoscopy 2022;54:591-622.
- <sup>11</sup> Yahagi N, Fujishiro M, Kakushima N, et al. Endoscopic submucosal dissection for early gastric cancer using the tip of an electrosurgical snare (thin type). Dig Endosc 2004;16:34-38.
- <sup>12</sup> Ahn JY, Jung HY, Choi KD. Endoscopic and oncologic outcomes after endoscopic resection for early gastric cancer: 1370 cases of absolute and extended indications. Gastrointest Endosc 2011;74:485-493.
- <sup>13</sup> Park SR, Lee JS, Kim CG, et al. Endoscopic ultrasound and computed tomography in restaging and predicting prognosis after neoadjuvant chemotherapy in patients with locally advanced gastric cancer. Cancer 2008;112:2368-2376.
- <sup>14</sup> Sarkaria IS, Rizk NP, Bains MS, et al. Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg 2009;249:764-767.
- <sup>15</sup> Schmidt C, Gerdes H, Hawkins W, et al. A prospective observational study examining quality of life in patients with malignant gastric outlet obstruction. Am J Surg 2009;198:92-99.
- <sup>16</sup> Vakil N, Morris AI, Marcon N, et al. A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. Am J Gastroenterol 2001;96:1791-1796.
- <sup>17</sup> Shike M, Latkany L, Gerdes H, Bloch AS. Direct percutaneous endoscopic jejunostomies for enteral feeding. Gastrointest Endosc 1996;44:536-540.
- <sup>18</sup> Lightdale CJ, Botet JF, Kelsen DP, et al. Diagnosis of recurrent upper gastrointestinal cancer at the surgical anastomosis by endoscopic ultrasound. Gastrointest Endosc 1989;35:407-412.

Note: All recommendations are category 2A unless otherwise indicated.

**GAST-A**  
**4 OF 4**

**NCCN Guidelines Version 3.2025**  
**Gastric Cancer**
[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)
**Pathologic Review****Table 1**

Specimen Type	Analysis/Interpretation/Reporting <sup>a</sup>
Biopsy	<b>Include in pathology report:</b> <ul style="list-style-type: none"> <li>• Invasion, if present</li> <li>• Histologic type<sup>b</sup></li> <li>• Grade</li> <li>• Universal testing for MSI by PCR/NGS or MMR by IHC and PD-L1 testing by IHC are recommended in all newly diagnosed patients</li> </ul>
Endoscopic mucosal resection (EMR)	<b>Include in pathology report:</b> <ul style="list-style-type: none"> <li>• Invasion, if present</li> <li>• Histologic type<sup>b</sup></li> <li>• Grade</li> <li>• Depth of tumor invasion</li> <li>• Vascular/lymphatic invasion</li> <li>• Status of mucosal and deep margins</li> <li>• Universal testing for MSI by PCR/NGS or MMR by IHC and PD-L1 testing by IHC are recommended in all newly diagnosed patients</li> </ul>
Gastrectomy	<b>For pathology report, include all elements as for EMR plus:</b> <ul style="list-style-type: none"> <li>• Location of tumor midpoint in relationship to EGJ<sup>c</sup></li> <li>• Whether tumor crosses EGJ</li> <li>• Lymph node status and number of lymph nodes recovered<sup>d</sup></li> <li>• Universal testing for MSI by PCR/NGS or MMR by IHC and PD-L1 testing by IHC are recommended in all newly diagnosed patients, if not previously performed</li> </ul>
Gastrectomy, with prior chemoradiation in unresectable gastric cancer treated with chemoradiation followed by surgery	<ul style="list-style-type: none"> <li>• Tumor site should be thoroughly sampled for specimens s/p chemoradiation without grossly obvious residual tumor</li> <li>• For pathology report, include all elements of resection and assessment of treatment effect</li> </ul>

<sup>a</sup> Use of a standardized minimum dataset such as the College of American Pathologists Cancer Protocols (available at <http://www.cap.org>) for reporting pathologic findings is recommended.

<sup>b</sup> Subclassification of gastric adenocarcinomas as intestinal or diffuse type may have implications for therapy, as intestinal type cancers may be more likely to overexpress HER2.<sup>1</sup>

<sup>c</sup> Midpoint of tumors arising in the proximal 2 cm of the stomach and crossing the EGJ are classified for purposes of staging as esophageal carcinomas, while those with the epicenter located >2 cm into the proximal stomach are staged as gastric carcinomas.<sup>2</sup>

<sup>d</sup> For patients with surgically managed cancer, ≥16 regional lymph nodes are removed and pathologically examined during resection for curative intent therapy.

[Continued](#)  
[References](#)

Note: All recommendations are category 2A unless otherwise indicated.

## PRINCIPLES OF PATHOLOGIC REVIEW AND BIOMARKER TESTING

### Assessment of Treatment Response

Response of the primary tumor and lymph node metastases to previous chemotherapy or RT should be reported. Although scoring systems for tumor response in gastric cancer have not been uniformly adopted, in general, 3-category systems provide good reproducibility among pathologists. The following system developed for rectal cancer is reported to provide good interobserver agreement, but other systems may also be used. Sizable pools of acellular mucin may be present after chemoradiation but should not be interpreted as representing residual tumor.<sup>3</sup>

**Table 2<sup>e</sup>**

Tumor Regression Score	Description
0 (Complete response)	No viable cancer cells, including lymph nodes
1 (Near complete response)	Single cells or rare small groups of cancer cells
2 (Partial response)	Residual cancer cells with evident tumor regression but more than single cells or rare small groups of cancer cells
3 (Poor or no response)	Extensive residual cancer with no evident tumor regression

### Number of Lymph Nodes Retrieved

- Although it is suggested that  $\geq 16$  regional lymph nodes be pathologically assessed, removal and assessment of  $>30$  lymph nodes is desirable.<sup>2</sup>

<sup>e</sup> Reproduced and adapted with permission from Shi C, Berlin J, Branton PA, et al. Protocol for the examination of specimens from patients with carcinoma of the stomach. In: Cancer Protocol Templates. Northfield, IL: College of American Pathologists; 2017. (available at <http://www.cap.org>).

**Note:** All recommendations are category 2A unless otherwise indicated.

**Continued**  
**References**

**GAST-B**  
**2 OF 7**

## PRINCIPLES OF PATHOLOGIC REVIEW AND BIOMARKER TESTING

### Assessment of Overexpression or Amplification of HER2 in Gastric Cancer

For patients with inoperable locally advanced, recurrent, or metastatic adenocarcinoma of the stomach for whom trastuzumab<sup>f</sup> therapy is being considered, assessment for tumor HER2 overexpression using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) or other in situ hybridization (ISH) method is recommended.<sup>4</sup> NGS offers the opportunity to assess numerous mutations simultaneously, along with other molecular events such as amplification, deletions, tumor mutational burden (TMB), and MSI status. IHC/ISH/targeted PCR is the preferred approach to assess biomarkers initially. However, NGS testing through a CLIA-approved laboratory may be considered later in the clinical course of patients with sufficient tumor tissue available for testing. Repeat biomarker testing may be considered at clinical or radiologic progression for patients with advanced/metastatic gastric adenocarcinoma.

**Table 3: Immunohistochemical Criteria for Scoring HER2 Expression in Gastric Cancer<sup>g,h</sup>**

	Surgical Specimen Expression Pattern, Immunohistochemistry	Biopsy Specimen Expression Pattern, Immunohistochemistry	HER2 Overexpression Assessment
0	No reactivity or membranous reactivity in <10% of cancer cells	No reactivity or no membranous reactivity in any cancer cell	Negative
1+	Faint or barely perceptible membranous reactivity in ≥10% of cancer cells; cells are reactive only in part of their membrane	Cluster of five or more cancer cells with a faint or barely perceptible membranous reactivity irrespective of percentage of cancer cells positive	Negative
2+	Weak to moderate complete, basolateral, or lateral membranous reactivity in ≥10% of cancer cells	Cluster of five or more cancer cells with a weak to moderate complete, basolateral, or lateral membranous reactivity irrespective of percentage of cancer cells positive	Equivocal
3+	Strong complete, basolateral, or lateral membranous reactivity in ≥10% of cancer cells	Cluster of five or more cancer cells with a strong complete, basolateral, or lateral membranous reactivity irrespective of percentage of cancer cells positive	Positive

<sup>f</sup> An FDA-approved biosimilar is an appropriate substitute for any recommended systemic biologic therapy in the NCCN Guidelines.

<sup>g</sup> The NCCN Guidelines Panel recommends that HER2 IHC be ordered/Performed first, followed by ISH methods in cases showing 2+ (equivocal) expression by IHC. Positive (3+) or negative (0 or 1+) HER2 IHC results do not require further ISH testing. Cases with *HER2:CEP17* ratio ≥2 or an average HER2 copy number ≥6.0 signals/cell are considered positive by ISH/FISH.

<sup>h</sup> Reprinted and adapted from Bartley AN, Washington MK, Colasacco C, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society of Clinical Pathology, and American Society of Clinical Oncology. *J Clin Oncol* 2017;35:446-464 with permission from the American Society of Clinical Oncology.

[Continued](#)  
[References](#)

Note: All recommendations are category 2A unless otherwise indicated.

**GAST-B**  
**3 OF 7**

# NCCN Guidelines Version 3.2025

## Gastric Cancer

[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)

### PRINCIPLES OF PATHOLOGIC REVIEW AND BIOMARKER TESTING

#### Assessment of Positivity of Claudin 18 Isoform 2 (CLDN18.2) in Gastric Cancer<sup>5-7</sup>

- For patients with untreated inoperable locally advanced, recurrent, or metastatic adenocarcinoma of the stomach for whom zolbetuximab therapy is being considered

**Table 4: Immunohistochemical Criteria for Assessing CLDN18.2 Expression in Gastric Cancer**

CLDN18.2 Assessment	Biopsy or Surgical Specimen Expression Pattern by IHC
Positive	≥75% viable tumor cells demonstrating moderate to strong membrane CLDN18.2 staining (2+ or 3+ intensity)
Negative	<75% viable tumor cells demonstrating moderate to strong membrane CLDN18.2 staining

[Continued](#)  
[References](#)

Note: All recommendations are category 2A unless otherwise indicated.

**GAST-B**  
**4 OF 7**

## PRINCIPLES OF PATHOLOGIC REVIEW AND BIOMARKER TESTING

### Microsatellite Instability (MSI) or Mismatch Repair (MMR) Testing<sup>i</sup>

- Universal testing for MSI by polymerase chain reaction (PCR), NGS, or MMR by IHC should be performed for all newly diagnosed gastric cancers.<sup>8</sup> The testing is performed on formalin-fixed paraffin-embedded (FFPE) tissue and results are interpreted as MSI-H or dMMR in accordance with [CAP DNA Mismatch Repair Biomarker Reporting Guidelines](#).<sup>9</sup> Testing should be performed only in Clinical Laboratory Improvement Amendments (CLIA)-approved laboratories. Patients with MSI-H or dMMR tumors should be referred to a genetics counselor for further assessment in the appropriate clinical context.

#### ► MMR Interpretation

- ◊ No loss of nuclear expression of MMR proteins: No evidence of dMMR (low probability of MSI-H)
- ◊ Loss of nuclear expression of one or more MMR proteins: dMMR

#### ► MSI Interpretation

- ◊ Microsatellite stable (MSS)
- ◊ MSI-low (MSI-L)
  - 1%–29% of the markers exhibit instability
  - 1 of the 5 National Cancer Institute (NCI) or mononucleotide markers exhibits instability
- ◊ MSI-H
  - ≥30% of the markers exhibit instability
  - ≥2 of the 5 NCI or mononucleotide markers exhibit instability

### PD-L1 Testing

- Universal testing for PD-L1 by IHC should be performed for all newly diagnosed patients with gastric cancer who are candidates for treatment with programmed cell death protein 1 (PD-1) or PD-L1 inhibitors. A companion diagnostic test should be used on FFPE tissue as an aid in identifying patients for treatment with PD-1/PD-L1 inhibitors. PD-L1 testing should be performed only in CLIA-approved laboratories.
- Assessment of PD-L1 Protein Expression in Gastric Cancers
  - This is a qualitative IHC assay using anti-PD-L1 antibodies for the detection of PD-L1 protein in FFPE tissues from gastric adenocarcinoma. A minimum of 100 tumor cells must be present in the PD-L1-stained slide for the specimen to be considered adequate for PD-L1 evaluation. A specimen is considered to have PD-L1 expression if the combined positive score (CPS) is ≥1. CPS is the number of PD-L1 staining cells (ie, tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100.
  - CPS and tumor area positivity (TAP) score have high concordance and may be interchangeable.<sup>10,11</sup>

<sup>i</sup> PCR/NGS for MSI and IHC for MMR proteins measure different biological effects caused by dMMR function.

Note: All recommendations are category 2A unless otherwise indicated.

[Continued](#)  
[References](#)

**GAST-B**  
**5 OF 7**



## PRINCIPLES OF PATHOLOGIC REVIEW AND BIOMARKER TESTING

### Next-Generation Sequencing (NGS):

- At present, several targeted therapeutic agents (GAST-F) have been approved by the FDA for use in gastric cancer. IHC/ISH/targeted PCR is the preferred approach to assess biomarkers, initially. However, NGS testing through a CLIA-approved laboratory may be considered later in the clinical course of patients with sufficient tumor tissue available for testing. The list of targeted biomarkers includes:

- ▶ HER2 overexpression/amplification
- ▶ PD-L1 expression
- ▶ MSI
- ▶ CLDN18.2
- ▶ TMB
- ▶ NTRK gene fusion
- ▶ RET gene fusion
- ▶ BRAF V600E mutation

### Liquid Biopsy<sup>12,13</sup>

- The genomic alterations of solid cancers may be identified by evaluating circulating tumor DNA (ctDNA) in the blood, hence a form of “liquid biopsy.” The detection of mutations/alterations or fusions in DNA shed from gastric carcinomas can identify targetable alterations or the evolution of clones with altered treatment response profiles. Therefore, when limited tissue is available or for patients who have metastatic or advanced gastric cancer who are not able to undergo a traditional biopsy, testing using a validated NGS-based comprehensive genomic profiling assay performed in a CLIA-approved laboratory may be considered. A negative result should be interpreted with caution, as this does not exclude the presence of tumor.

### [References](#)

Note: All recommendations are category 2A unless otherwise indicated.

**GAST-B**  
**6 OF 7**

## PRINCIPLES OF PATHOLOGIC REVIEW AND BIOMARKER TESTING REFERENCES

- <sup>1</sup> Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. *Histopathology* 2008;52:797-805.
- <sup>2</sup> Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8th ed. New York, NY; Springer: 2017.
- <sup>3</sup> Ryan R, Gibbons D, Hyland JMP, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. *Histopathology* 2005;47:141-146.
- <sup>4</sup> Bartley AN, Washington MK, Colasacco C, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society of Clinical Pathology, and American Society of Clinical Oncology. *J Clin Oncol* 2017;35:446-464.
- <sup>5</sup> Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. *Nat Med* 2023;29:2133-2141.
- <sup>6</sup> Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. *Lancet* 2023;401:1655-1668.
- <sup>7</sup> Shitara K, Xu RH, Ajani JA, et al. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. *Gastric Cancer* 2024;27:1058-1068.
- <sup>8</sup> Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med* 2015;372:2509-2520.
- <sup>9</sup> Bartley AN, Fitzgibbons PL, Broaddus RR, Shi C. Template for Reporting Results of DNA Mismatch Repair Testing in Patients Being Considered for Checkpoint Inhibitor Immunotherapy. College of American Pathologists. 2018.
- <sup>10</sup> Qiu MZ, Oh DY, Kato K, et al. RATIONALE-305 Investigators. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. *BMJ* 2024;385:e078876.
- <sup>11</sup> Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. *Lancet Oncol* 2023;24:483-495.
- <sup>12</sup> Kato S, Okamura R, Baumgartner JM, et al. Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma. *Clin Cancer Res* 2018;24:6248-6256.
- <sup>13</sup> Willis J, Lefterova MI, Artyomenko A, et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel. *Clin Cancer Res* 2019;25:7035-7045.

Note: All recommendations are category 2A unless otherwise indicated.

**GAST-B**  
**7 OF 7**

## PRINCIPLES OF SURGERY

### N Category Determination

- Determine extent of disease by CT scan (chest, abdomen, and pelvis) ± EUS (if no metastatic disease seen on CT).
- In patients being considered for surgical resection without preoperative therapy, laparoscopy<sup>1</sup> may be useful in detecting radiographically occult metastatic disease in patients with cT3 and/or cN+ disease seen on preoperative imaging. If laparoscopy is planned as a separate procedure, peritoneal washings with cytology should be performed as well.
- In patients receiving preoperative therapy, a baseline laparoscopy along with peritoneal washings should be considered.
- Positive peritoneal cytology (performed in the absence of visible peritoneal implants) is associated with poor prognosis and is defined as pM1 disease.<sup>2</sup>

### Siewert Classification

- Siewert tumor type should be assessed in all patients with adenocarcinomas involving the EGJ.<sup>3,4</sup>
  - ▶ Siewert Type I: adenocarcinoma of the lower esophagus (often associated with Barrett esophagus) with the epicenter located within 1 cm to 5 cm above the anatomic EGJ.
  - ▶ Siewert Type II: true carcinoma of the cardia at the EGJ, with the tumor epicenter within 1 cm above and 2 cm below the EGJ.
  - ▶ Siewert Type III: subcardial carcinoma with the tumor epicenter between 2 cm and 5 cm below the EGJ, which infiltrates the EGJ and lower esophagus from below.
- The treatment of Siewert types I and II is as described in the [NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers](#).
- Siewert type III lesions are considered gastric cancers, and thus should be treated as described in the NCCN Guidelines for Gastric Cancer. In some cases additional esophageal resection may be needed in order to obtain adequate margins.<sup>3,5,6</sup>

### Criteria of Unresectability for Cure

- Locoregionally advanced
  - ▶ Disease infiltration of the root of the mesentery or para-aortic lymph node highly suspicious on imaging or confirmed by biopsy
  - ▶ Invasion or encasement of major vascular structures (excluding the splenic vessels)
- Distant metastasis or peritoneal seeding (including positive peritoneal cytology)

[Continued](#)  
[References](#)

Note: All recommendations are category 2A unless otherwise indicated.

GAST-C  
1 OF 5

## PRINCIPLES OF SURGERY

### Resectable Tumors

- Tis or T1<sup>7</sup> tumors limited to mucosa (T1a) may be candidates for EMR or ESD if they meet appropriate criteria (in experienced centers).<sup>8</sup>
- T1b–T3<sup>9</sup>: Adequate gastric resection to achieve negative microscopic margins along with lymphadenectomy.
  - ▶ Distal gastrectomy
  - ▶ Subtotal gastrectomy
  - ▶ Total gastrectomy
- T4b tumors require en bloc resection of involved structures.
- Gastric resection should include the regional lymphatics—perigastric lymph nodes (D1) and those along the named vessels of the celiac axis (D2), with a goal of examining ≥16 lymph nodes.<sup>10–12</sup>
  - ▶ Definition of D1 and D2 lymph node dissections
    - ◊ D1 dissection entails gastrectomy and the resection of both the greater and lesser omenta (which would include the lymph nodes along the right and left cardiac, lesser and greater curvature, suprapyloric along the right gastric artery, and infrapyloric area);
    - ◊ D2 dissection is a D1 plus all the nodes along the left gastric artery, common hepatic artery, celiac artery, and splenic artery.
- Routine splenectomy is not indicated unless the spleen is involved or extensive hilar adenopathy is noted.<sup>13</sup>
- Consider placing feeding tube in select patients undergoing total gastrectomy (especially if postoperative chemoradiation appears a likely recommendation).
- Minimally invasive surgical approaches may be considered for selected cases based on the following criteria:
  - ▶ The surgeon has experience performing laparoscopic or robotic foregut procedures and has experience in lymphadenectomy.
  - ▶ Both early and locally advanced gastric cancers can be considered for laparoscopic or robotic gastrectomy given evidence that supports equivalent oncologic outcomes from the East and West.<sup>14–17</sup>
  - ▶ Minimally invasive approaches are generally not recommended for T4b or N2 bulky gastric cancer.

[Continued](#)  
[References](#)

Note: All recommendations are category 2A unless otherwise indicated.

GAST-C  
2 OF 5



## PRINCIPLES OF SURGERY

### Resectable Tumors—continued

- IC/HIPEC/Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC)<sup>18-21</sup>
  - ▶ The evidence for the use of IC/HIPEC/PIPAC is limited. There are no randomized trials to demonstrate efficacy, and results are limited to case reports and small series. However, IC/HIPEC may be effective in selected patients with low burden of tumor. The decision to pursue IC/HIPEC should be made only after multidisciplinary discussion.
  - ▶ PIPAC is investigational and should only be done in the context of a clinical trial.
  - ▶ IC/HIPEC may be a therapeutic alternative for carefully selected patients with peritoneal carcinoma as only disease.
    - ◊ Patients who are being considered for IC/HIPEC should undergo pre-treatment evaluation with a chest/abdomen/pelvis CT, diagnostic laparoscopy with washings to assess for PCI and/or cytology-positive disease, and consider a PET scan to rule out distant metastatic disease. Patients with documented peritoneal metastatic disease should begin with systemic therapy given for a minimum of 3 months. Then patients should undergo re-staging and demonstrate stable or improving disease to be considered for further therapy. Treatment decisions should be made in the context of a multidisciplinary tumor board. In this setting:
      - IC/HIPEC can be used in conjunction with cytoreductive surgery<sup>a</sup> for patients with low PCI ( $\leq 10$ ) who are candidates to undergo complete cytoreduction.
      - In patients with a higher burden of peritoneal disease (PCI  $> 10$ ), IC/HIPEC may be considered in the setting of a clinical trial.
      - The role of prophylactic IC/HIPEC/PIPAC is currently investigational for patients with non-metastatic cancers and should only be performed in the setting of a clinical trial.

<sup>a</sup> Cytoreduction of all visible nodules/plaques.

[Continued](#)  
[References](#)

Note: All recommendations are category 2A unless otherwise indicated.

**GAST-C**  
**3 OF 5**



## PRINCIPLES OF SURGERY

### **Palliative Procedures**

- Gastric resections should be reserved for the palliation of symptoms (eg, obstruction or uncontrollable bleeding) in patients with incurable disease when non-surgical options are not feasible such as endoscopic or interventional radiology procedures (ie, endoscopic stenting).
- Lymph node dissection is not required.
- In patients fit for surgery and who have a reasonable prognosis, gastrojejunostomy (open or laparoscopic) or endoluminal stenting are options. Except for rare cases that may have slow growth, endoluminal stenting is preferred in patients with gastric outlet obstruction/disease and very minimal metastatic disease, in the liver or other area not affecting the GI tract. If longer term palliation is needed, surgical bypass may be considered.<sup>22,23</sup>
- Venting gastrostomy and/or feeding tube may be considered.

### [References](#)

**Note:** All recommendations are category 2A unless otherwise indicated.



**PRINCIPLES OF SURGERY**  
**REFERENCES**

- <sup>1</sup> Sarela AI, Lefkowitz R, Brennan MF, Karpeh MS. Selection of patients with gastric adenocarcinoma for laparoscopic staging. *Am J Surg* 2006;191:134-138.
- <sup>2</sup> Mezhir JJ, Shah MA, Jacks LM, et al. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. *Ann Surg Oncol* 2010;17:3173-3180.
- <sup>3</sup> Siewert JR, Stein HJ. Adenocarcinoma of the gastroesophageal junction: classification, pathology and extent of resection. *Dis Esophagus* 1996;9:173-182.
- <sup>4</sup> Stewart JR, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction. Results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. *Ann Surg* 2000;232:353-361.
- <sup>5</sup> Rusch VW. Are cancers of the esophagus, gastroesophageal junction, and cardia one disease, two, or several? *Semin Oncol* 2004;31:444-449.
- <sup>6</sup> Siewert JR, Stein HJ, Feith M. Adenocarcinoma of the esophago-gastric junction. *Scan J Surg* 2006; 95:260-269.
- <sup>7</sup> Soetikno R, Kaltenbach T, Yeh R, Gotoda T. Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. *J Clin Oncol* 2005;23:4490-4498.
- <sup>8</sup> Ono H, Kondo H, Gotoda T, et al. Endoscopic mucosal resection for treatment of early gastric cancer. *Gut* 2001;48:225-229.
- <sup>9</sup> Ito H, Clancy TE, Osteen RT, et al. Adenocarcinoma of the gastric cardia: what is the optimal surgical approach? *J Am Coll Surg* 2004;199:880-886.
- <sup>10</sup> Songun I, Putter H, Kranenborg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomized nationwide Dutch D1D2 trial. *Lancet Oncol* 2010;11:439-449.
- <sup>11</sup> Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. *Ann Surg Oncol* 2007;14:317-328.
- <sup>12</sup> Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. *Ann Surg* 2000;232:362-571.
- <sup>13</sup> Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. *Br J Surg* 2006;93:559-563.
- <sup>14</sup> Kim HH, Han SU, Kim MC, et al. Effect of laparoscopic distal gastrectomy vs open distal gastrectomy on long-term survival among patients with stage I gastric cancer: the KLASS-01 randomized clinical trial. *JAMA Oncol* 2019;5:506-513.
- <sup>15</sup> Lee HJ, Hyung WJ, Yang HK, et al. Short-term outcomes of a multicenter randomized controlled trial comparing laparoscopic distal gastrectomy with D2 lymphadenectomy to open distal gastrectomy for locally advanced gastric cancer (KLASS-02-RCT). *Ann Surg* 2019;270:983-991.
- <sup>16</sup> Yu J, Huang C, Sun Y, et al. Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial. *JAMA* 2019;321:1983-1992.
- <sup>17</sup> Huscher CGS, Mingoli A, Sgarzini, et al. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial. *Ann Surg* 2005;241:232-237.
- <sup>18</sup> Badgwell B, Ikoma N, Murphy MB, et al. A phase II trial of cytoreduction, gastrectomy, and hyperthermic intraperitoneal perfusion with chemotherapy for patients with gastric cancer and carcinomatosis or positive cytology. *Ann Surg Oncol* 2021;28:258-264.
- <sup>19</sup> Yang X, Huang C, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. *Ann Surg Oncol* 2011;18:1575-1581.
- <sup>20</sup> Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): A propensity score analysis. *J Clin Oncol* 2019;37:2028-2040.
- <sup>21</sup> Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: Management of gastric metastases. *Ann Surg Oncol* 2020;27:1768-1773.
- <sup>22</sup> Jeurink SM, Steyerberg EW, van Hooft JE, et al. Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial. *Gastrointest Endosc* 2010;71:490-499.
- <sup>23</sup> Halpern AL, McCarter MD. Palliative management of gastric and esophageal cancer. *Surg Clin North Am* 2019;99:555-569.

**Note:** All recommendations are category 2A unless otherwise indicated.



## PRINCIPLES OF GENETIC RISK ASSESSMENT FOR GASTRIC CANCER

See [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric](#) - Hereditary Diffuse Gastric Cancer for information on:

- Testing Criteria for Hereditary Diffuse Gastric Cancer
- *CDH1* Gastric Cancer Risks
- Management of Gastric Cancer in *CDH1* Pathogenic Variant Carriers

Note: All recommendations are category 2A unless otherwise indicated.



## PRINCIPLES OF MULTIDISCIPLINARY TEAM APPROACH FOR ESOPHAGOGASTRIC CANCERS

**Category 1 evidence supports the notion that the combined modality therapy is effective for patients with localized esophagogastric cancer.<sup>1,2,3</sup> The NCCN Panel believes in an infrastructure that encourages multidisciplinary treatment decision-making by members of all disciplines taking care of this group of patients.**

**The combined modality therapy for patients with localized esophagogastric cancer may be optimally delivered when the following elements are in place:**

- The involved institution and individuals from relevant disciplines are committed to jointly reviewing the detailed data on patients on a regular basis. Frequent meetings (either once a week or once every 2 weeks) are encouraged.
- Optimally at each meeting, all relevant disciplines should be encouraged to participate and these may include: surgical oncology, medical oncology, gastroenterology, radiation oncology, radiology, and pathology. In addition, the presence of nutritional services, social workers, nursing, palliative care specialists, and other supporting disciplines are also desirable.
- All long-term therapeutic strategies are best developed after adequate staging procedures are completed, but ideally prior to any therapy that is rendered.
- Joint review of the actual medical data is more effective than reading reports for making sound therapy decisions.
- A brief documentation of the consensus recommendation(s) by the multidisciplinary team for an individual patient may prove useful.
- The recommendations made by the multidisciplinary team may be considered advisory to the primary group of treating physicians of the particular patient.
- Re-presentation of select patient outcomes after therapy is rendered may be an effective educational method for the entire multidisciplinary team.
- A periodic formal review of relevant literature during the course of the multidisciplinary meeting is highly encouraged.

<sup>1</sup> Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 2006;355:11-20.

<sup>2</sup> Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). *Radiation Therapy Oncology Group. JAMA* 1999;281:1623-1627.

<sup>3</sup> Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001;345:725-730.

**Note: All recommendations are category 2A unless otherwise indicated.**



### PRINCIPLES OF SYSTEMIC THERAPY

- Systemic therapy regimens recommended for advanced esophageal adenocarcinoma, EGJ adenocarcinoma, and gastric adenocarcinoma may be used interchangeably (except as indicated).
- Regimens should be chosen in the context of performance status (PS), medical comorbidities, and toxicity profile.
- Trastuzumab should be added to first-line chemotherapy for advanced HER2 overexpression-positive adenocarcinoma.
- Two-drug cytotoxic regimens are preferred for patients with advanced disease because of lower toxicity. The use of three cytotoxic drugs in a regimen should be reserved for patients who are medically fit with excellent PS and easy access to frequent toxicity evaluations.
- Modifications of category 1 regimen or use of category 2A or 2B regimens may be preferred (as indicated), with evidence supporting a more favorable toxicity profile without compromising efficacy.<sup>1</sup>
- Doses and schedules for any regimen that is not derived from category 1 evidence are a suggestion, and are subject to appropriate modifications depending on the circumstances.
- Alternate combinations and schedules of cytotoxics based on the availability of the agents, practice preferences, and contraindications are permitted.
- Perioperative systemic therapy<sup>2,3</sup> is a category 1 recommendation for localized gastric cancer.
- Postoperative chemotherapy plus chemoradiation<sup>4</sup> is an alternative option for patients who received less than a D2 lymph node dissection.
- Postoperative chemotherapy is recommended following primary D2 lymph node dissection<sup>5,6</sup> (see [Principles of Surgery \[GAST-C\]](#)).
- In the adjuvant setting, upon completion of systemic therapy or chemoradiation, patients should be monitored for any long-term therapy-related complications.
- An FDA-approved biosimilar is an appropriate substitute for any recommended systemic biologic therapy in the NCCN Guidelines.
- A checkpoint inhibitor should be added to first-line chemotherapy for patients with advanced disease with PD-L1 CPS  $\geq 1$ .
  - CPS and TAP score have high concordance and may be interchangeable.<sup>7,8</sup>
- Nivolumab and hyaluronidase-nvhy is not approved for concurrent use with IV ipilimumab; however, for nivolumab monotherapy, nivolumab and hyaluronidase-nvhy subcutaneous injection may be substituted for IV nivolumab. Nivolumab and hyaluronidase-nvhy has different dosing and administration instructions compared to IV nivolumab.

### References

- <sup>1</sup> Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. *J Clin Oncol* 2006;24:4991-4997.
- <sup>2</sup> Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. *J Clin Oncol* 2011;29:1715-1721.
- <sup>3</sup> Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. *Lancet* 2019;393:1948-1957.
- <sup>4</sup> Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. *J Clin Oncol* 2012;30:2327-2333 ([GAST-F 7 of 20](#)).
- <sup>5</sup> Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. *Lancet Oncol* 2014;15:1389-1396.
- <sup>6</sup> Park SH, Sohn TS, Lee J, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. *J Clin Oncol* 2015;33:3130-3136.
- <sup>7</sup> Qiu MZ, Oh DY, Kato K, et al. RATIONALE-305 Investigators. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. *BMJ* 2024;385:e078876.
- <sup>8</sup> Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. *Lancet Oncol* 2023;24:483-495.

Note: All recommendations are category 2A unless otherwise indicated.

**Continued**  
**GAST-F**  
**1 OF 20**

# NCCN Guidelines Version 3.2025

## Gastric Cancer

[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)

### PRINCIPLES OF SYSTEMIC THERAPY

The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Modifications of drug dose and schedule and initiation of supportive care interventions are often necessary because of expected toxicities and because of individual patient variability, prior treatment, nutritional status, and comorbidity. The optimal delivery of anticancer agents therefore requires a health care delivery team experienced in the use of anticancer agents and the management of associated toxicities in patients with cancer.

Note: All recommendations are category 2A unless otherwise indicated.

**Continued**  
**GAST-F**  
**2 OF 20**

# NCCN Guidelines Version 3.2025

## Gastric Cancer

[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)

### PRINCIPLES OF SYSTEMIC THERAPY

#### Perioperative Systemic Therapy

##### Preferred Regimens

- Fluorouracil,<sup>a</sup> leucovorin, oxaliplatin, and docetaxel (FLOT)<sup>b</sup> (category 1)<sup>1</sup>
- FLOT<sup>a</sup> + durvalumab<sup>c</sup> for PD-L1 CPS ≥1 or TAP ≥1%<sup>b</sup> (category 1)<sup>d,\*</sup>
- Fluoropyrimidine and oxaliplatin<sup>a,e</sup>

##### Other Recommended Regimens

- Fluorouracil and cisplatin (category 1)<sup>2</sup>

#### Neoadjuvant or Perioperative Immunotherapy

##### Useful in Certain Circumstances

- MSI-H/dMMR tumors<sup>b</sup>
  - ▶ Nivolumab and ipilimumab followed by nivolumab<sup>c,3</sup>
  - ▶ Pembrolizumab<sup>c,4,5</sup>
  - ▶ Tremelimumab and durvalumab for neoadjuvant therapy only<sup>c,6,7</sup>

#### Postoperative Chemoradiation

(For patients who received less than a D2 lymph node dissection [[Principles of Surgery \(GAST-C\)](#)])

- Fluoropyrimidine (infusional fluorouracil<sup>a</sup> or capecitabine) before and after fluoropyrimidine-based chemoradiation<sup>8</sup>

#### Postoperative Chemotherapy

(For patients who have undergone primary D2 lymph node dissection [[Principles of Surgery \(GAST-C\)](#)])

##### Preferred Regimens

- Capecitabine and oxaliplatin (category 1)<sup>9</sup>
- Fluorouracil<sup>a</sup> and oxaliplatin

#### Chemoradiation for Unresectable Disease

(Infusional fluorouracil<sup>a</sup> can be replaced with capecitabine)

##### Preferred Regimens

- Fluorouracil<sup>a</sup> and oxaliplatin<sup>10,11</sup>
- Fluorouracil and cisplatin<sup>12,13</sup>

##### Other Recommended Regimens

- Fluoropyrimidine (fluorouracil or capecitabine) and paclitaxel (category 2B)<sup>14</sup>

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see [Discussion](#).

<sup>b</sup> [Principles of Pathologic Review and Biomarker Testing \(GAST-B\)](#).

<sup>c</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

<sup>d</sup> In the MATTERHORN trial, diffuse type gastric or EGJ adenocarcinoma showed no EFS advantage when durvalumab was added to FLOT.

<sup>e</sup> The use of this regimen and dosing schedules is based on extrapolations from published literature and clinical practice.

[Continued](#)  
[References](#)

Note: All recommendations are category 2A unless otherwise indicated.

# NCCN Guidelines Version 3.2025

## Gastric Cancer

[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)

### PRINCIPLES OF SYSTEMIC THERAPY

#### Systemic Therapy for Unresectable Locally Advanced, Recurrent, or Metastatic Disease (where local therapy is not indicated)

##### First-Line Therapy

- Oxaliplatin is preferred over cisplatin due to lower toxicity.

##### Preferred Regimens

- HER2 overexpression positive<sup>b</sup>
  - Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and trastuzumab
  - Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, trastuzumab, and pembrolizumab for PD-L1 CPS ≥1 (category 1)<sup>c,f,15-16</sup>
  - Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), cisplatin, and trastuzumab (category 1)<sup>17</sup>
  - Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), cisplatin, trastuzumab, and pembrolizumab for PD-L1 CPS ≥1 (category 1)<sup>c,f,15-16</sup>
- HER2 overexpression negative<sup>b</sup>
  - Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and nivolumab for PD-L1 CPS ≥1 (category 1 for PD-L1 CPS ≥5)<sup>c,f,18</sup>
  - Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and pembrolizumab for PD-L1 CPS ≥1 (category 1 for PD-L1 CPS ≥5)<sup>c,f,19</sup>
  - Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and tislelizumab-jsgr for PD-L1 CPS ≥1 (category 1 for PD-L1 CPS ≥5)<sup>c,f,20</sup>
  - Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and zolbetuximab-clzb for CLDN18.2 positive<sup>b</sup> (category 1)<sup>21,22</sup>
  - Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine) and oxaliplatin<sup>23-25</sup>
  - Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), cisplatin, and pembrolizumab for PD-L1 CPS ≥1 (category 1 for PD-L1 CPS ≥5)<sup>c,f,19</sup>
  - Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), cisplatin, and tislelizumab-jsgr for PD-L1 CPS ≥1 (category 1 for PD-L1 CPS ≥5)<sup>c,f,20</sup>
  - Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine) and cisplatin<sup>23,26-28</sup>
- MSI-H/dMMR tumors (independent of PD-L1 status)<sup>b</sup>
  - Pembrolizumab<sup>c,f,29-31</sup>
  - Dostarlimab-gxly<sup>c,f,32</sup>
  - Nivolumab and ipilimumab<sup>c,f,18</sup>
  - Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and nivolumab<sup>c,f,18</sup>
  - Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and pembrolizumab<sup>c,f,30,31</sup>

##### Other Recommended Regimens

- Fluorouracil<sup>a,g</sup> and irinotecan<sup>h,33</sup>
- Paclitaxel with or without carboplatin or cisplatin<sup>h,34-38</sup>
- Docetaxel with or without cisplatin<sup>h,39-42</sup>
- Fluoropyrimidine<sup>h,27,43,44</sup> (fluorouracil<sup>a</sup> or capecitabine)
- Docetaxel, cisplatin or oxaliplatin, and fluorouracil<sup>a,h,45,46</sup>

##### Useful in Certain Circumstances

- Entrectinib, larotrectinib, or repotrectinib for *NTRK* gene fusion-positive tumors (category 2B)<sup>47-49</sup>

#### Footnotes on GAST-F (4A of 20)

Note: All recommendations are category 2A unless otherwise indicated.

Continued  
References

**GAST-F**  
**4 OF 20**



### FOOTNOTES FOR GAST-F 4 OF 20

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see [Discussion](#).

<sup>b</sup> [Principles of Pathologic Review and Biomarker Testing \(GAST-B\)](#).

<sup>c</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

<sup>f</sup> If no prior checkpoint inhibitor therapy or no tumor progression while on therapy with a checkpoint inhibitor.

<sup>g</sup> Capecitabine may not be used interchangeably with fluorouracil in regimens containing irinotecan.

<sup>h</sup> Trastuzumab should be added to first-line chemotherapy for HER2 overexpression-positive adenocarcinoma.

[Continued](#)  
[References](#)

**GAST-F**  
**4A OF 20**

**Note: All recommendations are category 2A unless otherwise indicated.**

## PRINCIPLES OF SYSTEMIC THERAPY

### Systemic Therapy for Unresectable Locally Advanced, Recurrent or Metastatic Disease (where local therapy is not indicated)

#### Second-Line or Subsequent Therapy

- Dependent on prior therapy and PS

#### Preferred Regimens

- Ramucirumab and paclitaxel (category 1)<sup>50</sup>
- Fam-trastuzumab deruxtecan-nxki for HER2 overexpression-positive adenocarcinoma<sup>51</sup>
- Docetaxel (category 1)<sup>41,42</sup>
- Paclitaxel (category 1)<sup>37,38,52</sup>
- Irinotecan (category 1)<sup>52-55</sup>
- Fluorouracil<sup>a,g</sup> and irinotecan<sup>53,56,57</sup>
- Trifluridine and tipiracil for third-line or subsequent therapy (category 1)<sup>58</sup>

#### Other Recommended Regimens

- Ramucirumab (category 1)<sup>59</sup>
- Irinotecan and cisplatin<sup>24,60</sup>
- Fluorouracil and irinotecan + ramucirumab<sup>a,g,61</sup>
- Irinotecan and ramucirumab<sup>62</sup>
- Docetaxel and irinotecan (category 2B)<sup>63</sup>

#### Useful in Certain Circumstances

- Entrectinib, larotrectinib, or repotrectinib<sup>i</sup> for *NTRK* gene fusion-positive tumors<sup>47-49</sup>
- Pembrolizumab<sup>c,f</sup> for MSI-H/dMMR tumors<sup>64-66</sup>
- Nivolumab and ipilimumab<sup>c,f</sup> for MSI-H/dMMR tumors<sup>18</sup>
- Pembrolizumab<sup>c,f</sup> for TMB-high (TMB-H) ( $\geq 10$  mutations/megabase) tumors<sup>67</sup>
- Dostarlimab-gxly<sup>c,f,j</sup> for MSI-H/dMMR tumors<sup>32</sup>
- Dabrafenib and trametinib for *BRAF* V600E-mutated tumors<sup>68</sup>
- Selpercatinib for *RET* gene fusion-positive tumors<sup>69</sup>

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see [Discussion](#).

<sup>c</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

<sup>f</sup> If no prior checkpoint inhibitor therapy or no tumor progression while on therapy with a checkpoint inhibitor.

<sup>g</sup> Capecitabine may not be used interchangeably with fluorouracil in regimens containing irinotecan.

<sup>i</sup> Repotrectinib can be used in patients whose disease progressed on a prior *NTRK*-targeted therapy.

<sup>j</sup> For patients whose cancer is progressing on or following prior treatment (that did not include a checkpoint inhibitor like PD-1i, PD-L1i, or CTLA4i) and who have no satisfactory alternative treatment options. Prior use of immuno-oncology therapy in these patients will make them ineligible for dostarlimab-gxly.

[Continued](#)  
[References](#)

**Note:** All recommendations are category 2A unless otherwise indicated.

**GAST-F**  
**5 OF 20**



## PRINCIPLES OF SYSTEMIC THERAPY—REGIMENS AND DOSING SCHEDULES<sup>k</sup>

### PERIOPERATIVE SYSTEMIC THERAPY

#### PREFERRED REGIMENS

Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT)<sup>a</sup>

(4 cycles preoperative and 4 cycles postoperative)

Fluorouracil 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours on Day 1

Leucovorin 200 mg/m<sup>2</sup> IV on Day 1

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1

Docetaxel 50 mg/m<sup>2</sup> IV on Day 1

Cycled every 14 days<sup>1</sup>

FLOT + durvalumab<sup>a,c,d</sup>

Durvalumab 1500 mg IV on Day 1

Fluorouracil 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours on Day 1 and 15

Leucovorin 200 mg/m<sup>2</sup> IV on Day 1 and 15

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1 and 15

Docetaxel 50 mg/m<sup>2</sup> IV on Day 1 and 15

Cycled every 28 days

(2 cycles preoperative and 2 cycles postoperative, 4 cycles total)

followed by Durvalumab 1500 mg IV on Day 1 every 4 weeks for 10 additional cycles\*

#### PREFERRED REGIMENS

Fluoropyrimidine and oxaliplatin<sup>a</sup>  
(4 cycles preoperative and 4 cycles postoperative)

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1

Leucovorin 400 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1

Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1 and 2

Cycled every 14 days<sup>24</sup>

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1

Leucovorin 200 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours on Day 1

Cycled every 14 days<sup>23</sup>

Capecitabine 1000 mg/m<sup>2</sup> PO BID on Days 1–14

Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1

Cycled every 21 days<sup>25</sup>

#### OTHER RECOMMENDED REGIMENS

Fluorouracil and cisplatin  
(4 cycles preoperative and 4 cycles postoperative)

Fluorouracil 2000 mg/m<sup>2</sup> IV continuous infusion over 48 hours on Days 1–2

Cisplatin 50 mg/m<sup>2</sup> IV on Day 1

Cycled every 14 days

### NEOADJUVANT OR PERIOPERATIVE IMMUNOTHERAPY

#### USEFUL IN CERTAIN CIRCUMSTANCES (MSI-H/dMMR tumors)

Nivolumab and ipilimumab followed by nivolumab<sup>c</sup>

Nivolumab 240 mg IV every 2 weeks,  
Ipilimumab 1 mg/kg IV every 6 weeks  
(preoperative for at least 12 total weeks),  
followed by surgery and  
adjuvant nivolumab 480 mg IV every 4 weeks for 9 cycles<sup>3</sup>

#### Pembrolizumab<sup>c</sup>

Pembrolizumab 200 mg IV every 3 weeks for at least 12 total weeks  
followed by surgery and adjuvant pembrolizumab 200 mg IV  
every 3 weeks x 16 cycles<sup>4,5</sup>

#### Tremelimumab and durvalumab (for neoadjuvant therapy only)<sup>c</sup>

Tremelimumab 300 mg IV on Day 1  
Durvalumab 1500 mg IV on Days 1, 29, and 57  
for 12 weeks preoperatively for 1 cycle only<sup>6,7</sup>

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see [Discussion](#).

<sup>c</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

<sup>d</sup> In the MATTERHORN trial, diffuse type gastric or EGJ adenocarcinoma showed no EFS advantage when durvalumab was added to FLOT.

<sup>k</sup> Systemic therapy regimen and dosing schedules are based on extrapolations from published literature and clinical practice.

Note: All recommendations are category 2A unless otherwise indicated.

Continued  
References

GAST-F  
6 OF 20

# NCCN Guidelines Version 3.2025

## Gastric Cancer

[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)

### PRINCIPLES OF SYSTEMIC THERAPY—REGIMENS AND DOSING SCHEDULES<sup>k</sup>

#### POSTOPERATIVE CHEMORADIATION

(for patients who received less than a D2 lymph node dissection)

THE PANEL ACKNOWLEDGES THAT THE INTERGROUP 0116 TRIAL<sup>8,70</sup> FORMED THE BASIS FOR POSTOPERATIVE ADJUVANT CHEMORADIATION STRATEGY. HOWEVER, THE PANEL DOES NOT RECOMMEND THE DOSES AND SCHEDULE OF CYTOTOXIC AGENTS SPECIFIED IN THIS TRIAL DUE TO CONCERNs REGARDING TOXICITY. THE PANEL RECOMMENDS ONE OF THE FOLLOWING MODIFICATIONS INSTEAD:

#### Fluorouracil<sup>a</sup>

2 cycles before and 4 cycles after chemoradiation. For cycles after chemoradiation, begin chemotherapy 1 month after chemoradiation.

Leucovorin 400 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1

Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion

over 24 hours daily on Days 1 and 2

Cycled every 14 days

#### With radiation

Fluorouracil 200–250 mg/m<sup>2</sup> IV continuous infusion

over 24 hours daily on Days 1–5

Weekly for 5 weeks<sup>71</sup>

#### Capecitabine

1 cycle before and 2 cycles after chemoradiation.

For cycles after chemoradiation,

begin chemotherapy 1 month after chemoradiation.

Capecitabine 750–1000 mg/m<sup>2</sup> PO BID on Days 1–14

Cycled every 21 days<sup>72</sup>

#### With radiation

Capecitabine 625–825 mg/m<sup>2</sup> PO BID on Days 1–5

Weekly for 5 weeks<sup>73</sup>

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see [Discussion](#).

<sup>k</sup> Systemic therapy regimen and dosing schedules are based on extrapolations from published literature and clinical practice.

**Continued  
References**

**Note:** All recommendations are category 2A unless otherwise indicated.



## PRINCIPLES OF SYSTEMIC THERAPY—REGIMENS AND DOSING SCHEDULES<sup>k</sup>

### **CHEMORADIATION FOR UNRESECTABLE DISEASE**

(Infusional fluorouracil<sup>a</sup> can be replaced with capecitabine)

#### **PREFERRED REGIMENS**

##### **Fluorouracil and oxaliplatin<sup>a</sup>**

Oxaliplatin 85 mg/m<sup>2</sup> IV

on Days 1, 15, and 29 for 3 doses

Fluorouracil 180 mg/m<sup>2</sup> IV daily on Days 1–33<sup>11</sup>

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1

Leucovorin 400 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1

Fluorouracil 800 mg/m<sup>2</sup> IV continuous infusion

over 24 hours daily on Days 1 and 2

Cycled every 14 days for 3 cycles with radiation

followed by 3 cycles without radiation<sup>10</sup>

##### **Capecitabine and oxaliplatin**

Oxaliplatin 85 mg/m<sup>2</sup> IV on Days 1, 15, and 29 for 3 doses

Capecitabine 625 mg/m<sup>2</sup> PO BID

on Days 1–5 weekly for 5 weeks<sup>74</sup>

##### **Fluorouracil and cisplatin**

Cisplatin 75–100 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 750–1000 mg/m<sup>2</sup> IV continuous infusion

over 24 hours daily on Days 1–4

Cycled every 28 days for 2 cycles with radiation

followed by 2 cycles without radiation<sup>75</sup>

##### **Capecitabine and cisplatin**

Cisplatin 30 mg/m<sup>2</sup> IV on Day 1

Capecitabine 800 mg/m<sup>2</sup> PO BID on Days 1–5

Weekly for 5 weeks<sup>76</sup>

### **OTHER RECOMMENDED REGIMENS**

##### **Paclitaxel and fluoropyrimidine**

Paclitaxel 45–50 mg/m<sup>2</sup> IV on Day 1 weekly

Fluorouracil 300 mg/m<sup>2</sup> IV continuous infusion daily  
on Days 1–5

Weekly for 5 weeks<sup>14</sup>

Paclitaxel 45–50 mg/m<sup>2</sup> IV on Day 1

Capecitabine 625–825 mg/m<sup>2</sup> PO BID

on Days 1–5

Weekly for 5 weeks<sup>14</sup>

Note: All recommendations are category 2A unless otherwise indicated.

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see [Discussion](#).

<sup>k</sup> Systemic therapy regimen and dosing schedules are based on extrapolations from published literature and clinical practice.



**PRINCIPLES OF SYSTEMIC THERAPY—REGIMENS AND DOSING SCHEDULES<sup>k</sup>**  
**SYSTEMIC THERAPY FOR METASTATIC OR LOCALLY ADVANCED CANCER (WHERE LOCAL THERAPY IS NOT INDICATED)**

**FIRST-LINE THERAPY**

**HER2 overexpression-positive**

**Trastuzumab with chemotherapy**

(See [GAST-F \[4 of 20\]](#) for list of regimens)

Trastuzumab 8 mg/kg IV loading dose

on Day 1 of cycle 1, then

Trastuzumab 6 mg/kg IV every 21 days<sup>17</sup>

or

Trastuzumab 6 mg/kg IV loading dose on

Day 1 of cycle 1, then 4 mg/kg IV every 14 days

**PREFERRED REGIMENS**

**Fluoropyrimidine and oxaliplatin<sup>a</sup>**

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1

Leucovorin 400 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1

Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion

over 24 hours daily on Days 1 and 2

Cycled every 14 days<sup>24</sup>

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1

Leucovorin 200 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 2600 mg/m<sup>2</sup> IV continuous infusion

over 24 hours on Day 1<sup>23</sup>

Cycled every 14 days<sup>23</sup>

Capecitabine 850–1000 mg/m<sup>2</sup>

PO BID on Days 1–14

Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1

Cycled every 21 days<sup>25</sup>

Capecitabine 625 mg/m<sup>2</sup> PO BID on Days 1–14<sup>l,m</sup>

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1

Cycled every 21 days<sup>77</sup>

**PREFERRED REGIMENS—continued**

**Fluoropyrimidine and cisplatin<sup>a</sup>**

Cisplatin 75–100 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 750–1000 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1–4

Cycled every 28 days<sup>26</sup>

Cisplatin 50 mg/m<sup>2</sup> IV daily on Day 1

Leucovorin 200 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 2000 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Day 1

Cycled every 14 days<sup>23,27</sup>

Cisplatin 80 mg/m<sup>2</sup> IV daily on Day 1

Capecitabine 850–1000 mg/m<sup>2</sup>

PO BID on Days 1–14

Cycled every 21 days<sup>28</sup>

**PREFERRED REGIMENS—continued**

**Fluoropyrimidine (fluorouracil or capecitabine), oxaliplatin, and nivolumab<sup>a,c</sup>**

Nivolumab 360 mg IV on Day 1

(per study maximum of 2 years)

Capecitabine 850–1000 mg/m<sup>2</sup>

PO BID Days 1–14

Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1

Cycled every 21 days<sup>18</sup>

Nivolumab 240 mg IV on Day 1

(per study maximum of 2 years)

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1

Leucovorin 400 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1

Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1 and 2

Cycled every 14 days<sup>18</sup>

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see [Discussion](#).

<sup>c</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

<sup>k</sup> Systemic therapy regimen and dosing schedules are based on extrapolations from published literature and clinical practice.

<sup>l</sup> Based on consensus opinion, the Panel revised the doses and schedule studied in level C of the GO2 trial.

<sup>m</sup> This regimen is recommended for patients who are frail and/or older. [Continued References](#)

Note: All recommendations are category 2A unless otherwise indicated.

# NCCN Guidelines Version 3.2025

## Gastric Cancer

[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)

### PRINCIPLES OF SYSTEMIC THERAPY—REGIMENS AND DOSING SCHEDULES<sup>k</sup> SYSTEMIC THERAPY FOR METASTATIC OR LOCALLY ADVANCED CANCER (WHERE LOCAL THERAPY IS NOT INDICATED)

#### FIRST-LINE THERAPY—continued

##### PREFERRED REGIMENS—continued

Trastuzumab and pembrolizumab<sup>c</sup> with fluoropyrimidine and oxaliplatin or cisplatin (only for HER2 overexpression-positive adenocarcinoma)

Trastuzumab 8 mg/kg IV loading dose on Day 1 of cycle 1, then

Trastuzumab 6 mg/kg IV every 21 days<sup>16,17</sup> or

Trastuzumab 6 mg/kg IV loading dose on Day 1 of cycle 1, then 4 mg/kg IV every 14 days

Pembrolizumab 200 mg IV on Day 1

Cycled every 3 weeks

or

Pembrolizumab 400 mg IV on Day 1

Cycled every 6 weeks<sup>15,16</sup>

##### PREFERRED REGIMENS—continued

Fluoropyrimidine and oxaliplatin<sup>a</sup>

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1

Leucovorin 400 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1

Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1 and 2

Cycled every 14 days<sup>24</sup>

Capecitabine 850–1000 mg/m<sup>2</sup>

PO BID on Days 1–14

Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1

Cycled every 21 days<sup>25</sup>

##### PREFERRED REGIMENS—continued

Fluoropyrimidine and cisplatin

Cisplatin 80 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 800 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1–5

Cycled every 21 days<sup>15</sup>

Cisplatin 80 mg/m<sup>2</sup> IV daily on Day 1

Capecitabine 850–1000 mg/m<sup>2</sup> PO BID on Days 1–14

Cycled every 21 days<sup>28</sup>

**Note:** All recommendations are category 2A unless otherwise indicated.

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see [Discussion](#).

<sup>c</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

<sup>k</sup> Systemic therapy regimen and dosing schedules are based on extrapolations from published literature and clinical practice.

**Continued  
References**

# NCCN Guidelines Version 3.2025

## Gastric Cancer

[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)

### PRINCIPLES OF SYSTEMIC THERAPY—REGIMENS AND DOSING SCHEDULES<sup>k</sup> **SYSTEMIC THERAPY FOR METASTATIC OR LOCALLY ADVANCED CANCER (WHERE LOCAL THERAPY IS NOT INDICATED)**

#### FIRST-LINE THERAPY—continued

##### PREFERRED REGIMENS—continued

###### HER2 Overexpression Negative

Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and pembrolizumab<sup>c,f</sup>

Pembrolizumab 200 mg IV

every 21 days for up to 2 years

Capecitabine 850–1000 mg/m<sup>2</sup> PO BID Days 1–14

Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1

Cycled every 21 days for up to 6 cycles (total 18 weeks)<sup>19</sup>

Pembrolizumab 200 mg IV

every 21 days for up to 2 years

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1

Leucovorin 400 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1

Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion

over 24 hours daily on Days 1 and 2

Cycled every 14 days for up to 9 cycles

(total 18 weeks)<sup>19</sup>

#### FIRST-LINE THERAPY—continued

##### PREFERRED REGIMENS—continued

###### HER2 Overexpression Negative

Fluoropyrimidine (fluorouracil or capecitabine), cisplatin, and pembrolizumab<sup>c,f</sup>

Pembrolizumab 200 mg IV

every 21 days for up to 2 years

Cisplatin 80 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 800 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1–5

Cycled every 21 days for up to 6 cycles<sup>19</sup>

Pembrolizumab 200 mg IV

every 21 days for up to 2 years

Cisplatin 80 mg/m<sup>2</sup> IV on Day 1

Capecitabine 850–1000 mg/m<sup>2</sup> PO twice daily on Days 1–14

Cycled every 21 days for up to 6 cycles (total of 18 weeks)<sup>19</sup>

#### FIRST-LINE THERAPY—continued

##### PREFERRED REGIMENS—continued

###### HER2 Overexpression Negative, CLDN18.2 Positive

Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and zolbetuximab-clzb

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1

(per study maximum of 12 doses)

Leucovorin 400 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1

Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1 and 2

Zolbetuximab-clzb 800 mg/m<sup>2</sup> IV (first-dose only) on Day 1 (subsequent doses 400 mg/m<sup>2</sup>)

Cycled every 14 days<sup>21</sup>

Capecitabine 850–1000 mg/m<sup>2</sup> PO BID on Days 1–14

Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1 (per study maximum of 8 doses)

Zolbetuximab-clzb 800 mg/m<sup>2</sup> IV (first-dose only) on Day 1 (subsequent doses 600 mg/m<sup>2</sup>)

Cycled every 21 days<sup>22</sup>

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see [Discussion](#).

<sup>c</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

<sup>f</sup> If no prior checkpoint inhibitor therapy or no tumor progression while on therapy with a checkpoint inhibitor.

<sup>k</sup> Systemic therapy regimen and dosing schedules are based on extrapolations from published literature and clinical practice.

**Continued  
References**

**Note:** All recommendations are category 2A unless otherwise indicated.

**GAST-F  
11 OF 20**



**PRINCIPLES OF SYSTEMIC THERAPY—REGIMENS AND DOSING SCHEDULES<sup>k</sup>**  
**SYSTEMIC THERAPY FOR METASTATIC OR LOCALLY ADVANCED CANCER (WHERE LOCAL THERAPY IS NOT INDICATED)**

**FIRST-LINE THERAPY**

**PREFERRED REGIMENS**

Tislelizumab-jsgc<sup>c,f</sup> with fluoropyrimidine and oxaliplatin or cisplatin

(see [GAST-F \[4 of 20 and 5 of 20\]](#) for list of regimens)

Tislelizumab 200 mg IV on Day 1 every 21 days<sup>20</sup>

in combination with:

Fluoropyrimidine and oxaliplatin<sup>a</sup>

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1

Leucovorin 200 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion

over 24 hours daily on Days 1 and 2

Cycled every 14 days for 12 cycles<sup>20</sup>

Capecitabine 850–1000 mg/m<sup>2</sup> PO BID on Days 1–14

Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1 (per study maximum of 6 doses)

Cycled every 21 days<sup>20</sup>

**PREFERRED REGIMENS—continued**

Fluoropyrimidine and cisplatin

Cisplatin 60–80 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 750–800 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1–5

Cycled every 21 days for 6 cycles<sup>20</sup>

Cisplatin 60–80 mg/m<sup>2</sup> IV on Day 1 (per study maximum of 6 doses)

Capecitabine 850–1000 mg/m<sup>2</sup>

PO BID on Days 1–14

Cycled every 21 days<sup>20</sup>

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see [Discussion](#).

<sup>c</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

<sup>f</sup> If no prior checkpoint inhibitor therapy or no tumor progression while on therapy with a checkpoint inhibitor.

<sup>k</sup> Systemic therapy regimen and dosing schedules are based on extrapolations from published literature and clinical practice.

**Continued  
References**

**Note: All recommendations are category 2A unless otherwise indicated.**

**GAST-F  
12 OF 20**



### PRINCIPLES OF SYSTEMIC THERAPY—REGIMENS AND DOSING SCHEDULES<sup>k</sup>

#### SYSTEMIC THERAPY FOR METASTATIC OR LOCALLY ADVANCED CANCER (WHERE LOCAL THERAPY IS NOT INDICATED)

##### FIRST-LINE THERAPY—continued

##### PREFERRED REGIMENS—continued

##### MSI-H/dMMR tumors

##### (independent of PD-L1 status)

##### Pembrolizumab<sup>c,f</sup>

Pembrolizumab 200 mg IV on Day 1

Cycled every 21 days (up to 2 years)<sup>29</sup>

or

Pembrolizumab 400 mg IV on Day 1

Cycled every 6 weeks (up to 2 years)<sup>30,78</sup>

##### Dostarlimab-gxly<sup>c,f</sup>

Dostarlimab-gxly 500 mg IV every 3 weeks for 4 doses

followed by 1000 mg IV every 6 weeks<sup>32</sup>

##### Nivolumab and ipilimumab<sup>c,f</sup>

Nivolumab 1 mg/kg IV on Day 1

Ipilimumab 3 mg/kg IV on Day 1

Cycled every 21 days for 4 cycles

followed by

Nivolumab 240 mg IV every 14 days

(maximum to 2 years)<sup>18</sup>

**THE PANEL ACKNOWLEDGES THAT THE CHECKMATE-649 TRIAL<sup>18</sup> FORMED THE BASIS FOR FIRST-LINE THERAPY STRATEGY FOR METASTATIC OR LOCALLY ADVANCED CANCER. HOWEVER, THE PANEL DOES NOT RECOMMEND THE DOSES AND SCHEDULE OF AGENTS SPECIFIED IN THIS TRIAL DUE TO CONCERNs REGARDING TOXICITY. THE PANEL RECOMMENDS THE FOLLOWING MODIFICATIONS INSTEAD:**

##### Nivolumab and ipilimumab<sup>c,f</sup>

Nivolumab 240 mg IV every 2 weeks

Ipilimumab 1 mg/kg IV every 6 weeks

For 16 weeks, followed by

Nivolumab 240 mg IV every 2 weeks or

Nivolumab 480 mg IV every 4 weeks

(maximum of 2 years)

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see [Discussion](#).

<sup>c</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

##### FIRST-LINE THERAPY—continued

##### PREFERRED REGIMENS—continued

##### MSI-H/dMMR tumors

##### (independent of PD-L1 status)

##### Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and nivolumab<sup>c,f</sup>

Nivolumab 360 mg IV on Day 1

(per study maximum of 2 years)

Capecitabine 850–1000 mg/m<sup>2</sup>

PO BID Days 1–14

Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1

Cycled every 21 days<sup>18</sup>

Nivolumab 240 mg IV on Day 1

(per study maximum of 2 years)

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1

Leucovorin 400 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1

Fluorouracil 1200 mg/m<sup>2</sup> IV continuous

infusion over 24 hours daily on Days 1 and 2

Cycled every 14 days<sup>18</sup>

##### FIRST-LINE THERAPY—continued

##### PREFERRED REGIMENS—continued

##### MSI-H/dMMR tumors

##### (independent of PD-L1 status)

##### Fluoropyrimidine (fluorouracil<sup>a</sup> or capecitabine), oxaliplatin, and pembrolizumab<sup>c,f</sup>

Pembrolizumab 200 mg IV

every 21 days for up to 2 years

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1

Leucovorin 400 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1

Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion

over 24 hours daily on Days 1 and 2

Cycled every 14 days for up to 9 cycles

(total 18 weeks)<sup>30</sup>

Note: All recommendations are category 2A unless otherwise indicated.

<sup>f</sup> If no prior checkpoint inhibitor therapy or no tumor progression while on therapy with a checkpoint inhibitor.

<sup>k</sup> Systemic therapy regimen and dosing schedules are based on extrapolations from published literature and clinical practice.

**Continued References**

# NCCN Guidelines Version 3.2025

## Gastric Cancer

[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)

### PRINCIPLES OF SYSTEMIC THERAPY—REGIMENS AND DOSING SCHEDULES<sup>k</sup> SYSTEMIC THERAPY FOR METASTATIC OR LOCALLY ADVANCED CANCER (WHERE LOCAL THERAPY IS NOT INDICATED)

#### FIRST-LINE THERAPY—continued

#### OTHER RECOMMENDED REGIMENS

##### Fluorouracil and irinotecan<sup>a</sup>

Irinotecan 180 mg/m<sup>2</sup> IV on Day 1

Leucovorin 400 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1

Fluorouracil 1200 mg/m<sup>2</sup> IV continuous

infusion over 24 hours daily on Days 1 and 2

Cycled every 14 days<sup>33</sup>

##### Paclitaxel with or without carboplatin or cisplatin

Paclitaxel 200 mg/m<sup>2</sup> IV on Day 1

Carboplatin AUC 5 IV on Day 1

Cycled every 21 days<sup>36</sup>

Paclitaxel 135–200 mg/m<sup>2</sup> IV on Day 1

Cisplatin 75 mg/m<sup>2</sup> IV on Day 1

Cycled every 21 days<sup>34</sup>

Paclitaxel 90 mg/m<sup>2</sup> IV on Day 1

Cisplatin 50 mg/m<sup>2</sup> IV on Day 1

Cycled every 14 days<sup>35</sup>

Paclitaxel 135–250 mg/m<sup>2</sup> IV on Day 1

Cycled every 21 days<sup>38</sup>

Paclitaxel 80 mg/m<sup>2</sup> IV weekly

Cycled every 28 days<sup>37</sup>

#### OTHER RECOMMENDED REGIMENS—continued

##### Docetaxel with or without cisplatin

Docetaxel 70–85 mg/m<sup>2</sup> IV on Day 1

Cisplatin 70–75 mg/m<sup>2</sup> IV on Day 1

Cycled every 21 days<sup>39,40</sup>

Docetaxel 75–100 mg/m<sup>2</sup> IV on Day 1

Cycled every 21 days<sup>41,42</sup>

##### Fluoropyrimidine<sup>a</sup>

Leucovorin 400 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1

Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion

over 24 hours daily on Days 1 and 2

Cycled every 14 days<sup>27</sup>

Fluorouracil 800 mg/m<sup>2</sup> IV continuous infusion

over 24 hours daily on Days 1–5

Cycled every 28 days<sup>43</sup>

Capecitabine 850–1000 mg/m<sup>2</sup>

PO BID on Days 1–14

Cycled every 21 days<sup>44</sup>

#### OTHER RECOMMENDED REGIMENS—continued

##### Docetaxel, cisplatin or oxaliplatin, and

##### fluorouracil<sup>a</sup>

Docetaxel 40 mg/m<sup>2</sup> IV on Day 1

Leucovorin 400 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 400 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 1000 mg/m<sup>2</sup> IV continuous infusion

over 24 hours daily on Days 1 and 2

Cisplatin 40 mg/m<sup>2</sup> IV on Day 3

Cycled every 14 days<sup>45</sup>

Docetaxel 50 mg/m<sup>2</sup> IV on Day 1

Oxaliplatin 85 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion

over 24 hours daily on Days 1 and 2

Cycled every 14 days<sup>46</sup>

#### USEFUL IN CERTAIN CIRCUMSTANCES

##### Entrectinib, larotrectinib, or repotrectinib

(For NTRK gene fusion-positive tumors)

Entrectinib 600 mg PO once daily<sup>47</sup>

Larotrectinib 100 mg PO twice daily<sup>48</sup>

##### Repotrectinib<sup>49</sup>

160 mg PO Daily Days 1–14 of cycle 1

160 mg PO BID Days 15–28 of cycle 1

160 mg PO BID Days 1–28 of cycle 2 and beyond

Cycled every 28 days

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see [Discussion](#).

<sup>k</sup> Systemic therapy regimen and dosing schedules are based on extrapolations from published literature and clinical practice.

Note: All recommendations are category 2A unless otherwise indicated.

[Continued References](#)

GAST-F

14 OF 20



**PRINCIPLES OF SYSTEMIC THERAPY—REGIMENS AND DOSING SCHEDULES<sup>k</sup>**  
**SYSTEMIC THERAPY FOR METASTATIC OR LOCALLY ADVANCED CANCER (WHERE LOCAL THERAPY IS NOT INDICATED)**

**SECOND-LINE AND SUBSEQUENT THERAPY**

**PREFERRED REGIMENS**

**Ramucirumab and paclitaxel**

Ramucirumab 8 mg/kg IV on Days 1 and 15

Paclitaxel 80 mg/m<sup>2</sup> IV on Days 1, 8, and 15

Cycled every 28 days<sup>50</sup>

**Fam-trastuzumab deruxtecan-nxki**

**(for HER2 overexpression-positive**

**adenocarcinoma)**

6.4 mg/kg IV on Day 1

cycled every 21 days<sup>n,51</sup>

**Taxane**

**Docetaxel 75–100 mg/m<sup>2</sup> IV on Day 1**

Cycled every 21 days<sup>41,42</sup>

**Paclitaxel 135–250 mg/m<sup>2</sup> IV on Day 1**

Cycled every 21 days<sup>38</sup>

**Paclitaxel 80 mg/m<sup>2</sup> IV weekly**

Cycled every 28 days<sup>37</sup>

**Paclitaxel 80 mg/m<sup>2</sup> IV on Days 1, 8, and 15**

Cycled every 28 days<sup>52</sup>

**PREFERRED REGIMENS—continued**

**Irinotecan**

Irinotecan 150–180 mg/m<sup>2</sup> IV on Day 1

Cycled every 14 days<sup>52,53</sup>

Irinotecan 125 mg/m<sup>2</sup> IV on Days 1 and 8

Cycled every 21 days<sup>55</sup>

Irinotecan 250–350 mg/m<sup>2</sup> IV on Day 1

Cycled every 21 days<sup>54</sup>

**Fluorouracil and irinotecan<sup>a</sup>**

Irinotecan 180 mg/m<sup>2</sup> IV on Day 1

Leucovorin 400 mg/m<sup>2</sup> IV on Day 1

Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1

Fluorouracil 1200 mg/m<sup>2</sup> IV continuous

infusion over 24 hours daily on Days 1 and 2

Cycled every 14 days<sup>53</sup>

**Trifluridine and tipiracil**

Trifluridine and tipiracil 35 mg/m<sup>2</sup> up to a

maximum dose of 80 mg per dose

(based on the trifluridine component)

PO twice daily on Days 1–5 and 8–12

Repeat every 28 days<sup>58</sup>

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin.

For important information regarding the leucovorin shortage, please see [Discussion](#).

<sup>k</sup> Systemic therapy regimen and dosing schedules are based on extrapolations from published literature and clinical practice.

<sup>n</sup> Fam-trastuzumab deruxtecan-nxki is approved for metastatic HER2-positive breast cancer at a different dose of 5.4 mg/kg IV on Day 1, cycled every 21 days.

**Continued  
References**

**GAST-F**

**15 OF 20**

**Note:** All recommendations are category 2A unless otherwise indicated.



### PRINCIPLES OF SYSTEMIC THERAPY—REGIMENS AND DOSING SCHEDULES<sup>k</sup>

#### SYSTEMIC THERAPY FOR METASTATIC OR LOCALLY ADVANCED CANCER (WHERE LOCAL THERAPY IS NOT INDICATED)

##### SECOND-LINE AND SUBSEQUENT THERAPY

###### OTHER RECOMMENDED REGIMENS

###### Ramucirumab

Ramucirumab 8 mg/kg IV on Day 1  
Cycled every 14 days<sup>59</sup>

###### Irinotecan and cisplatin

Irinotecan 65 mg/m<sup>2</sup> IV on Days 1 and 8  
Cisplatin 25–30 mg/m<sup>2</sup> IV on Days 1 and 8  
Cycled every 21 days<sup>24,60</sup>

###### Fluorouracil and irinotecan + ramucirumab<sup>a</sup>

Ramucirumab 8 mg/kg IV on Day 1  
Irinotecan 180 mg/m<sup>2</sup> IV on Day 1  
Leucovorin 400 mg/m<sup>2</sup> IV on Day 1  
Fluorouracil 400 mg/m<sup>2</sup> IV Push on Day 1  
Fluorouracil 1200 mg/m<sup>2</sup> IV continuous infusion over 24 hours daily on Days 1 and 2  
Cycled every 14 days<sup>79</sup>

###### Irinotecan and ramucirumab

Irinotecan 150 mg/m<sup>2</sup> IV on Day 1  
Ramucirumab 8 mg/kg IV on Day 1  
Cycled every 14 days<sup>62</sup>

###### Docetaxel and irinotecan

Docetaxel 35 mg/m<sup>2</sup> IV on Days 1 and 8  
Irinotecan 50 mg/m<sup>2</sup> IV on Days 1 and 8  
Cycled every 21 days<sup>63</sup>

###### USEFUL IN CERTAIN CIRCUMSTANCES

Entrectinib, larotrectinib, or repotrectinib  
(for *NTRK* gene fusion-positive tumors)  
Entrectinib 600 mg PO once daily<sup>47</sup>

Larotrectinib 100 mg PO twice daily<sup>48</sup>

###### Repotrectinib<sup>i,49</sup>

160 mg PO daily Days 1–14 of cycle 1  
160 mg PO BID Days 15–28 of cycle 1  
160 mg PO BID Days 1–28 of cycle 2 and beyond  
Cycled every 28 days

###### Pembrolizumab<sup>c,f</sup>

(for MSI-H/dMMR tumors or TMB-H [≥10 mutations/megabase] tumors)  
Pembrolizumab 200 mg IV on Day 1<sup>29</sup>  
Cycled every 21 days

Pembrolizumab 400 mg IV on Day 1  
Cycled every 6 weeks<sup>78</sup>

###### Nivolumab and ipilimumab<sup>c,f</sup>

(for MSI-H/dMMR tumors)  
Nivolumab 1 mg/kg IV on Day 1  
Ipilimumab 3 mg/kg IV on Day 1  
Cycled every 21 days for 4 cycles  
followed by  
Nivolumab 240 mg IV every 14 days  
(maximum to 2 years)<sup>18</sup>

THE PANEL ACKNOWLEDGES THAT THE CHECKMATE-649<sup>18</sup> FORMED THE BASIS FOR THERAPEUTIC STRATEGY FOR METASTATIC OR LOCALLY ADVANCED CANCER. HOWEVER, THE PANEL DOES NOT RECOMMEND THE DOSES AND SCHEDULE OF AGENTS SPECIFIED IN THIS TRIAL DUE TO CONCERN REGARDING TOXICITY. THE PANEL RECOMMENDS THE FOLLOWING MODIFICATIONS INSTEAD:

Nivolumab and ipilimumab<sup>c,f</sup>  
Nivolumab 240 mg IV every 2 weeks  
Ipilimumab 1 mg/kg IV every 6 weeks  
For 16 weeks, followed by  
Nivolumab 240 mg IV every 2 weeks or Nivolumab 480 mg IV every 4 weeks  
(maximum to 2 years)

###### USEFUL IN CERTAIN CIRCUMSTANCES-continued

Dostarlimab-gxly<sup>c,f,j</sup>  
(for MSI-H/dMMR tumors)  
Dostarlimab-gxly 500 mg IV every 3 weeks for 4 doses followed by 1000 mg IV every 6 weeks<sup>32</sup>

Dabrafenib and trametinib  
(for *BRAF* V600E-mutated tumors)

Dabrafenib 150 mg PO twice daily  
Trametinib 2 mg PO daily<sup>68</sup>

Selpercatinib  
(for *RET* gene fusion-positive tumors)

Selpercatinib  
Patients ≥50 kg: 160 mg PO twice daily  
Patients <50 kg: 120 mg PO twice daily<sup>69</sup>

### Footnotes on GAST-F (16A of 20)

Note: All recommendations are category 2A unless otherwise indicated.

### References

**GAST-F  
16 OF 20**



### **FOOTNOTES FOR GAST-F 16 OF 20**

<sup>a</sup> Leucovorin is indicated with certain fluorouracil-based regimens. Depending on availability, these regimens may be used with or without leucovorin. For important information regarding the leucovorin shortage, please see [Discussion](#).

<sup>c</sup> [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

<sup>f</sup> If no prior checkpoint inhibitor therapy or no tumor progression while on therapy with a checkpoint inhibitor.

<sup>i</sup> Repotrectinib can be used in patients whose disease progressed on a prior *NTRK*-targeted therapy.

<sup>j</sup> For patients whose cancer is progressing on or following prior treatment (that did not include a checkpoint inhibitor like PD-1i, PD-L1i, or CTLA4i) and who have no satisfactory alternative treatment options. Prior use of immuno-oncology therapy in these patients will make them ineligible for dostarlimab-gxly.

<sup>k</sup> Systemic therapy regimen and dosing schedules are based on extrapolations from published literature and clinical practice.

### **References**

**Note: All recommendations are category 2A unless otherwise indicated.**

**GAST-F  
16A OF 20**

# NCCN Guidelines Version 3.2025

## Gastric Cancer

[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)

- \* Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. *N Engl J Med* 2025;393:217-230.
- <sup>1</sup> Al-Batran S-E, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. *Lancet* 2019;393:1948-1957.
- <sup>2</sup> Ychou M, Boige V, Pignon J-P, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. *J Clin Oncol* 2011;29:1715-1721.
- <sup>3</sup> Andre T, Tougeron D, Piessen G, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: The GERCOR NEONIPIGA phase II study. *J Clin Oncol* 2023;41:255-265.
- <sup>4</sup> Ludford K, Ho WJ, Thomas JV, et al. Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors. *J Clin Oncol* 2023;41:2181-2190.
- <sup>5</sup> Liu L, Woo Y, D'Apuzzo M, et al. Immunotherapy-based neoadjuvant treatment of advanced microsatellite instability-high gastric cancer: A case series. *J Natl Compr Canc Netw* 2022;20:857-865.
- <sup>6</sup> Kelly RJ, Lee J, Bang YJ, et al. Safety and efficacy of durvalumab and tremelimumab alone or in combination in patients with advanced gastric and gastroesophageal junction adenocarcinoma. *Clin Cancer Res* 2020;26:846-854.

### PRINCIPLES OF SYSTEMIC THERAPY—REFERENCES

- <sup>7</sup> Pietrantonio F, Raimondi A, Lonardi S, et al. INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC). *Journal of Clinical Oncology* 2023;41:358-358.
- <sup>8</sup> Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed Intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. *J Clin Oncol* 2012;30:2327-2333.
- <sup>9</sup> Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. *Lancet Oncol* 2014;15:1389-1396.
- <sup>10</sup> Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. *Lancet Oncol* 2014;15:305-314.
- <sup>11</sup> Khushalani NI, Leichman CG, Proulx G, et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. *J Clin Oncol* 2002;20:2844-2850.
- <sup>12</sup> Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. *J Clin Oncol* 2008;26:1086-1092.
- <sup>13</sup> Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. *J Clin Oncol* 2007;25:1160-1168.
- <sup>14</sup> Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. *J Clin Oncol* 2006;24:3953-3958.
- <sup>15</sup> Janjigian YY, Kawazoe A, Yanez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. *Nature* 2021;600:727-730.
- <sup>16</sup> Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. *Lancet* 2023;402:2197-2208.
- <sup>17</sup> Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010;376:687-697.
- <sup>18</sup> Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. *Lancet* 2021;398:27-40.
- <sup>19</sup> Rha SY, Oh DY, Yanez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. *Lancet Oncol* 2023;24:1181-1195.
- <sup>20</sup> Qiu MZ, Oh DY, Kato K, et al. RATIONALE-305 Investigators. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. *BMJ* 2024;385:e078876.

Note: All recommendations are category 2A unless otherwise indicated.

**Continued**

**GAST-F**  
**17 OF 20**

# NCCN Guidelines Version 3.2025

## Gastric Cancer

[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)

### PRINCIPLES OF SYSTEMIC THERAPY—REFERENCES

- <sup>21</sup> Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 2023;401:1655-1668.
- <sup>22</sup> Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med 2023;29:2133-2141.
- <sup>23</sup> Al-Batran S-E, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26:1435-1442.
- <sup>24</sup> Enzinger PC, Burtness BA, Niedzwiecki D, et al. CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. J Clin Oncol 2016;34:2736-2742.
- <sup>25</sup> Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer 2012;48:518-526.
- <sup>26</sup> Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009;20:1667-1673.
- <sup>27</sup> Bouche O, Raoul JL, Bonnetaud F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803. J Clin Oncol 2004;22:4319-4328.
- <sup>28</sup> Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666-673.
- <sup>29</sup> Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 2018;4:e180013.
- <sup>30</sup> Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: The KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol 2020;6:1571-1580.
- <sup>31</sup> Chao J, Fuchs CS, Shitara K, et al. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncol 2021;7:895-902.
- <sup>32</sup> Berton D, Banerjee SN, Curigliano G, et al. Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability-high tumors: A combined analysis of two cohorts in the GARNET study. J Clin Oncol 2021;39:2564.
- <sup>33</sup> Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French Intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopératif Multidisciplinaire en Oncologie) study. J Clin Oncol 2014;32:3520-3526.
- <sup>34</sup> Ilson DH, Forastiere A, Arquette M, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 2000;6:316-323.
- <sup>35</sup> Petrasch S, Welt A, Reinacher A, et al. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer 1998;78:511-514.
- <sup>36</sup> Gadgeel SM, Shields AF, Heilbrun LK, et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol 2003;26:37-41.
- <sup>37</sup> Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol 2007;18:898-902.
- <sup>38</sup> Ajani JA, Ilson DH, Daugherty K, et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994;86:1086-1091.
- <sup>39</sup> Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 2005;23:5660-5667.

[Continued](#)

Note: All recommendations are category 2A unless otherwise indicated.

**GAST-F**  
**18 OF 20**



### PRINCIPLES OF SYSTEMIC THERAPY—REFERENCES

- <sup>40</sup> Kim JY, Do YR, Park KU, et al. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. *Cancer Chemother Pharmacol* 2010;66:31-36.
- <sup>41</sup> Ford ER, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. *Lancet Oncol* 2014;15:78-86.
- <sup>42</sup> Albertsson M, Johansson B, Friesland S, et al. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. *Med Oncol* 2007;24:407-412.
- <sup>43</sup> Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). *J Clin Oncol* 2003;21:54-59.
- <sup>44</sup> Hong YS, Song SY, Lee SI, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. *Ann Oncol* 2004;15:1344-1347.
- <sup>45</sup> Shah MA, Janjigian YY, Stoller R, et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium. *J Clin Oncol* 2015;33:3874-3879.
- <sup>46</sup> Blum Murphy MA, Qiao W, Mewada N, et al. A phase I/II study of docetaxel, oxaliplatin, and fluorouracil (D-FOX) chemotherapy in patients with untreated locally unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction. *Am J Clin Oncol* 2018;41:321-325.
- <sup>47</sup> Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. *Lancet Oncol* 2020;21:271-282.
- <sup>48</sup> Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. *N Engl J Med* 2018;378:731-739.
- <sup>49</sup> Solomon BJ, Drilon A, Lin JJ, et al. 1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial. *Annals of Oncology* 2023;34:S787-S788.
- <sup>50</sup> Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *Lancet Oncol* 2014;15:1224-1235.
- <sup>51</sup> Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. *N Engl J Med* 2020;382:2419-2430.
- <sup>52</sup> Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. *J Clin Oncol* 2013;31:4438-4444.
- <sup>53</sup> Sym SJ, Hong J, Park J, et al. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. *Cancer Chemother Pharmacol* 2013;71:481-488.
- <sup>54</sup> Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). *Eur J Cancer* 2011;47:2306-2314.
- <sup>55</sup> Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. *J Clin Oncol* 2003;21:807-814.
- <sup>56</sup> Sym SJ, Ryu MH, Lee JL, et al. Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane. *Am J Clin Oncol* 2008;31:151-156.
- <sup>57</sup> Assersohn L, Brown G, Cunningham D, et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. *Ann Oncol* 2004;15:64-69.
- <sup>58</sup> Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2018;19:1437-1448.
- <sup>59</sup> Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet* 2014;383:31-39.
- <sup>60</sup> Ilson DH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. *Oncology (Williston Park)* 2004;18:22-25.

**Continued**

**Note:** All recommendations are category 2A unless otherwise indicated.

**GAST-F**  
**19 OF 20**



## PRINCIPLES OF SYSTEMIC THERAPY—REFERENCES

- <sup>61</sup> Klempner SJ, Maron SB, Chase L, et al. Initial report of second-line FOLFIRI in combination with ramucirumab in advanced gastroesophageal adenocarcinomas: a multi-institutional retrospective analysis. *Oncologist* 2019;24:475-482.
- <sup>62</sup> Sakai D, Boku N, Kodera Y, et al. An intergroup phase III trial of ramucirumab plus irinotecan in third or more line beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial). *J Clin Oncol* 2018;36:TPS4138.
- <sup>63</sup> Burtress B, Gibson M, Egleston B, et al. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. *Ann Oncol* 2009;20:1242-1248.
- <sup>64</sup> Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med* 2015;372:2509-2520.
- <sup>65</sup> Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science* 2017;357:409-413.
- <sup>66</sup> Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. *J Clin Oncol* 2020;38:1-10.
- <sup>67</sup> Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. *Lancet Oncol* 2020;21:1353-1365.
- <sup>68</sup> Salama AKS, Li S, Macrae ER, et al. Dabrafenib and trametinib in patients with tumors with BRAF(V600E) mutations: Results of the NCI-MATCH trial subprotocol H. *J Clin Oncol* 2020;38:3895-3904.
- <sup>69</sup> Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpleratinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. *Lancet Oncol* 2022;23:1261-1273.
- <sup>70</sup> Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001;345:725-730.
- <sup>71</sup> Leong T, Joon DL, Willis D, et al. Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the Trans-Tasman Radiation Oncology Group. *Int J Radiat Oncol Biol Phys* 2011;79:690-695.
- <sup>72</sup> Jansen EP, Boot H, Saunders MP, et al. A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. *Int J Radiat Oncol Biol Phys* 2007;69:1424-1428.
- <sup>73</sup> Lee HS, Choi Y, Hur WJ, et al. Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine. *World J Gastroenterol* 2006;12:603-607.
- <sup>74</sup> Jasle MM, Yang G, Nwogu CE, et al. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. *Cancer Invest* 2009;27:193-200.
- <sup>75</sup> Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. *J Clin Oncol* 2002;20:1167-1174.
- <sup>76</sup> Lee SS, Kim SB, Park SI, et al. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer. *Jpn J Clin Oncol* 2007;37:829-835.
- <sup>77</sup> Hall PS, Swinson D, Waters JS, et al. Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): the GO2 phase III trial. *J Clin Oncol* 2019;37:4006.
- <sup>78</sup> Lala M, Li TR, de Alwis DP, et al. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. *Eur J Cancer* 2020;131:68-75.
- <sup>79</sup> Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. *Lancet Oncol* 2015;16:499-508.

Note: All recommendations are category 2A unless otherwise indicated.



## PRINCIPLES OF RADIATION THERAPY

### General Guidelines

- Treatment recommendations should be made after joint consultation and/or discussion by a multidisciplinary team including surgical oncologists, radiation oncologists, medical oncologists, radiologists, gastroenterologists, and pathologists.
- CT scans, EUS, endoscopy reports, and FDG-PET or FDG-PET/CT scans, when available, should be reviewed by the multidisciplinary team. This will allow an informed determination of treatment volume and field borders prior to simulation.
- All available information from pretreatment diagnostic studies should be used to determine the target volume.
- In general, Siewert I and II tumors should be managed with RT guidelines applicable to esophageal and EGJ cancers. Depending on the clinical situation, Siewert III tumors may be more appropriately managed with RT guidelines applicable to either esophageal and EGJ or gastric cancers. These recommendations may be modified depending on the location of the bulk of the tumor.
- Image guidance may be used appropriately to enhance clinical targeting.

### Simulation and Treatment Planning

- CT simulation and conformal treatment planning should be used with either three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT).
- The patient should be instructed to avoid intake of a heavy meal for 3 hours before simulation and treatment. When clinically appropriate, IV and/or oral contrast for CT simulation may be used to aid in target localization.
- Use of an immobilization device is strongly recommended for reproducibility of daily setup.
- It is optimal to treat patients in the supine position as the setup is generally more stable and reproducible.
- Four-dimensional (4D)-CT planning or other motion management may be appropriately utilized in select circumstances where organ motion with respiration may be significant.
- Target volumes need to be carefully defined and encompassed while designing IMRT plans. Uncertainties from variations in stomach filling and respiratory motion should be taken into account.

[Continued](#)

Note: All recommendations are category 2A unless otherwise indicated.

**GAST-G**  
**1 OF 5**



## PRINCIPLES OF RADIATION THERAPY

### Target Volume (General Guidelines)

- Postoperative<sup>1</sup>

- ▶ Pretreatment diagnostic studies (EUS, EGD, FDG-PET, and CT scans) and clip placement should be used to identify the tumor/gastric bed, the anastomosis or stumps, and pertinent nodal groups.<sup>2,3</sup>
- ▶ Treatment of the remaining stomach should depend on a balance of the likely normal tissue morbidity and the perceived risk of local relapse in the residual stomach. The relative risk of nodal metastases at a specific nodal location is dependent on both the site of origin of the primary tumor and other factors including width and depth of invasion of the gastric wall.<sup>4</sup>
- ▶ Coverage of nodal areas may be modified based on clinical circumstances and the risks of toxicity.

### Proximal One-Third/Fundus/Cardia/Esophagogastric Junction Primaries

- With proximal gastric lesions or lesions at the EGJ, a 3- to 5-cm margin of distal esophagus and nodal areas at risk should be included. Nodal areas at risk include: perigastric, celiac, left gastric artery, splenic artery, splenic hilar, hepatic artery, and porta hepatic lymph nodes.

### Middle One-Third/Body Primaries

- Nodal areas at risk include: perigastric, celiac, left gastric artery, splenic artery, splenic hilar, hepatic artery, porta hepatic, suprapyloric, subpyloric, and pancreaticoduodenal lymph nodes.

### Distal One-Third/Antrum/Pylorus Primaries

- A 3- to 5-cm margin of duodenum or duodenal stump should be included if the gross lesion extended to the gastroduodenal junction. Nodal areas at risk include: perigastric, left gastric artery, celiac, hepatic artery, porta hepatic, suprapyloric, subpyloric, and pancreaticoduodenal lymph nodes.

Note: All recommendations are category 2A unless otherwise indicated.

[Continued](#)  
[References](#)

**GAST-G**  
**2 OF 5**

## PRINCIPLES OF RADIATION THERAPY

### Normal Tissue Tolerance Dose-Limits<sup>5,6</sup>

- Treatment planning is essential to reduce unnecessary dose to organs at risk.
- It is recognized that these dose guidelines may be appropriately exceeded based on clinical circumstances.

<b>Lungs<sup>a</sup></b>	<b>Heart</b>
<ul style="list-style-type: none"><li>• <math>V_{40\text{Gy}} \leq 10\%</math></li><li>• <math>V_{30\text{Gy}} \leq 15\%</math></li><li>• <math>V_{20\text{Gy}} \leq 20\%</math></li><li>• <math>V_{10\text{Gy}} \leq 40\%</math></li><li>• <math>V_{05\text{Gy}} \leq 50\%</math></li><li>• Mean &lt;20 Gy</li></ul>	<ul style="list-style-type: none"><li>• <math>V_{30\text{Gy}} \leq 30\%</math> (closer to 20% preferred)</li><li>• Mean &lt;30 Gy (closer to 26 Gy preferred)</li></ul>
<b>Spinal Cord</b>	<b>Left Kidney, Right Kidney</b> (evaluate each one separately):
<ul style="list-style-type: none"><li>• Max ≤45 Gy</li></ul>	<ul style="list-style-type: none"><li>• <math>V_{20\text{Gy}} \leq 33\%</math></li><li>• Mean &lt;18 Gy</li></ul>
<b>Bowel</b>	<b>Liver</b>
<ul style="list-style-type: none"><li>• Max dose &lt;54 Gy</li><li>• <math>V_{45\text{Gy}} &lt; 195 \text{ cc}</math></li></ul>	<ul style="list-style-type: none"><li>• <math>V_{30\text{Gy}} \leq 33\%</math></li><li>• Mean &lt;25 Gy</li></ul>

### RT Dosing

- 45–50.4 Gy (1.8 Gy/day) (total 25–28 fractions)
  - ▶ Higher doses may be used for positive surgical margins in selected cases as a boost to that area.

<sup>a</sup> Lung dose-volume histogram (DVH) parameters as predictors of pulmonary complications in patients with gastric/EGJ cancer treated with concurrent chemoradiotherapy should be strongly considered, though consensus on optimal criteria has not yet emerged. Every effort should be made to keep the lung volume and doses to a minimum. Treating physicians should be aware that the DVH reduction algorithm is hardly the only risk factor for pulmonary complications. DVH parameters as predictors of pulmonary complications in patients with gastric/EGJ cancer are an area of active development among the NCCN Member Institutions and others.

Note: All recommendations are category 2A unless otherwise indicated.

## PRINCIPLES OF RADIATION THERAPY

### Supportive Therapy

- Treatment interruptions or dose reductions for manageable acute toxicities should be avoided. Careful patient monitoring and aggressive supportive care are preferable to treatment interruptions.
- During a radiation treatment course, patients should be seen for a status check at least once a week with notation of vital signs, weight, and blood counts.
- Antiemetics should be given on a prophylactic basis, and antacid and antidiarrheal medications may be prescribed when needed.
- If estimated caloric intake is <1500 kcal/day, oral and/or enteral nutrition should be considered. When indicated, feeding J-tubes or nasogastric feeding tubes may be placed to ensure adequate caloric intake. During surgery, a J-tube may be placed for postoperative nutritional support.
- Adequate enteral and/or IV hydration is necessary during chemoradiation and recovery.

### [References](#)

**Note:** All recommendations are category 2A unless otherwise indicated.

**GAST-G**  
**4 OF 5**



## PRINCIPLES OF RADIATION THERAPY REFERENCES

- <sup>1</sup> Macdonald JS, Smalley S, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001;345:725-730.
- <sup>2</sup> Willett CG, Gunderson LL. Stomach. In: Perez and Brady's principles and practice of radiation oncology, 5th ed. Lippincott Williams & Wilkins; 2007:1318-1335.
- <sup>3</sup> Smalley SR, Gunderson L, Tepper J, et al. Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. *Int J Radiat Oncol Biol Phys* 2002;52:283-293.
- <sup>4</sup> Tepper JE, Gunderson LE. Radiation treatment parameters in the adjuvant postoperative therapy of gastric cancer. *Semin Radiat Oncol* 2002;12:187-195.
- <sup>5</sup> Gagliardi G, Constine LS, Moiseenko V, et al. Radiation dose-volume effects in the heart. *Int J Radiat Oncol Biol Phys* 2010;76(3 Suppl):S77-S85.
- <sup>6</sup> Kavanagh BD, Pan CC, Dawson LA, et al. Radiation dose-volume effects in the stomach and small bowel. *Int J Radiat Oncol Biol Phys* 2010;76(3 Suppl):S101-S107.

**Note:** All recommendations are category 2A unless otherwise indicated.



## PRINCIPLES OF SURVEILLANCE

- All patients with *H. pylori* infection who underwent curative ER or gastric subtotal resection must receive an *H. pylori* eradication regimen. The choice and duration of the eradication regimen should follow the recommendations of the latest American (American College of Gastroenterology) or international (Maastricht consensus report) *H. pylori* guidelines.<sup>1</sup>
- Surveillance strategies after curative intent resection (R0) for gastric cancer remain controversial, with sparse prospective data to construct evidence-based algorithms that balance benefits and risks (including cost) within this cohort.
- The guidance provided on [GAST-7](#) for stage-specific surveillance is based on the currently available retrospectively analyzed literature<sup>2-11</sup> and expert consensus.
- While the majority of gastric cancer relapses occur within 2 years (70%–80%) and almost all recurrences by 5 years (~90%) after completion of local therapy, it is important to note that occasionally potentially actionable relapses have been recognized >5 years after curative intent therapy. Therefore, after 5 years additional follow-up may be considered based on risk factors and comorbidities.
- Differences in follow-up for early-stage gastric cancer reflect a heterogeneous potential for relapse and overall survival.<sup>2-11</sup> Whereas R0-resected Tis disease has a prognosis that approximates a non-cancer cohort, T1aN0 and T1b disease do not have such a favorable prognosis. Thus, recommendations vary according to the depth of invasion and treatment modality.

## References

Note: All recommendations are category 2A unless otherwise indicated.

**GAST-H**  
**1 OF 2**

## PRINCIPLES OF SURVEILLANCE REFERENCES

- <sup>1</sup> Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. *N Engl J Med* 2018;378:1085-1095.
- <sup>2</sup> Lee JH, Kim HI, Kim MG, et al. Recurrence of gastric cancer in patients who are disease-free for more than 5 years after primary resection. *Surgery* 2016;159:1090-1098.
- <sup>3</sup> Cao L, Selby LV, Hu X, et al. Risk factors for recurrence in T1-2N0 gastric cancer in the United States and China. *J Surg Oncol* 2016;113:745-749.
- <sup>4</sup> Jin LX, Moses LE, Squires MH, et al. Factors associated with recurrence and survival in lymph node-negative gastric adenocarcinoma: A 7-institution study of the US Gastric Cancer Collaborative. *Ann Surg* 2015;262:999-1005.
- <sup>5</sup> Baiocchi GL, Marrelli D, Verlato G, et al. Follow-up after gastrectomy for cancer: an appraisal of the Italian research group for gastric cancer. *Ann Surg Oncol* 2014;21:2005-2011.
- <sup>6</sup> Fields RC, Strong VE, Gonan M, et al. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastroesophageal adenocarcinoma. *Br J Cancer* 2011;104:1840-1847.
- <sup>7</sup> Youn HG, An JY, Choi MG, et al. Recurrence after curative resection of early gastric cancer. *Ann Surg Oncol* 2010;17:448-454.
- <sup>8</sup> Yoo CH, Noh SH, Shin DW, et al. Recurrence following curative resection for gastric carcinoma. *Br J Surg* 2000;87:236-242.
- <sup>9</sup> D'Angelica M, Gonan M, Brennan MF, et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. *Ann Surg* 2004;240:808-816.
- <sup>10</sup> Song J, Lee HJ, Cho GS, et al. Recurrence following laparoscopy-assisted gastrectomy for gastric cancer: a multicenter retrospective analysis of 1,417 patients. *Ann Surg Oncol* 2010;17:1777-1786.
- <sup>11</sup> Honda M, Hiki N, Kinoshita T, et al. Long-term outcomes of laparoscopic versus open surgery for clinical stage I gastric cancer: The LOC-1 Study. *Ann Surg* 2016;264:214-222.

Note: All recommendations are category 2A unless otherwise indicated.

**GAST-H  
2 OF 2**



## PRINCIPLES OF SURVIVORSHIP

### Surveillance: (GAST-7)

- Surveillance should be performed in conjunction with good routine medical care, including routine health maintenance, preventive care, and cancer screening.
- Routine gastric cancer-specific surveillance (ie, radiologic imaging, endoscopic evaluation, tumor markers) is not recommended beyond 5 years.

### Management of Long-Term Sequelae of Disease or Treatment: (For common survivorship issues, see [NCCN Guidelines for Survivorship](#))

- General issues in gastric cancer survivors:

- ▶ Weight loss:
  - ◊ Monitor weight regularly after gastrectomy to ensure stability
  - ◊ Encourage more frequent feeding and avoiding fluid intake with meals
  - ◊ Consider referral to dietitian or nutrition services for individualized counseling
  - ◊ Assess for and address contributing medical and/or psychosocial factors
- ▶ Diarrhea: Consider anti-diarrheal agents, bulk-forming agents, and diet manipulation
- ▶ Chemotherapy-induced neuropathy:
  - ◊ Consider duloxetine for painful neuropathy only (not effective for numbness or tingling)
  - ◊ Consider referral to occupational, rehabilitation, and/or physical therapy for patients with chemotherapy-induced neuropathy at risk for falls
  - ◊ See [NCCN Guidelines for Survivorship \(SPAIN-3\)](#) and [NCCN Guidelines for Adult Cancer Pain \(PAIN-F\)](#)
- ▶ Fatigue:
  - ◊ Encourage physical activity and energy conservation measures as tolerated
  - ◊ Assess and address contributing medical and/or psychosocial factors
  - ◊ See [NCCN Guidelines for Survivorship \(SFAT-1\)](#) and [NCCN Guidelines for Cancer-Related Fatigue](#)
- ▶ Bone health:
  - ◊ Screen for and manage low bone density at regular intervals as per established national guidelines
  - ◊ Consider vitamin D testing and replacement as clinically indicated

[Continued](#)  
[References](#)

Note: All recommendations are category 2A unless otherwise indicated.

GAST-I  
1 OF 4



## PRINCIPLES OF SURVIVORSHIP<sup>1-4</sup>

### Management of Long-Term Sequelae of Disease or Treatment (For common survivorship issues, see [NCCN Guidelines for Survivorship](#))

- Issues in gastrectomy survivors:<sup>a,b</sup>
  - ▶ Postprandial fullness or eating dysfunction:
    - ◊ Encourage small portions and more frequent eating
    - ◊ Avoid fluid intake with meals
  - ▶ Dumping syndrome:
    - ◊ Early:
      - Occurs within 30 minutes of meal
      - Associated with palpitations, diarrhea, nausea, and cramps
    - ◊ Late:
      - Occurs within 2–3 hours of a meal
      - Associated with dizziness, hunger, cold sweats, faintness
    - ◊ Encourage frequent meals scheduled throughout day
    - ◊ Consume a diet high in protein and fiber, and low in simple carbohydrates or concentrated sweets
    - ◊ Avoid fluid consumption with meals
  - ▶ Vitamin B<sub>12</sub> deficiency:
    - ◊ Supplement B<sub>12</sub>, following local practice for route of administration and monitoring levels
    - ◊ Monitor B<sub>12</sub> level at least every 6 months (if not on parenteral B<sub>12</sub> supplement)
  - ▶ Iron deficiency:
    - ◊ Monitor CBC and iron levels at least annually
    - ◊ Supplement iron orally or intravenously as clinically indicated and according to local practice; avoid sustained-release or enteric-coated formulations if possible
  - ▶ Small intestine bacterial overgrowth (blind loop)
    - ◊ Consider treatment with antibiotics  
(rifaximin 550 mg TID x 7–10 days preferred)
    - ◊ Consume a diet high in protein and low in carbohydrates
  - ▶ Other micronutrient deficiencies:
    - ◊ Supplement with a daily multivitamin and mineral complex, to include vitamins A, C, E, D, folate, thiamine, magnesium, zinc, selenium, copper, and iron, with monitoring levels as clinically indicated
  - ▶ Vitamin D and calcium supplementation
    - ◊ Supplement vitamin D, following local practice for dose and monitoring levels
    - ◊ Ensure adequate calcium intake
  - ▶ Osteopenia/osteoporosis screening
    - ◊ Consider bone density testing at 3 years post-gastrectomy and in individuals who are post-menopausal or >50 years of age

<sup>a</sup> Follow-up with appropriate practitioners or specialists should be established for lifelong monitoring and management of potential nutritional sequelae of gastrectomy, which may include, but are not limited to, vitamin B<sub>12</sub>, iron, zinc, calcium, and vitamin D deficiencies. Consider routine supplementation with a daily multivitamin/mineral complex, vitamin B<sub>12</sub>, calcium, and vitamin D.

<sup>b</sup> Patients with subtotal gastrectomy are at decreased risk of postoperative complications including nutritional deficiencies, and thus the protocol for monitoring and replacement in these patients can be individualized.

[Continued](#)

[References](#)

Note: All recommendations are category 2A unless otherwise indicated.

**GAST-I**  
**2 OF 4**

# NCCN Guidelines Version 3.2025

## Gastric Cancer

[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)

### PRINCIPLES OF SURVIVORSHIP

#### Counseling Regarding Health Behaviors (NCCN Guidelines for Survivorship [HL-1])

- Maintain a healthy body weight throughout life.
- Adopt a physically active lifestyle and avoid inactivity. Goal: at least 30 minutes of moderate-intensity activity most days of the week. Modify physical activity recommendations based on treatment sequelae (ie, neuropathy).
- Consume a healthy diet with emphasis on plant sources, with modifications as needed based on treatment sequelae (ie, dumping syndrome, bowel dysfunction).
- Limit alcohol consumption.
- Recommend smoking cessation as appropriate. See [NCCN Guidelines for Smoking Cessation](#).
- Additional preventive health measures and immunizations should be performed as indicated under the care of or in conjunction with a primary care physician.

#### Cancer Screening Recommendations (for average-risk survivors)

- Breast Cancer: [NCCN Guidelines for Breast Cancer Screening and Diagnosis](#)
- Colorectal Cancer: [NCCN Guidelines for Colorectal Cancer Screening](#)
- Prostate Cancer: [NCCN Guidelines for Prostate Cancer Early Detection](#)
- Lung Cancer: [NCCN Guidelines for Lung Cancer Screening](#)

#### Survivorship Care Planning and Coordination of Care:

- See [NCCN Guidelines for Survivorship \(SURV-1 through SURV-B\)](#)
- See [NCCN Guidelines for Prevention and Treatment of Cancer-Related Infections](#)
- Encourage maintenance of a therapeutic relationship with a primary care physician (PCP) throughout life. The oncologist and PCP should have defined roles in survivorship care, with roles communicated to the patient.
- Planning for ongoing survivorship care<sup>a</sup>
  - Information on treatment received including all surgeries, RT, and systemic therapies
  - Information regarding follow-up care, surveillance, and screening recommendations
  - Information on post-treatment needs, including information regarding acute, late, and long-term treatment-related effects and health risks when possible ([NCCN Guidelines: Treatment by Cancer Type](#))
  - Delineation regarding roles of oncologists, PCPs, and subspecialty care physicians in long-term care and the timing of transfer of care if appropriate
  - Healthy behavior recommendations ([NCCN Guidelines for Survivorship \[HL-1\]](#))
  - Periodic assessment of ongoing needs and identification of appropriate resources

<sup>a</sup> From Commission on Cancer. Optimal Resources for Cancer Care (2020 Standards): [https://www.facs.org/-/media/files/quality-programs/cancer/coc/\\_optimal\\_resources\\_for\\_cancer\\_care\\_2020\\_standards.ashx](https://www.facs.org/-/media/files/quality-programs/cancer/coc/_optimal_resources_for_cancer_care_2020_standards.ashx) and [NCCN Guidelines for Survivorship](#).

Note: All recommendations are category 2A unless otherwise indicated.

### References

GAST-I  
3 OF 4



## PRINCIPLES OF SURVIVORSHIP REFERENCES

- <sup>1</sup> Roberts G, Benusiglio PR, Bisseling T, et al; LAP-TG Study Group. International Delphi consensus guidelines for follow-up after prophylactic total gastrectomy: the Life after Prophylactic Total Gastrectomy (LAP-TG) study. *Gastric Cancer* 2022;25:1094-1104.
- <sup>2</sup> Baiocchi GL, D'Ugo D, Coit D, et al. Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference. *Gastric Cancer* 2016;19:15-20.
- <sup>3</sup> Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures—2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists—executive summary. *Endocr Pract* 2019;25:1346-1359.
- <sup>4</sup> Nilsson M. Postgastrectomy follow-up in the West: evidence base, guidelines, and daily practice. *Gastric Cancer* 2017;20(Suppl 1):135-140.

**Note:** All recommendations are category 2A unless otherwise indicated.

**GAST-I**  
**4 OF 4**



## PRINCIPLES OF PALLIATIVE CARE/BEST SUPPORTIVE CARE<sup>a</sup>

The goal of best supportive care is to prevent and relieve suffering and to support the best possible quality of life for patients and their families, regardless of the stage of the disease or the need for other therapies. For gastric cancer, interventions undertaken to relieve major symptoms may result in prolongation of life. This appears to be particularly true when a multimodality interdisciplinary approach is pursued, and, therefore, a multimodality interdisciplinary approach to palliative care of the patient with gastric cancer is encouraged.<sup>b</sup>

### Bleeding

- Acute bleeding is common in patients with gastric cancer and may directly arise from the tumor or as a consequence of therapy. Patients with acute severe bleeding (hematemesis or melena) should undergo prompt endoscopic assessment.<sup>1</sup>
  - ▶ Endoscopic Treatment
    - ◊ The efficacy of endoscopic therapy for bleeding in patients with gastric cancer is not well studied.<sup>2</sup> The limited data suggest that while endoscopic therapies may initially be effective, the rate of recurrent bleeding is very high.<sup>3</sup>
    - ◊ Widely available treatment options include injection therapy, mechanical therapy (eg, endoscopic clips), ablative therapy (eg, argon plasma coagulation), or a combination of methods.
  - ▶ Interventional Radiology
    - ◊ Angiographic embolization techniques may be useful in those situations where endoscopy is not helpful or bleeding occurs.
  - ▶ Palliative gastrectomy in select patients
- Chronic blood loss from gastric cancer
  - ▶ Although proton pump inhibitors can be prescribed to reduce bleeding risk from gastric cancer, there are no definite data supporting its use at this time.
  - ▶ External beam RT (EBRT) has been shown to effectively manage acute and chronic GI bleeding in multiple small series.<sup>4,5</sup>

<sup>a</sup> [NCCN Guidelines for Palliative Care](#).

<sup>b</sup> For patients who have immune-mediated toxicity, see the [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

[Continued](#)  
[References](#)

Note: All recommendations are category 2A unless otherwise indicated.



## PRINCIPLES OF PALLIATIVE CARE/BEST SUPPORTIVE CARE<sup>a</sup>

### Obstruction

The primary goals of palliation for patients with malignant gastric obstruction are to reduce nausea and vomiting and, when possible, allow resumption of an oral diet.

- Alleviate or bypass obstruction
  - ▶ Endoscopy
    - ◊ Placement of enteral stent for relief of outlet obstruction,<sup>6</sup> or esophageal stent for EGJ/gastric cardia obstruction  
([NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers](#))
  - ▶ Surgery
    - ◊ Gastrojejunostomy<sup>6</sup>
    - ◊ Gastrectomy in select patients<sup>7</sup>
  - ▶ EBRT
  - ▶ Chemotherapy<sup>c</sup>
- When obstruction cannot be alleviated or bypassed, the primary goal is to reduce the symptoms of obstruction via venting gastrostomy (if endoscopic lumen enhancement is not undertaken or is unsuccessful).<sup>8</sup>
  - ▶ Percutaneous, endoscopic, surgical, or interventional radiology gastrostomy tube placement can be placed for gastric decompression if tumor location permits.
  - ▶ Ascites, if present, should be drained prior to venting gastrostomy tube placement to reduce the risk of infectious complications.
- In patients who cannot take an oral diet, feeding gastrostomy tubes for patients with EGJ/gastric cardia obstruction or jejunal feeding tubes for patients with mid and distal gastric obstruction can be placed if tumor location permits.

### Pain

- EBRT
- Chemotherapy<sup>c</sup>
- If patient is experiencing tumor-related pain, then the pain should be assessed and treated in accordance with the [NCCN Guidelines for Adult Cancer Pain](#).
  - ▶ Severe uncontrolled pain following gastric stent placement should be treated with endoscopic removal of the stent once the uncontrollable nature of the pain is established.

### Nausea/Vomiting

- If patient is experiencing nausea and vomiting, then the patient should be treated in accordance with the [NCCN Guidelines for Antiemesis](#).
- Nausea and vomiting may be associated with luminal obstruction, so endoscopic or fluoroscopic evaluation should be performed to determine if obstruction is present.

<sup>a</sup> [NCCN Guidelines for Palliative Care](#).

<sup>c</sup> [Principles of Systemic Therapy \(GAST-F\)](#).



## PRINCIPLES OF PALLIATIVE CARE/BEST SUPPORTIVE CARE REFERENCES

- <sup>1</sup> Imbesi JJ, Kurtz RC. A multidisciplinary approach to gastrointestinal bleeding in cancer patients. *J Support Oncol* 2005;3:101-110.
- <sup>2</sup> Kim Y, Choi IJ. Endoscopic management of tumor bleeding from inoperable gastric cancer. *Clin Endosc* 2015;48:121-127.
- <sup>3</sup> Sheibani S, Kim JJ, Chen B, et al. Natural history of acute upper GI bleeding due to tumours: short-term success and long-term recurrence with or without endoscopic therapy. *Aliment Pharmacol Ther* 2013;38:144-150.
- <sup>4</sup> Kim MM, Rana V, Janjan NA, et al. Clinical benefit of palliative radiation therapy in advanced gastric cancer. *Acta Oncol* 2008;47:421-427.
- <sup>5</sup> Kondoh C, Shitara K, Nomura M, et al. Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study. *BMC Palliat Care* 2015;14:37.
- <sup>6</sup> Journink SM, van Eijck CH, Steyerberg EW, et al. Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review. *BMC Gastroenterol* 2007;7:18.
- <sup>7</sup> Lim S, Muhs BE, Marcus SG, et al. Results following resection for stage IV gastric cancer; are better outcomes observed in selected patient subgroups? *J Surg Oncol* 2007;95:118-122.
- <sup>8</sup> Issaka RB, Shapiro DM, Parikh ND, et al. Palliative venting percutaneous endoscopic gastrostomy tube is safe and effective in patients with malignant obstruction. *Surg Endosc* 2014;28:1668-1673.

Note: All recommendations are category 2A unless otherwise indicated.

**GAST-J**  
**3 OF 3**



**American Joint Committee on Cancer (AJCC)**  
**TNM Staging Classification for Carcinoma of the Stomach (8th ed., 2017)**

**Table 1. Definitions for T, N, M**

<b>T</b>	<b>Primary Tumor</b>	<b>N</b>	<b>Regional Lymph Nodes</b>
<b>TX</b>	Primary tumor cannot be assessed	<b>NX</b>	Regional lymph node(s) cannot be assessed
<b>T0</b>	No evidence of primary tumor	<b>N0</b>	No regional lymph node metastasis
<b>Tis</b>	Carcinoma <i>in situ</i> : intraepithelial tumor without invasion of the lamina propria, high-grade dysplasia	<b>N1</b>	Metastasis in one or two regional lymph nodes
<b>T1</b>	Tumor invades the lamina propria, muscularis mucosae, or submucosa	<b>N2</b>	Metastasis in three to six regional lymph nodes
	T1a Tumor invades the lamina propria or muscularis mucosae	<b>N3</b>	Metastasis in seven or more regional lymph nodes
	T1b Tumor invades the submucosa	<b>N3a</b>	Metastasis in seven to 15 regional lymph nodes
<b>T2</b>	Tumor invades the muscularis propria*	<b>N3b</b>	Metastasis in 16 or more regional lymph nodes
<b>T3</b>	Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures**,***		
<b>T4</b>	Tumor invades the serosa (visceral peritoneum) or adjacent structures**,***		
	T4a Tumor invades the serosa (visceral peritoneum)	<b>M</b>	<b>Distant Metastasis</b>
	T4b Tumor invades adjacent structures/organs	<b>M0</b>	No distant metastasis
		<b>M1</b>	Distant metastasis

\*A tumor may penetrate the muscularis propria with extension into the gastrocolic or gastrohepatic ligaments, or into the greater or lesser omentum, without perforation of the visceral peritoneum covering these structures. In this case, the tumor is classified as T3. If there is perforation of the visceral peritoneum covering the gastric ligaments or the omentum, the tumor should be classified as T4.

\*\*The adjacent structures of the stomach include the spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, and retroperitoneum.

\*\*\*Intramural extension to the duodenum or esophagus is not considered invasion of an adjacent structure, but is classified using the depth of the greatest invasion in any of these sites.

[\*\*Continued\*\*](#)

Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.



American Joint Committee on Cancer (AJCC)  
 TNM Staging Classification for Carcinoma of the Stomach (8th ed., 2017)

**Table 2. AJCC Prognostic Stage Groups**

Clinical Staging (cTNM)			Pathological Staging (pTNM)			Post-Neoadjuvant Therapy (ypTNM)			
	cT	cN	M	pT	pN	M	ypT	ypN	M
<b>Stage 0</b>	Tis	N0	M0	<b>Stage 0</b>	Tis	N0	M0		
<b>Stage I</b>	T1	N0	M0	<b>Stage IA</b>	T1	N0	M0	T1	N0
	T2	N0	M0	<b>Stage IB</b>	T1	N1	M0	T1	N1
<b>Stage IIA</b>	T1	N1, N2, N3	M0		T2	N0	M0	T2	N1
	T2	N1, N2, N3	M0	<b>Stage IIA</b>	T1	N2	M0	T1	M0
<b>Stage IIB</b>	T3	N0	M0		T2	N1	M0	T2	N1
	T4a	N0	M0		T3	N0	M0	T1	M0
<b>Stage III</b>	T3	N1, N2, N3	M0	<b>Stage IIIB</b>	T1	N3a	M0	T3	N1
	T4a	N1, N2, N3	M0		T2	N2	M0	T2	N2
<b>Stage IVA</b>	T4b	Any N	M0		T3	N1	M0	T1	N3
<b>Stage IVB</b>	Any T	Any N	M1		T4a	N0	M0	<b>Stage III</b>	N1
				<b>Stage IIIA</b>	T2	N3a	M0	T3	N2
					T3	N2	M0	T2	N3
					T4a	N1 or N2	M0	T4b	N0
					T4b	N0	M0	T4b	N1
				<b>Stage IIIB</b>	T1	N3b	M0	T4a	N2
					T2	N3b	M0	T3	N3
					T3	N3a	M0	T4b	N2
					T4a	N3a	M0	T4b	N3
					T4b	N1 or N2	M0	T4a	N3
				<b>Stage IIIC</b>	T3	N3b	M0	<b>Stage IV</b>	Any T
					T4a	N3b	M0		Any N
					T4b	N3a or N3b	M0		M1
				<b>Stage IV</b>	Any T	Any N	M1		

Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.



**ABBREVIATIONS**

3D-CRT	three-dimensional conformal radiation therapy	FNA	fine-needle aspiration	PCR	polymerase chain reaction
4D-CT	four-dimensional computed tomography therapy	GI	gastrointestinal	PCI	peritoneal cancer index
AUC	area under the curve	H&P	history and physical	PCP	primary care physician
CBC	complete blood count	HIPEC	hyperthermic intraperitoneal chemotherapy	PD-1	programmed cell death protein 1
CLIA	Clinical Laboratory Improvement Amendments	IC	intraperitoneal chemotherapy	PD-L1	programmed death ligand 1
CPS	combined positive score	ICI	immune checkpoint inhibitor	PIPAC	pressurized intraperitoneal aerosolized chemotherapy
ctDNA	circulating tumor DNA	IHC	immunohistochemistry	PS	performance status
dMMR	mismatch repair deficient	IMRT	intensity-modulated radiation therapy	sm	submucosal
DVH	dose-volume histogram	ISH	in situ hybridization	TMB	tumor mutational burden
EBRT	external beam radiation therapy	J-tube	jejunostomy tube	TMB-H	tumor mutational burden-high
ECOG	Eastern Cooperative Oncology Group	LVI	lymphovascular invasion		
EGD	esophagogastroduodenoscopy	MMR	mismatch repair		
EGJ	esophagogastric junction	MSI	microsatellite instability		
EMR	endoscopic mucosal resection	MSI-H	microsatellite instability-high		
ER	endoscopic resection	MSI-L	microsatellite instability-low		
ESD	endoscopic submucosal dissection	MSS	microsatellite stable		
EUS	endoscopic ultrasound	NGS	next-generation sequencing		
FDG	fluorodeoxyglucose				
FFPE	formalin-fixed paraffin-embedded				
FISH	fluorescence in situ hybridization				

# NCCN Guidelines Version 3.2025

## Gastric Cancer

[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)

### NCCN Categories of Evidence and Consensus

<b>Category 1</b>	Based upon high-level evidence ( $\geq 1$ randomized phase 3 trials or high-quality, robust meta-analyses), there is uniform NCCN consensus ( $\geq 85\%$ support of the Panel) that the intervention is appropriate.
<b>Category 2A</b>	Based upon lower-level evidence, there is uniform NCCN consensus ( $\geq 85\%$ support of the Panel) that the intervention is appropriate.
<b>Category 2B</b>	Based upon lower-level evidence, there is NCCN consensus ( $\geq 50\%$ , but $< 85\%$ support of the Panel) that the intervention is appropriate.
<b>Category 3</b>	Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise indicated.

### NCCN Categories of Preference

<b>Preferred intervention</b>	Interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability.
<b>Other recommended intervention</b>	Other interventions that may be somewhat less efficacious, more toxic, or based on less mature data; or significantly less affordable for similar outcomes.
<b>Useful in certain circumstances</b>	Other interventions that may be used for selected patient populations (defined with recommendation).

All recommendations are considered appropriate.



# NCCN Guidelines Version 3.2025

## Gastric Cancer

### Discussion

This discussion corresponds to the NCCN Guidelines for Gastric Cancer. Last updated on August 22, 2025.

### Table of Contents

Overview.....	MS-2
Literature Search Criteria and Guidelines Update Methodology.....	MS-3
Sensitive/Inclusive Language Usage .....	MS-3
Hereditary Cancer Predisposition Syndromes Associated with Gastric Cancer .....	MS-3
Staging.....	MS-3
<b>Overview of Treatment Guidelines.....</b>	<b>MS-6</b>
Workup .....	MS-6
Additional Evaluation.....	MS-6
Primary Treatment .....	MS-7
Postoperative Management.....	MS-8
Follow-up/Surveillance .....	MS-8
<b>Principles of Endoscopy .....</b>	<b>MS-9</b>
Diagnosis.....	MS-9
Staging .....	MS-9
Treatment .....	MS-10
Surveillance .....	MS-11
<b>Principles of Pathologic Review and Biomarker Testing .....</b>	<b>MS-11</b>
Principles of Pathologic Review.....	MS-11
Principles of Biomarker Testing .....	MS-12
<b>Principles of Surgery .....</b>	<b>MS-16</b>
Lymph Node Dissection .....	MS-17
Laparoscopic Resection .....	MS-18
<b>Principles of Radiation Therapy .....</b>	<b>MS-20</b>
General Guidelines .....	MS-20
Simulation and Treatment Planning .....	MS-21
Target Volume .....	MS-21
Normal Tissue Tolerance and Dose Limits.....	MS-21

Supportive Care .....	MS-22
<b>Combined Modality Therapy .....</b>	<b>MS-22</b>
Perioperative Systemic Therapy .....	MS-22
Preoperative or Perioperative Immunotherapy .....	MS-24
Postoperative Chemoradiation Therapy .....	MS-24
Postoperative Chemotherapy .....	MS-25
<b>Peritoneal Carcinoma as Only Disease .....</b>	<b>MS-26</b>
IC/HIPEC .....	MS-26
<b>Unresectable Locally Advanced, Recurrent, or Metastatic Disease MS-27</b>	<b>MS-27</b>
Chemoradiation for Unresectable Disease .....	MS-28
First-Line Therapy .....	MS-29
Second-Line and Subsequent Therapy .....	MS-30
<b>Targeted Therapies .....</b>	<b>MS-31</b>
Trastuzumab .....	MS-31
Pembrolizumab .....	MS-32
Nivolumab .....	MS-34
Tislelizumab-jsgr .....	MS-35
Zolbetuximab-clzb .....	MS-36
Ramucirumab .....	MS-36
Fam-trastuzumab deruxtecan-nxki.....	MS-37
Entrectinib, Larotrectinib, and Repotrectinib .....	MS-38
Dostarlimab-gxly .....	MS-39
Dabrafenib and Trametinib .....	MS-39
Selplercatinib .....	MS-40
Leucovorin Shortage .....	MS-40
Survivorship .....	MS-40
Palliative/Best Supportive Care .....	MS-42
Summary .....	MS-43
References .....	MS-45



# NCCN Guidelines Version 3.2025

## Gastric Cancer

### Overview

The incidence of gastric cancer has decreased substantially in the United States and Western Europe over the past several decades.<sup>1-4</sup> However, gastric cancer still constitutes a major global health problem, especially in East Asian countries.<sup>5,6</sup> Globally, there were more than 968,000 new cases resulting in approximately 660,000 deaths in 2022, making gastric cancer the fifth most frequently diagnosed cancer and the fifth leading cause of cancer-related deaths in the world.<sup>7,8</sup> The global incidence of gastric cancer shows wide geographic variation, with a 15- to 20-fold difference between high- and low-incidence regions.<sup>1</sup> The highest gastric cancer incidence rates occur in Northeast Asia, South and Central America, and Eastern Europe.<sup>5,6</sup> Rates are particularly high in Japan and Korea, where gastric cancer is the most commonly diagnosed cancer in males, and in China, where gastric cancer is a leading cause of cancer-related mortality.<sup>5,6,9</sup> In contrast, gastric cancer is one of the least commonly diagnosed cancers in Western Europe, sub-Saharan Africa, Australia, and North America.<sup>6</sup> Based on SEER data for 2024, gastric cancer is the 15<sup>th</sup> most commonly diagnosed cancer and the 15<sup>th</sup> leading cause of cancer-related death in the United States.<sup>4</sup> In the United States for 2025, an estimated 30,300 people will be diagnosed and 10,780 people are expected to die of this disease.<sup>10</sup> Despite overall declining rates, evidence suggests that the incidence of early-onset gastric cancer may be rising in the United States and other western countries.<sup>11,12</sup> A recent global meta-analysis suggests factors that may contribute to risk of early-onset gastric cancer include family history, *Helicobacter pylori*, infection, and diet.<sup>13</sup>

Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location (cardia/proximal or non-cardia/distal) and histologic type (diffuse or intestinal).<sup>3</sup> The diffuse type, which is characterized by poorly differentiated and discohesive tumor cells with a signet-ring or non-signet-ring morphology diffusely infiltrating the

gastric wall in a desmoplastic stroma, is more prevalent in low-risk areas and is mostly associated with heritable genetic abnormalities.<sup>3,9,14-16</sup> The intestinal type, which tends to form a mass lesion and is characterized by variably differentiated tumor cells arranged in a tubular or glandular pattern with scattered goblet cells present, occurs more frequently in high-risk areas and accounts for most of the geographic variation seen with this disease. Intestinal type gastric cancer is often related to environmental factors such as *H. pylori* infection, tobacco smoking, high salt intake, and other dietary factors.<sup>2,3,9,14-16</sup> However, the role of alcohol as a risk factor for gastric cancer is without consensus. While the results of several meta-analyses have shown no appreciable association between light or moderate alcohol consumption and gastric cancer risk, they showed a positive association between heavy alcohol use and gastric cancer, particularly non-cardia gastric cancer.<sup>17-20</sup>

A dramatic shift in the type and location of upper gastrointestinal (GI) tract tumors has occurred in North America and Europe.<sup>2,21,22</sup> There has been a marked decline in intestinal type gastric cancers of the distal stomach in North American and Western European countries over the past several decades, mainly due to enhanced access to clean drinking water, improved food preservation, an average diet with low promotion of gastric cancer, and *H. pylori* eradication.<sup>1,3,16,23</sup> However, incidence rates of diffuse type gastric cancer of the proximal stomach are rising.<sup>1,3,23</sup> The etiology of this increase remains elusive and may be multifactorial. In contrast to the incidence trends in high income countries, tumors of the distal stomach continue to predominate in low and middle income countries.<sup>23</sup> Gastric cancer generally carries a poor prognosis since it is often diagnosed at an advanced stage. In Japan and South Korea, where population screening is performed widely, early detection often results in improved outcomes.<sup>1,6</sup> In the United States, survival rates from gastric cancer remain poor as early detection continues to pose a major challenge for health care professionals.



# NCCN Guidelines Version 3.2025

## Gastric Cancer

### Literature Search Criteria and Guidelines Update

#### Methodology

Prior to the update of this version of the NCCN Clinical Practice Guidelines (NCCN Guidelines®) for Gastric Cancer, an electronic search of the PubMed database was performed to obtain key literature published since the last Guidelines update, using the following search terms: gastric cancer, gastric adenocarcinoma, and stomach cancer. The PubMed database was chosen as it remains the most widely used resource for medical literature and indexes peer reviewed biomedical literature.

The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; Guideline; Practice Guideline; Randomized Controlled Trial; Meta-Analysis; Systematic Reviews; and Validation Studies.

The data from key PubMed articles selected by the Panel for review during the Guidelines update meeting as well as articles from additional sources deemed as relevant to these Guidelines and discussed by the Panel have been included in this version of the Discussion section (eg, e-publications ahead of print, meeting abstracts). Recommendations for which high-level evidence is lacking are based on the Panel's review of lower-level evidence and expert opinion.

The complete details of the Development and Update of the NCCN Guidelines are available at [www.nccn.org](http://www.nccn.org).

#### Sensitive/Inclusive Language Usage

NCCN Guidelines strive to use language that advances the goals of equity, inclusion, and representation.<sup>24</sup> NCCN Guidelines endeavor to use language that is person-first; not stigmatizing; anti-racist, anti-classist, anti-misogynist, anti-ageist, anti-ableist, and anti-weight-biased; and inclusive of individuals of all sexual orientations and gender identities. NCCN

Guidelines incorporate non-gendered language, instead focusing on organ-specific recommendations. This language is both more accurate and more inclusive and can help fully address the needs of individuals of all sexual orientations and gender identities. NCCN Guidelines will continue to use the terms *men*, *women*, *female*, and *male* when citing statistics, recommendations, or data from organizations or sources that do not use inclusive terms. Most studies do not report how sex and gender data are collected and use these terms interchangeably or inconsistently. If sources do not differentiate gender from sex assigned at birth or organs present, the information is presumed to predominantly represent cisgender individuals. NCCN encourages researchers to collect more specific data in future studies and organizations to use more inclusive and accurate language in their future analyses.

#### Hereditary Cancer Predisposition Syndromes Associated with Gastric Cancer

While most gastric cancers are considered sporadic, it is estimated that 1% to 3% of gastric cancers are associated with inherited cancer predisposition syndromes. These syndromes include hereditary diffuse gastric cancer, Lynch syndrome, juvenile polyposis syndrome, and familial adenomatous polyposis syndrome. See the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric (available at [www.nccn.org](http://www.nccn.org)) for hereditary diffuse gastric cancer testing, *CDH1* risk assessment, and more information on these syndromes.

#### Staging

The tumor (T), node (N), and metastasis (M) staging system used by the American Joint Committee on Cancer (AJCC) is the internationally accepted standard for cancer staging and is a major factor influencing prognosis and treatment decisions. Staging recommendations for gastric



## NCCN Guidelines Version 3.2025

# Gastric Cancer

cancer presented in the Eighth Edition of the AJCC Cancer Staging Manual include clinical staging (cTNM; newly diagnosed, not-yet-treated patients), pathologic staging (pTNM; patients undergoing resection without prior treatment), and post neoadjuvant pathologic staging (ypTNM; patients receiving preoperative therapy).<sup>25</sup> The Eighth Edition also introduced modifications regarding tumors located at the esophagogastric junction (EGJ) and within the gastric cardia. Using this system, tumors involving the EGJ with an epicenter located >2 cm into the proximal stomach are now staged as gastric carcinomas. Tumors involving the EGJ with an epicenter ≤2 cm into the proximal stomach will still be staged as esophageal carcinomas. Cancers located within the gastric cardia that do not involve the EGJ are staged as gastric carcinomas.

The Eighth Edition of the AJCC Cancer Staging Manual provides additional resources for gastric cancer not available in the Seventh Edition, including the addition of new cTNM and ypTNM stage groupings, to fulfill unmet needs in staging patients under different circumstances. Due to the lack of an official clinical stage classification in the past, treating physicians have typically used the pathologic stage to clinically stage patients. Furthermore, due to the lack of yp stage groupings, pathologic staging was also applied to patients who had received preoperative therapy. The use of pathology assessments to establish cTNM and ypTNM stages has never been validated and may not be appropriate. Therefore, new cTNM and ypTNM stage groupings and prognostic information were added to the Eighth Edition to overcome these issues. New clinical stage groupings and prognostic information are based on datasets from the National Cancer Database (NCDB), representing patients treated surgically or nonsurgically in the United States, and the Shizuoka Cancer Center dataset, representing patients treated surgically in Japan, for a total of 4091 patients. These clinical stage groupings are different from groupings used for pathologic or post neoadjuvant staging. The prognostic value of the newly proposed cTNM stage criteria has been

externally validated in a cohort of 4374 patients in Japan surgically treated for gastric cancer.<sup>26</sup> Newly provided prognostic information for ypTNM staging is presented using only the four broad stage categories (stage I–IV) due to the limited number of patients (n = 700) available for analysis. The addition of this new ypTNM stage grouping system fulfills an unmet need in the clinics since many patients with gastric cancer are now treated with preoperative therapy. Furthermore, the stage groupings and prognostic information for pTNM staging presented in the Eighth Edition are now based on data from >25,000 patients with gastric cancer from the International Gastric Cancer Association (IGCA) database who have had surgery with adequate lymph node removal. Patients treated with preoperative therapy were not included in the analysis. Pathologic stage groupings were refined based on 5-year survival data. Although most (84.8%) of the eligible cases from the IGCA database came from Japan and Korea, the predictive ability and accuracy of parameters used in the Eighth Edition for pTNM staging of gastric cancer have been validated for U.S. populations.<sup>27,28</sup> The new pTNM staging classification criteria have also been externally validated in a cohort with a higher proportion of advanced disease than the IGCA cohort (49% had stage III disease compared to 26% in the IGCA cohort;  $P < .001$ ).<sup>29</sup> However, limitations of this dataset still remain, including a lack of uniformity in initial clinical stage assessments, the lack of a uniform surgical approach, and the use of pTNM assessments for ypTNM staging.<sup>25</sup>

Baseline clinical stage provides useful information for the development of an initial treatment strategy. The availability of diagnostic modalities such as endoscopic ultrasound (EUS), CT, 18-fluorodeoxyglucose (FDG)-PET/CT, and laparoscopy has greatly improved baseline clinical staging of gastric cancer.<sup>30–32</sup> EUS is indicated for assessing the depth of tumor invasion (T category) as well as nodal involvement (N category).<sup>33</sup> However, the diagnostic accuracy of EUS is operator dependent, ranging from 57% to 88% for T staging and 30% to 90% for N staging.<sup>34</sup> In a large



## NCCN Guidelines Version 3.2025

# Gastric Cancer

multi-institutional study that evaluated the use and accuracy of EUS in patients undergoing curative intent resection for gastric adenocarcinoma, the overall accuracy of EUS was 46.2% for T category and 66.7% for N category.<sup>35</sup> Distant lymph node evaluation by EUS is also suboptimal given the limited depth and visualization of the transducer.<sup>36</sup> EUS may be useful for differentiating T3 and T4 tumors, but it should be used in combination with other staging modalities.<sup>34,35</sup> EUS is also useful to identify superficial tumors for potential endoscopic approaches. Therefore, EUS is recommended if early-stage disease is suspected or if early versus locally advanced disease needs to be determined.

CT scan is routinely used for preoperative staging and has an overall accuracy of 43% to 82% for measuring depth of invasion. In contrast, FDG-PET has a lower accuracy rate because of low FDG uptake in diffuse and mucinous tumor types, which are common in gastric cancer.<sup>37,38</sup> FDG-PET also has significantly lower sensitivity compared to CT in the detection of local lymph node involvement (56% vs. 78%), although FDG-PET has improved specificity (92% vs. 62%).<sup>39</sup> Thus, combined FDG-PET/CT imaging offers several potential advantages over FDG-PET or CT scans alone.<sup>40</sup> FDG-PET/CT has a significantly higher accuracy rate in preoperative staging (68%) than FDG-PET (47%) or CT (53%) alone. Additionally, reports have confirmed that FDG-PET alone is not an adequate diagnostic procedure in the detection and preoperative staging of gastric cancer, but can be helpful when used in conjunction with CT.<sup>41,42</sup> FDG-PET does not replace staging laparoscopy given its inability to detect peritoneal disease.

Pretreatment diagnostic laparoscopy can be used to detect occult metastases. In a study conducted at Memorial Sloan Kettering Cancer Center, 657 patients with potentially resectable gastric adenocarcinoma underwent laparoscopic staging over a period of 10 years.<sup>43</sup> Metastatic disease (M1) was detected in 31% of patients. However, limitations of laparoscopic staging include two-dimensional evaluation and limited use in

the identification of hepatic metastases and perigastric lymph nodes. Cytology testing of peritoneal fluid can help improve laparoscopic staging through identification of occult carcinomatosis.<sup>30</sup> Positive peritoneal cytology is associated with a poor prognosis in patients with gastric cancer and is an independent predictor for recurrence following curative resection.<sup>44-46</sup> Clearing of cytology-positive disease by chemotherapy is associated with a statistically significant improvement in disease-specific survival, but cures are rare and the role of surgery is uncertain.<sup>45</sup> Therefore, positive peritoneal cytology even in the absence of visible peritoneal implants should be considered as M1 disease, and surgery as initial treatment is not recommended. In patients being considered for surgical resection without preoperative therapy, laparoscopy may be useful for the detection of radiographically occult metastatic disease in patients with T3 and/or N+ tumors identified on preoperative imaging. The Panel recommends performing diagnostic laparoscopy to assess the peritoneal cavity (with biopsies as needed) and cytology of peritoneal washings in patients who are medically fit with potentially resectable stage cT1b or higher locoregional disease when considering perioperative therapy and/or surgery.<sup>43</sup> Laparoscopy with cytology can be considered for patients who are medically fit with surgically unresectable disease.

In most countries, where screening programs for early detection of gastric cancer are not in use or practical because of low incidence, diagnosis is often made late in the disease course. Approximately 50% of patients present with advanced disease at diagnosis and will likely have a poor outcome. Other measures of poor outcome include poor performance status, presence of metastases, and an alkaline phosphatase level  $\geq 100$  U/L.<sup>47</sup> Additionally, nearly 80% of patients have involvement of the regional lymph nodes and the number of positive lymph nodes has a profound influence on survival.<sup>48</sup> In patients with localized resectable disease, outcome depends on the surgical stage of the disease.

# NCCN Guidelines Version 3.2025

## Gastric Cancer

### Overview of Treatment Guidelines

The comprehensive care of patients with gastric cancer requires expertise in several disciplines, including surgical oncology, medical oncology, radiation oncology, gastroenterology, radiology, and pathology. In addition, the presence of nutritional services, social workers, nurses, palliative care specialists, and other supporting disciplines is also desirable.<sup>49</sup> Hence, the Panel believes in an infrastructure that encourages multidisciplinary treatment decision-making by members of all disciplines taking care of patients with gastric cancer. The recommendations made by the multidisciplinary team may be considered advisory to the primary group of treating physicians. See *Principles of Multidisciplinary Team Approach for Esophagogastric Cancers* in the algorithm for more information.

### Workup

Newly diagnosed patients should receive a complete history and physical examination, complete blood count (CBC), comprehensive chemistry profile, and esophagogastroduodenoscopy (EGD) with biopsy of the primary tumor. CT scan (with oral and IV contrast) of the chest, abdomen, and pelvis should also be performed. FDG-PET/CT evaluation from skull base to mid-thigh is recommended for locally advanced or metastatic disease or if clinically indicated. However, this may not be appropriate for T1 disease. EUS is recommended if early-stage disease is suspected or if early-stage versus locally advanced disease needs to be determined (preferred). Endoscopic resection (ER) is essential for the accurate staging of early-stage cancers (T1a or T1b). Early-stage cancers can best be diagnosed by ER. ER may also be therapeutic for early-stage disease. Biopsy of metastatic disease should be performed as clinically indicated. Assessment of Siewert tumor type should also be included as part of the initial workup in all patients with EGJ adenocarcinoma.<sup>50,51</sup>

Universal testing for microsatellite instability (MSI) status by polymerase chain reaction (PCR)/next-generation sequencing (NGS) or mismatch

repair (MMR) status by immunohistochemistry (IHC) is recommended in all newly diagnosed patients. Universal testing for programmed death ligand 1 (PD-L1) is also recommended for all newly diagnosed patients. HER2 and claudin 18 isoform 2 (CLDN18.2) testing are recommended at the time of diagnosis if advanced/metastatic disease is documented or suspected. NGS should be considered via a validated assay. See *Principles of Pathologic Review and Biomarker Testing* below for more information.

Nutritional assessment and counseling as well as smoking cessation advice, counseling, and pharmacotherapy (as indicated) are recommended for all patients. The guidelines also recommend screening for family history of gastric cancers. See *Heredity Cancer Predisposition Syndromes Associated with Gastric Cancer* above. Testing/screening for *H. pylori* and genetic testing should be considered as needed. The Panel recommends testing for *H. pylori* infection and to eradicate in all patients with early gastric cancer, if positive. If testing is positive, recommendations should be discussed with family members as appropriate. For close family members, *H. pylori* testing should be recommended, and genetic testing should be performed as needed.

Initial workup enables patients to be classified into three clinical stage groups:

- Localized cancer (stages cTis or cT1a)
- Locoregional cancer (stages cT1b–cT4a; cM0, Any N)
- Metastatic cancer (stage cT4b; cM1)

### Additional Evaluation

Additional evaluations are warranted to assess a patient's medical condition, their ability to tolerate major surgery, and the feasibility of resection. These evaluations may include pulmonary function studies, cardiac testing, and nutritional assessment. Laparoscopy with assessment

# NCCN Guidelines Version 3.2025

## Gastric Cancer

of cytology with or without biopsies is recommended to evaluate for peritoneal spread when considering local therapy for patients who are medically fit with stage cT1b or higher potentially resectable locoregional disease. Laparoscopy with cytology can be considered for patients who are medically fit with surgically unresectable disease. It is not indicated if a palliative resection is planned.

Additional evaluation enables patients with locoregional cancer to be further classified into the following groups:

- Medically fit with potentially resectable disease
- Medically fit with surgically unresectable disease
- Nonsurgical candidates (medically unable to tolerate major surgery or medically fit but decline surgery)

### Primary Treatment

#### *Patients Who Are Medically Fit*

ER or surgery are the primary treatment options for patients who are medically able to tolerate major surgery with localized (cTis or cT1a) tumors. Surgery is the treatment option for patients with potentially resectable cT1b tumors. For patients with cT2 or higher, any N tumors, surgery or perioperative systemic therapy (category 1) are recommended options.<sup>52-55</sup> For patients whose tumors are cT2 or higher, any N and are MSI-high (MSI-H)/MMR deficient (dMMR), preoperative or perioperative immune checkpoint inhibitor (ICI) therapy may be considered. See the *Combined Modality Therapy* section for important considerations on ICIs in this setting. Chemoradiation or systemic therapy are the recommended treatment options for patients who are medically fit whose locoregional cancer is found to be surgically unresectable after laparoscopic staging.<sup>56,57</sup> See *Combined Modality Therapy* below for more information.

#### *Nonsurgical Candidates*

ER is recommended for nonsurgical candidates with cTis or cT1a tumors. Nonsurgical candidates with locoregional disease (cM0, any N) should receive palliative management/best supportive care. All patients diagnosed with metastatic disease are considered nonsurgical candidates and should be treated with palliative management/best supportive care. See the *Principles of Palliative Care/Best Supportive Care* in the algorithm for more information.

#### *Response Assessment and Additional Management*

Additional management options are based on the assessment of response to primary treatment. Therefore, chest/abdomen/pelvis CT scan with contrast (oral and IV) should be performed in patients who are medically fit after the completion of perioperative systemic therapy and before surgical intervention. FDG-PET/CT scan can be performed as clinically indicated. Patients found to have resectable disease on imaging should proceed with surgery (preferred) or palliative management, while those found to have unresectable or metastatic disease after primary treatment should receive palliative management.

For those patients with MSI-H/dMMR tumors who received preoperative or perioperative ICI, response assessment should include an FDG-PET/CT (5–8 weeks after therapy) as clinically indicated and EGD and biopsy. A chest/abdomen CT with oral and IV contrast (including pelvis CT, if clinically indicated) is recommended but not required if FDG-PET/CT is performed. Patients with no evidence of disease should be discussed by a multidisciplinary team and may undergo observation or surgery. However, patients with persistent local disease have the option of surgery (preferred) or palliative management. Palliative management is recommended for patients with new metastatic disease.

Nonsurgical candidates should also be restaged using chest/abdomen/pelvis CT scan with oral and IV contrast following primary



# NCCN Guidelines Version 3.2025

## Gastric Cancer

treatment. FDG-PET/CT scan can be performed as clinically indicated in cases of renal insufficiency or allergy to CT contrast. A CBC and comprehensive chemistry profile are also recommended. Surgery is preferred, if appropriate, for patients found to have resectable, medically operable disease at restaging. Patients with unresectable, medically inoperable, or metastatic disease at restaging should receive palliative management.

### Postoperative Management

Postoperative management is based on pathologic tumor stage, nodal status, surgical margins, the extent of lymph node dissection, and previous treatment.

#### ***Patients Who Have Not Received Systemic Therapy***

The benefit of postoperative therapy for patients who have not received preoperative therapy has been established in randomized trials.<sup>58-60</sup> Therefore, postoperative chemoradiation is recommended for all patients following an R1 or R2 resection. Palliative management, as clinically indicated, is an alternative option for patients following an R2 resection. Postoperative chemoradiation is also recommended following an R0 resection for select patients with pT2, N0 tumors and high-risk features (eg, poorly differentiated or higher grade cancer, lymphovascular invasion [LVI], neural invasion, age <50 years, and not undergoing D2 lymph node dissection)<sup>61</sup> and for patients with pT3–pT4, any N or any pT, N+ tumors who received less than a D2 dissection (category 1). Patients with pT2, N0 tumors without high-risk features should undergo observation. Patients with pT3–pT4, any N or any pT, N+ tumors who have undergone primary D2 lymph node dissection should receive postoperative chemotherapy (category 1).<sup>62,63</sup> Given the relatively good prognosis combined with the lack of evidence from randomized clinical trials showing any survival benefit from postoperative chemoradiation for patients with pTis or pT1,

N0 tumors following R0 resection, the Panel recommends observation for this group of patients.

#### ***Patients Who Have Received Systemic Therapy***

Patients who have received preoperative systemic therapy should receive postoperative systemic therapy (perioperative therapy) following R0 resection (category 1). In the absence of distant metastases, chemoradiation is recommended for patients following R1 or R2 resection. Although this approach has not been evaluated in prospective studies, the Panel feels this is a reasonable treatment option given the significantly worse prognosis associated with margin-positive resections. Re-resection, if feasible, can also be considered following R1 resection. Palliative management should be offered to all patients with new metastatic disease and may also be offered to patients with R2 resection, as clinically indicated.

### **Follow-up/Surveillance**

Patients who are positive for *H. pylori* and who underwent curative endoscopic resection or gastric subtotal resection should receive an *H. pylori* eradication regimen. Choice of regimen and duration should be based on the latest American College of Gastroenterology or Maastricht Consensus Report *H. pylori* guidelines.<sup>64</sup> All patients should be followed systematically. However, surveillance strategies after curative intent (R0) resection for gastric cancer remain controversial with sparse prospective data to construct evidence-based recommendations that balance the benefits and risks, including costs, within this cohort. The surveillance strategies provided in this guideline are based on the currently available retrospectively analyzed literature<sup>65-74</sup> and expert consensus. While studies have shown that most gastric cancer recurrences occur within the first 2 years after the completion of local therapy (70%–80%) and almost all recurrences occur by 5 years (~90%),<sup>65,67,72</sup> a study of 1573 patients who underwent curative intent therapy showed that 7.6% of recurrences



# NCCN Guidelines Version 3.2025

## Gastric Cancer

occurred >5 years after treatment.<sup>68</sup> Therefore, additional follow-up after 5 years may be considered based on risk factors and comorbidities.

Differences in follow-up for early-stage gastric cancer reflect a heterogeneous potential for relapse and overall survival (OS).<sup>65-74</sup> For example, whereas R0-resected Tis disease has a prognosis that approximates a non-cancer cohort, T1a, N0 and T1b disease do not perform as well. Thus, surveillance recommendations vary according to the depth of invasion and treatment modality received by the patient.

In general, surveillance for all patients should include a complete history and physical examination every 3 to 6 months for the first 2 years and then every 6 to 12 months for years 3 to 5. CBC and chemistry profile should be obtained as clinically indicated. Patients with early-stage (Tis or T1a) tumors treated by ER should be surveilled with EGD every 6 months for the first year, and then annually for either 3 years (Tis) or 5 years (T1a). EGD surveillance beyond 5 years for patients with T1a tumors should be based on symptoms and/or radiographic findings. Patients with stage I disease (T1a or T1b) treated with surgery should receive EGD as clinically indicated. EGD should also be performed as clinically indicated in patients who had partial or subtotal gastrectomy. Patients with Tis or stage I disease may receive CT scan of the chest, abdomen, and pelvis with contrast as clinically indicated based on symptoms and concern for recurrence. Patients with stage II or III disease should receive chest/abdomen/pelvis CT scan with oral and IV contrast every 6 months for the first 2 years, then annually for up to 5 years. For stage I–III, CT scan is preferred, but alternative imaging such as FDG-PET/CT or MRI can be considered as clinically indicated for patients who cannot undergo CT scan. Surveillance for patients undergoing curative intent total gastrectomy should follow these recommendations, except for endoscopy. Endoscopy is an option as clinically indicated for routine surveillance and should be used if patients are symptomatic. Patients with stage I–III disease who underwent surgical resection should also have lifelong

monitoring and management for nutritional deficiencies, especially after total gastrectomy, as indicated. See the *Survivorship* section for more details on nutritional deficiencies following gastrectomy.

### Principles of Endoscopy

Endoscopy has become an important tool in the diagnosis, staging, treatment, and palliation of patients with gastric cancer. Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) have been used as alternatives to surgery for the treatment of patients with early-stage gastric cancer in Asia. However, the applicability of these techniques in the United States is limited because of the low incidence of early-stage disease. Endoscopic procedures are best performed in centers with experienced physicians.

### Diagnosis

Diagnostic endoscopies are performed to determine the presence and location of gastric neoplasia and to biopsy suspicious lesions. The location of the tumor in the stomach (cardia, fundus, body, antrum, or pylorus) and relative to the EGJ should be carefully recorded to assist with treatment planning and follow-up. Multiple biopsies (6–8), using standard-size endoscopy forceps, should be performed to provide sufficient material for histologic and molecular interpretation.<sup>75,76</sup> Use of larger forceps may improve this yield.

EMR or ESD of focal nodules ( $\leq 2$  cm) can be safely performed in the setting of early-stage disease to provide greater information on the degree of differentiation, the presence of LVI, and the depth of invasion, with the added potential of being therapeutic.<sup>77,78</sup>

### Staging

EUS provides accurate initial clinical staging of locoregional gastric cancer. EUS performed prior to any treatment provides evidence of the



# NCCN Guidelines Version 3.2025

## Gastric Cancer

depth of tumor invasion (T), presence of abnormal or enlarged lymph nodes likely to harbor cancer (N), signs of metastasis, such as lesions in surrounding organs (M), or the presence of ascites.<sup>79,80</sup> Accurate clinical staging is especially important in patients who are being considered for ER.<sup>81</sup>

Hypoechoic (dark) expansion of the gastric wall layers identifies the location of the tumor, with gradual loss of the layered pattern of the normal stomach wall corresponding with greater depths of tumor infiltration and thus higher T-categories. See *Principles of Endoscopic Staging and Therapy* in the algorithm for detailed information on T-categories.

Perigastric lymph nodes are readily seen by EUS, and the identification of enlarged, hypoechoic, homogeneous, well-circumscribed, rounded structures around the stomach indicates the presence of malignant or inflammatory lymph nodes. The accuracy of this diagnosis is significantly increased with the combination of features, but can also be confirmed with the use of fine-needle aspiration (FNA) biopsy for cytology assessment.<sup>82</sup> FNA of suspicious lymph nodes should be performed, without traversing an area of primary tumor or major blood vessels, if it will impact treatment decisions. FNA should also be considered to rule out peritoneal spread of disease.

### Treatment

EMR represents a major advancement in minimally invasive approaches for the comprehensive care of patients with early-stage gastric cancer.<sup>83</sup> Most of the experience with EMR for early-stage disease has been gained by countries with a high incidence of gastric cancer and an active screening program.<sup>84-88</sup> In a study of 124 patients with early-stage mucosal gastric cancers, Uedo et al reported 5- and 10-year survival rates of 84% and 64%, respectively, for patients receiving EMR.<sup>85</sup> In another retrospective study of 215 patients with intramucosal gastric cancer, EMR resulted in significantly shorter hospital stays, but was comparable to

surgery in terms of risk of death and recurrence.<sup>88</sup> The proper selection of patients is essential to improve the clinical outcomes of EMR; endoscopic gross type (depressed lesion), the degree of differentiation, and the depth of invasion were identified as independent predictors of higher complete resection rates.<sup>86</sup>

ESD has also been reported to be a safe and effective procedure for patients with early-stage gastric cancer when performed by experienced endoscopists.<sup>89-96</sup> En-bloc excision of small gastric lesions by ESD has been shown to be more effective than EMR in several studies.<sup>97-104</sup> In a multicenter retrospective study of ER in patients with early-stage gastric cancer, the 3-year recurrence-free rate in the ESD group was significantly higher than that in the EMR group (98% vs. 93%, respectively).<sup>97</sup> The complete resection rates for ESD were significantly better for lesions >5 cm in diameter, whereas the rates were not different between EMR and ESD for lesions <5 cm in diameter regardless of location.<sup>98-100</sup> ESD requires a higher level of skill to perform and is also associated with higher rates of bleeding and perforation complications.<sup>102-105</sup> As these technologies continue to evolve as promising options for the diagnosis and treatment of early-stage gastric cancers, the NCCN Panel recommends that ER (EMR or ESD) be performed in high-volume medical centers with extensive experience in these techniques.

Early-stage gastric cancer that is ≤2 cm in diameter with favorable histology that is well to moderately differentiated, does not invade the deep submucosa, does not exhibit LVI or lymph node metastases, and has clear lateral and deep margins can be effectively treated with EMR or ESD.<sup>78,104,106-108</sup> ESD is preferred. A GI pathologist should then evaluate the specimen for features of curative resection, which include submucosal (sm) invasion <500 µm without poorly or undifferentiated pathology and with no evidence of LVI. The Panel recognizes many American and Japanese guidelines have expanded ESD indications, which are outlined in the algorithm. If margins are negative, curative resection is limited to



# NCCN Guidelines Version 3.2025

## Gastric Cancer

sm1 invasion, and there is no LVI, then these have potential to be curative resections. Importantly, there is a very small risk of lymph node involvement, so these decisions should be made after multidisciplinary discussion and careful explanation to the patient. Further treatment such as gastrectomy for patients who are medically fit, systemic therapy (ie, postoperative chemotherapy) or surveillance should be considered, depending on pathology.<sup>107,108</sup>

EMR or ESD of gastric cancers with unfavorable histology (poorly differentiated or diffuse type with evidence of LVI, invasion into the deep submucosa, and positive lateral or deep margins) should be considered incomplete and additional therapy (gastrectomy with lymph node dissection) should be considered for patients who are medically fit.<sup>107-109</sup>

Endoscopic therapies also play a role in palliative care. Endoscopic tumor ablation can be performed for the short-term control of gastric cancer-associated bleeding. Endoscopic insertion of self-expanding metal stents (SEMS) is effective for the long-term relief of tumor obstruction at the EGJ or gastric outlet, although surgical gastrojejunostomy may be more efficacious for those with longer-term predicted survival.<sup>110,111</sup> Long-term palliation of anorexia, dysphagia, or malnutrition may be achieved with endoscopic- or radiographic-assisted placement of a feeding gastrostomy tube in carefully selected cases where the distal stomach is uninvolved by tumor, or the placement of a feeding jejunostomy tube.<sup>112</sup>

### Surveillance

Endoscopic surveillance following definitive treatment of gastric cancer requires careful attention to detail for mucosal surface changes. Multiple (4–6) biopsies of any visualized abnormalities should be performed. Additionally, strictures should also be biopsied to rule out neoplastic cause. EUS performed in conjunction with endoscopy exams has a high sensitivity for detecting recurrent disease.<sup>113</sup> EUS-guided FNA should be performed if suspicious lymph nodes or areas of wall thickening are

observed. It should be noted that EUS performed after chemotherapy or radiation therapy (RT) has a reduced ability to accurately determine the post-treatment stage of disease.<sup>114</sup> Similarly, biopsies performed after chemotherapy or RT may not accurately diagnose the presence of residual disease but still provide useful information.<sup>115</sup>

### Principles of Pathologic Review and Biomarker Testing

Pathologic review and biomarker testing play important roles in the diagnosis, classification, and molecular characterization of gastric cancer. Classification based on histologic subtype and molecular features helps improve early diagnosis and has implications for therapy. An accumulation of genetic aberrations occurs during gastric carcinogenesis, resulting in overexpression of growth factors and/or receptors, loss of certain tumor suppressor genes, alterations in the cell cycle, and changes in the DNA repair and damage response.<sup>116,117</sup> Genome instability, which includes increased chromosomal instability and MSI, is often associated with some of these changes and can contribute to tumorigenesis.<sup>117-119</sup> Additionally, MSI-H in gastric tumors is frequently associated with an increase in immune checkpoint ligand expression.<sup>119-121</sup> A genomic stable subtype has also been identified by The Cancer Genome Atlas (TCGA) data.<sup>116</sup> Characterization of these alterations and pathways has enabled the application of molecular pathology to aid in the diagnosis, classification, and treatment of gastric cancer.

### Principles of Pathologic Review

A specific diagnosis of gastric adenocarcinoma should be established for staging and treatment purposes. Subclassification of gastric adenocarcinoma as intestinal or diffuse type may have implications for therapy since intestinal type tumors are more likely to be HER2 overexpression positive (see below). In addition to the histologic type, the

# NCCN Guidelines Version 3.2025

## Gastric Cancer

pathology report (regardless of the specimen type) should include specifics about tumor invasion and pathologic grade, which are required for staging. Universal testing for MSI by PCR/NGS or MMR deficiency by IHC and PD-L1 testing by IHC are recommended in all newly diagnosed patients. The pathology report of EMR specimens should include an assessment of LVI, depth of tumor invasion, tumor diameter, and the status of mucosal and deep margins. Pathology reports of gastrectomy specimens should also document the location of the tumor midpoint in relationship to the EGJ, whether the tumor crosses the EGJ, the lymph node status, and the number of lymph nodes recovered ( $\geq 16$ ). In patients who undergo gastrectomy following treatment with chemoradiation for unresectable gastric cancer, and without grossly obvious residual tumor, the tumor site should be thoroughly sampled to detect microscopic residual disease. The pathology report should include all the above elements plus an assessment of treatment effect.

### **Assessment of Treatment Response**

Response of the primary tumor and involved lymph nodes to previous chemotherapy or RT should be reported. Pathologic response and histologic tumor regression after neoadjuvant therapy have been shown to be predictors of survival in patients with gastric adenocarcinoma. Lowy et al reported that response to neoadjuvant chemotherapy was the only independent predictor of OS in patients who underwent curative resection for gastric cancer.<sup>122</sup> Additionally, Mansour et al reported that the 3-year disease-specific survival rate was significantly higher for patients with  $>50\%$  pathologic response to preoperative chemotherapy compared to those with  $<50\%$  pathologic response (69% and 44%, respectively).<sup>123</sup> In another study, Becker et al demonstrated that histopathologic grading of tumor regression was correlated with survival in patients treated with neoadjuvant chemotherapy.<sup>124</sup> Conversely, Smyth et al reported that lymph node metastasis, not pathologic response to therapy, was the only

independent predictor of survival in patients who received neoadjuvant chemotherapy as part of the MAGIC trial.<sup>125</sup>

Tumor response scoring systems for gastric cancer have not been uniformly adopted. The Panel recommends using the modified scheme developed by Ryan et al<sup>126,127</sup> because it generally provides good reproducibility among pathologists, but other systems may also be used. The following scheme is suggested: 0 (complete response [CR]; no viable cancer cells, including lymph nodes); 1 (near CR; single cells or rare small groups of cancer cells); 2 (partial response; residual cancer cells with evident tumor regression, but more than single cells or rare small groups of cancer cells); and 3 (poor or no response; extensive residual cancer with no evident tumor regression). Because of the impact of residual nodal metastases on survival, it is recommended that lymph nodes be included in the regression score. Sizable pools of acellular mucin may be present after chemoradiation but should not be interpreted as representing residual tumor.

Although it is suggested that  $\geq 16$  regional lymph nodes be pathologically assessed, removal and assessment of  $>30$  lymph nodes is desirable.<sup>25,128</sup> Analysis of data from the SEER database and NCDB showed a trend for improved OS with a higher number of lymph nodes examined after gastrectomy.<sup>128-130</sup> The trend for superior survival based on more lymph nodes examined was confirmed across all stage subgroups.

### **Principles of Biomarker Testing**

Presently, IHC and/or molecular testing for HER2/ERBB2 overexpression/amplification, MSI or MMR status, PD-L1 expression, CLDN18.2 positivity, tumor mutational burden-high (TMB-H) status, NTRK gene fusion, RET gene fusion, and BRAF V600E mutation are implicated in the clinical management of advanced gastric cancer. IHC, in situ hybridization (ISH), or targeted PCR is preferred to evaluate biomarkers. However, a validated NGS assay performed in a Clinical



# NCCN Guidelines Version 3.2025

## Gastric Cancer

Laboratory Improvement Amendments (CLIA)-approved laboratory may be considered later in the clinical course of a patient with sufficient tumor tissue available. NGS can assess several mutations and other molecular events simultaneously. Specific recommendations for HER2, PD-L1, MSI/MMR status, and CLDN18.2 are outlined in the following sections. The biomarkers that will define additional subsets are expected to grow.

### **Assessment of HER2 Overexpression**

Overexpression of the HER2 protein or amplification of the *ERBB2* gene has been implicated in the development of gastric adenocarcinoma.<sup>131</sup> However, unlike in breast cancer, the prognostic significance of HER2 status in gastric cancer is unclear. Some studies suggest that HER2 positivity is associated with poor prognosis<sup>132-137</sup> while others have shown that it is not an independent prognostic factor of patient outcome, except in a very small subgroup of patients with intestinal histology.<sup>138-140</sup> While further studies are needed to assess the prognostic significance of HER2 status in gastric cancer, the addition of HER2 monoclonal antibodies to chemotherapy regimens is a promising treatment option for patients with HER2 overexpression-positive disease.<sup>141</sup>

The reported rates of HER2 positivity in patients with gastric cancer range from 12% to 23%.<sup>132,133,139,140,142,143</sup> HER2 positivity also varies with the histologic subtype (intestinal > diffuse) and tumor grade (moderately differentiated > poorly differentiated).<sup>133,137,139,140,142</sup> HER2 positivity is reported in ≤20% of European and U.S. patients with metastatic gastric cancer with significantly higher rates seen in patients with intestinal histology (33% vs. 8% for diffuse/mixed histology;  $P = .001$ ).<sup>139</sup> In the U.S. population, the reported HER2 positivity rate in gastric cancer is 12% and is more often identified in the intestinal subtype rather than the diffuse subtype (19% and 6%, respectively).<sup>140</sup> The HER-EAGLE study, which examined the HER2 positivity rate in a large multinational population of nearly 5000 patients with gastric or EGJ adenocarcinoma, reported that

14.2% of samples were HER2 overexpression positive.<sup>144</sup> HER2 positivity was significantly higher in males versus females, in EGJ tumors versus stomach tumors, and in intestinal subtypes versus diffuse subtypes. In the ToGA trial, which evaluated the addition of trastuzumab to chemotherapy in patients with HER2 overexpression-positive advanced gastric or EGJ cancers, HER2 positivity rates were 32.2%, 21.4%, 31.8%, and 6.1%, respectively, in patients with EGJ adenocarcinoma, gastric adenocarcinoma, intestinal gastric adenocarcinoma, and diffuse gastric adenocarcinoma.<sup>145,146</sup> Therefore, subclassification of gastric adenocarcinomas as intestinal or diffuse type may have implications for therapy.

HER2 testing is recommended for all patients with gastric cancer at the time of diagnosis if advanced/metastatic disease is documented or suspected. In concordance with HER2 testing guidelines from the College of American Pathologists (CAP), the American Society for Clinical Pathology (ASCP), and the American Society for Clinical Oncology (ASCO),<sup>147</sup> the NCCN Guidelines® for Gastric Cancer recommend using IHC and, if needed, ISH techniques to assess HER2 status in gastric cancer. As stated above, IHC/ISH/targeted PCR is preferred, followed by NGS later in the clinical course as appropriate. Repeat biomarker testing may be considered at clinical or radiologic progression of advanced or metastatic disease.

IHC evaluates the membranous immunostaining of tumor cells, including the intensity and extent of staining and the percentage of immunoreactive tumor cells, with scores ranging from 0 (negative) to 3+ (positive). In 2008, Hofmann et al refined this 4-tiered scoring system to assess HER2 status in gastric cancer by using a cut-off of ≥10% immunoreactive tumor cells.<sup>146,148</sup> In a subsequent validation study ( $n = 447$  prospective diagnostic gastric cancer specimens), this scoring system was found to be reproducible between different pathologists.<sup>149</sup> This modified HER2 scoring system is therefore recommended by the

# NCCN Guidelines Version 3.2025

## Gastric Cancer

Panel. A score of 0 (membranous reactivity in <10% of cancer cells) or 1+ (faint membranous reactivity in ≥10% of cancer cells) is considered HER2-negative.<sup>147</sup> A score of 2+ (weak to moderate membranous reactivity in ≥10% of cancer cells) is considered equivocal and should be additionally examined by fluorescence in situ hybridization (FISH) or other ISH methods. FISH/ISH results are expressed as the ratio between the number of copies of the *ERBB2* gene and the number of chromosome 17 centromeres (CEP17) within the nucleus counted in at least 20 cancer cells (*ERBB2*:CEP17). Alternatively, FISH/ISH results may be given as the average *ERBB2* copy number per cell. Cases that have an IHC score of 3+ (strong membranous reactivity in ≥10% of cancer cells)<sup>147</sup> or an IHC score of 2+ and are FISH/ISH positive (*ERBB2*:CEP17 ratio ≥2 or average *ERBB2* copy number ≥6 signals/cell) are considered HER2 overexpression positive. Positive (3+) or negative (0 or 1+) HER2 IHC results do not require further ISH testing. See *Principles of Pathologic Review and Biomarker Testing: Assessment of Overexpression or Amplification of HER2 in Gastric Cancer - Table 3* in the algorithm for more information.

### **MSI and/or MMR Testing**

It is well-established that MSI-H or dMMR can occur in various malignancies. Microsatellites are mutational hotspots, and loss of functional MMR facilitates elevated mutation events at these sites.<sup>118</sup> Prevalence of MSI-H/dMMR in gastric cancer can vary depending on factors including disease stage, sex and age, histologic type, and tumor location. Specifically, MSI-H/dMMR status is associated with earlier stage, ≥68 years of age, intestinal subtype, and if the tumor is in the distal stomach.<sup>116,119,150-153</sup> Analysis of gastric adenocarcinoma data from TCGA showed an incidence of 22% for MSI-H tumors.<sup>116</sup> Similarly, a pan-cancer whole-exome sequencing analysis of numerous tumor-normal pairs from both TCGA and the Therapeutically Applicable Research to Generate Effective Treatments project reported an incidence of 19% in MSI-

H/dMMR in gastric tumors.<sup>154</sup> Better prognosis has been reported with MSI-H/dMMR gastric tumors compared to microsatellite stable/MMR-proficient tumors,<sup>150,151,155</sup> including for those with MSI-H/dMMR who receive immunotherapy.<sup>156,157</sup>

Universal testing for MSI by PCR/NGS or MMR by IHC should be performed for all newly diagnosed patients with gastric cancer. PCR/NGS for MSI and IHC for MMR proteins measure different biological effects caused by dMMR function. MSI status of the tumor can be assessed by PCR to determine shifts in validated microsatellite markers (eg, mononucleotide repeats *BAT25*, *BAT26*, *MONO27*, *NR21*, *NR24*).<sup>158</sup> MMR deficiency is evaluated by IHC to assess nuclear expression of proteins involved in DNA MMR (ie, *MLH1*, *MSH2*, *MSH6*, *PMS2*).<sup>159</sup> Testing is performed on formalin-fixed, paraffin-embedded (FFPE) tissue and results are interpreted as MSI-H or dMMR in accordance with [CAP DNA Mismatch Repair Biomarker Reporting Guidelines](#).<sup>160</sup> Testing should be performed only in CLIA-approved laboratories. Patients with MSI-H or dMMR tumors should be referred to a genetics counselor for further assessment in the appropriate clinical context.

### **PD-L1 Testing**

Binding of the programmed cell death protein 1 (PD-1) receptor by its ligand PD-L1 is a critical immune checkpoint blockade that negatively affects T cell function and proliferation. Tumor cells can express PD-L1 and exploit PD-1/L1 binding to facilitate immune evasion, tumor growth/survival, and moderate activity of different immune cell types and signaling.<sup>161-163</sup> This makes PD-1/L1 a valuable target, and PD-1/L1 inhibitors have emerged as beneficial therapeutic options for certain patients (see *Targeted Therapies*).

PD-L1 expression has been frequently observed in the intestinal subtype,<sup>164-166</sup> though some studies have not observed a significant



## NCCN Guidelines Version 3.2025

# Gastric Cancer

association with histologic subtype.<sup>167</sup> PD-L1 is reportedly associated with MSI-H and Epstein-Barr virus (EBV) positivity in gastric tumors.<sup>116,164,165,167,168</sup> The prognostic significance of PD-L1 in gastric cancer remains unclear. This may be due to different factors such as PD-L1 testing variability or small sample size. Currently, some studies suggest a significant favorable association with survival outcomes,<sup>157,165,166</sup> while others showed an unfavorable or no relationship between PD-L1 and survival.<sup>167,169</sup>

Universal testing for PD-L1 by IHC should be performed for all newly diagnosed patients with gastric cancer who are candidates for treatment with PD-1 or PD-L1 inhibitors. A companion diagnostic test should be used to identify patients for treatment with PD-1 or PD-L1 inhibitors. The companion diagnostic test is a qualitative IHC assay using anti-PD-L1 antibodies for the detection of PD-L1 protein levels in FFPE tumor tissue. A minimum of 100 tumor cells must be present in the PD-L1-stained slide for the specimen to be adequately evaluated. Combined positive score (CPS) is determined by the number of PD-L1-stained cells (ie, tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells evaluated, multiplied by 100. A specimen is considered to have PD-L1 expression if the CPS is  $\geq 1$ . PD-L1 testing should be performed only in CLIA-approved laboratories. Tumor proportion score (TPS) and tumor area positivity (TAP) score are also considered and reported in some trials. TPS is not included in these Guidelines. TAP score is a visual determinant of PD-L1 positivity, rather than counting individual cells. The percentage of tumor and immune cells stained for PD-L1 is divided by the whole tumor area.<sup>170</sup> CPS and TAP score have shown high concordance and appear interchangeable.<sup>171,172</sup>

### Claudin 18 Isoform 2

CLDN18.2 is a tight junction transmembrane protein that is typically expressed in normal gastric epithelia and is retained during malignant

transformation.<sup>173,174</sup> CLDN18.2-positive tumors represent 24% to 38% of advanced gastric and EGJ adenocarcinomas.<sup>175-178</sup> However, due to variations in detection methods, assays used, and differing definitions of CLDN18.2 positivity, the percentage of CLDN18.2-positive tumors can vary across the literature.<sup>179</sup> CLDN18.2 expression has been observed in intestinal-type gastric tumors, but is more commonly seen in the diffuse subtype.<sup>175,176,178,180</sup> CLDN18.2 positivity has been shown independent of other established molecular subtypes (eg, dMMR, HER2 status) and PD-L1.<sup>176-178</sup> Association between CLDN18.2 and EBV status is unclear, as certain studies have reported a significant correlation between the two,<sup>175,176</sup> while another study reported no significance.<sup>177</sup>

Changes in tumor cell adhesion and polarity expose the normally inaccessible CLDN18.2 protein, which makes it a unique molecular target.<sup>181,182</sup> Testing is recommended for untreated patients who have unresectable locally advanced, recurrent, or metastatic gastric adenocarcinoma and zolbetuximab is being considered. Tumors are considered CLDN18.2 positive if  $\geq 75\%$  of viable tumor cells demonstrate moderate to strong membranous CLDN18.2 staining (2+ or 3+ intensity) by a qualitative IHC assay for FFPE tumor tissue.<sup>173,183</sup>

### Liquid Biopsy

The genomic alterations of solid cancers may be identified by evaluating circulating tumor DNA (ctDNA) in the blood, hence a form of "liquid biopsy."<sup>135,184</sup> The detection of mutations/alterations or fusions in DNA shed from gastric carcinomas can identify targetable alterations or the evolution of clones with altered treatment response profiles. In one study, a complete or partial response to immunotherapy was achieved by 63% of patients with advanced gastric carcinoma who tested positive for MSI by cell-free DNA analysis.<sup>184</sup> In another study that analyzed the genomic alterations of 55 patients with advanced gastroesophageal adenocarcinomas using NGS performed on plasma-derived ctDNA, 69%

# NCCN Guidelines Version 3.2025

## Gastric Cancer

of patients had one or more characterized alterations theoretically targetable by a U.S. Food and Drug Administration (FDA)-approved agent (on- or off-label).<sup>135</sup> Therefore, when limited tissue is available or for patients who have advanced or metastatic gastric cancer who are not able to undergo a traditional biopsy, testing using a validated NGS-based comprehensive genomic profiling assay performed in a CLIA-approved laboratory may be considered. A negative result should be interpreted with caution, as this does not exclude the presence of a tumor.

### **Emerging Biomarkers**

#### *Tumor Epstein-Barr Virus*

Tumor EBV status is emerging as a potential biomarker for personalized treatment strategies in gastric cancer. An estimated 8% to 10% of gastric cancers are associated with EBV infection, making EBV-positive gastric cancer the largest group of EBV-associated malignancies.<sup>185,186</sup> EBV-positive tumors occur preferentially in the proximal stomach and are associated with diffuse-type histology and early onset.<sup>11</sup> Although the prognostic value of EBV status on the survival of patients with gastric cancer remains a subject of debate, several studies suggest that patients with EBV-positive gastric cancer have better OS rates compared to other genotypes.<sup>187-191</sup> Additional studies have shown that expression of PD-L1 is elevated in EBV-positive gastric cancers and is associated with decreased OS rates.<sup>192-194</sup> Furthermore, Derk et al reported that an interferon-γ-driven gene signature was enriched in EBV-positive gastric cancers, suggesting increased sensitivity to PD-1/PD-L1 immunotherapies.<sup>193</sup> Therefore, PD-1/PD-L1 immunotherapies may be a viable option to treat patients with EBV-positive gastric cancer; however, more data are needed to substantiate this claim. Due to the lack of prospective trials and limited understanding of the exact association between EBV and gastric cancer, testing for EBV status is not currently recommended for routine clinical care. However, EBV testing should be

performed if the morphology of the tumor contains prominent lymphoid stroma.

### **Principles of Surgery**

Surgery is the primary treatment option for patients with localized gastric cancer. Complete resection with negative margins is widely considered as a standard goal, whereas the type of resection (subtotal vs. total gastrectomy) and the extent of lymph node dissection remain subjects of controversy.

Clinical staging using chest/abdomen/pelvis CT scan, with or without EUS (if no metastatic disease is seen on CT), should be performed before surgery to assess the extent of the disease and degree of nodal involvement. The primary goal of surgery is to accomplish a complete resection with negative margins (R0 resection); however, only 50% of patients will have an R0 resection of their primary tumor.<sup>195,196</sup> An R1 resection indicates microscopic residual disease and an R2 resection indicates macroscopic residual disease in the absence of distant metastasis.<sup>197</sup> Adequate gastric resection to achieve negative microscopic margins along with lymphadenectomy is preferred for resectable T1b to T3 tumors, while T4b tumors require en-bloc resection of involved structures.<sup>198</sup> Patients with Tis or T1a tumors may be considered for EMR or ESD if they meet appropriate criteria (in experienced centers).

Subtotal gastrectomy has a similar surgical outcome compared to total gastrectomy for distal gastric cancers, although with significantly fewer complications.<sup>199</sup> Proximal gastrectomy and total gastrectomy are both indicated for proximal gastric cancers and are typically associated with postoperative nutritional impairment. Placement of a feeding tube should be considered for select patients undergoing total gastrectomy, especially those receiving postoperative chemoradiation.

# NCCN Guidelines Version 3.2025

## Gastric Cancer

Routine splenectomy is not indicated unless the spleen is involved or extensive hilar adenopathy is noted. In a randomized clinical study, postoperative mortality and morbidity rates were significantly higher in patients who underwent total gastrectomy combined with splenectomy compared to those who underwent total gastrectomy alone.<sup>200</sup> A recently published meta-analysis of randomized controlled trials also concluded that splenectomy should not be recommended for proximal gastric cancer since it increases operative morbidity without improving OS when compared to spleen-preserving procedures.<sup>201</sup> The results of these studies do not support the use of prophylactic splenectomy or removal of macroscopically negative lymph nodes near the spleen in patients undergoing total gastrectomy for proximal gastric cancer.

In patients with incurable disease, gastric resections should be reserved for the palliation of symptoms (eg, obstruction or uncontrollable bleeding) when nonsurgical options are not feasible such as endoscopic or interventional radiology procedures (ie, endoscopic stenting). Also, it does not need to include lymph node dissection.<sup>49,202</sup> In patients fit for surgery and who have a reasonable prognosis, gastrojejunostomy (open or laparoscopic) or endoluminal stenting are options. Except for rare cases that may have slow growth, endoluminal stenting is preferred in patients with gastric outlet obstruction/disease and very minimal metastatic disease in the liver or other area not affecting the GI tract. If longer-term palliation is needed, surgical bypass may be considered.<sup>203,204</sup> Venting gastrostomy and/or a feeding tube may also be considered.

Gastric adenocarcinoma is considered unresectable if there is evidence of peritoneal involvement (including positive peritoneal cytology), distant metastases, or locally advanced disease (N3 lymph node involvement or invasion/encasement of major vascular structures, excluding the splenic vessels). Limited gastric resection, even with positive margins, is acceptable for patients with unresectable tumors for the palliation of symptomatic bleeding.

### Lymph Node Dissection

Gastric resection should include the removal of regional lymph nodes (lymphadenectomy). Lymph node dissection may be classified as D0, D1, or D2 depending on the extent of lymph node removal at the time of gastrectomy. D0 dissection refers to an incomplete resection of lymph nodes along the lesser and greater curvature of the stomach. D1 dissection involves the removal of the greater and lesser omenta (which includes the right and left cardiac lymph nodes along lesser and greater curvature and the suprapyloric lymph nodes along the right gastric artery and infra-pyloric area). D2 involves D1 dissection plus the removal of all the lymph nodes along the left gastric artery, common hepatic artery, celiac artery, and splenic artery. The technical aspects of performing a D2 lymph node dissection require a significant degree of training and expertise. Therefore, D2 dissections should be performed in centers experienced with this technique.

Gastrectomy with D2 lymph node dissection is the standard treatment for curable gastric cancer in East Asia. In Western countries, extended dissection of distant lymph nodes contributes to accurate staging of the disease; however, its contribution to the prolongation of survival is unclear.<sup>129,205,206</sup> Results from two large randomized trials performed in Western countries did not demonstrate a significant survival benefit for D2 over D1 lymph node dissection.<sup>207,208</sup> In the Dutch Gastric Cancer Group Trial, 711 patients who underwent surgical resection with curative intent were randomized to undergo either a D1 or D2 lymph node dissection.<sup>207</sup> The postoperative morbidity (25% vs. 43%;  $P < .001$ ) and mortality (4% vs. 10%;  $P = .004$ ) rates were higher for patients who underwent D2 lymph node dissection, with no difference in OS (30% vs. 35%;  $P = .53$ ) between the two groups. After a median follow-up of 15 years, D2 lymph node dissection was associated with lower local recurrence (12% vs. 22%), regional recurrence (13% vs. 19%), and gastric cancer-related deaths (37% vs. 48%) than D1 lymph node dissection, but OS rates were similar.



# NCCN Guidelines Version 3.2025

## Gastric Cancer

between the two groups (21% and 29%, respectively;  $P = .34$ ).<sup>209</sup> The British Cooperative trial conducted by the Medical Research Council also did not demonstrate a survival benefit for D2 over D1 lymph node dissection (5-year OS rates of 35% and 33%, respectively).<sup>208</sup> Therefore, D2 lymph node dissection is considered a recommended but not required procedure in the West.

In contrast, other reports from Western countries have suggested that D2 lymph node dissection is associated with lower postoperative complications and a trend toward improved survival when performed in high-volume centers that have sufficient experience with the operation and postoperative management.<sup>210-213</sup> In an analysis involving patients from the Intergroup 0116 trial, Enzinger et al assessed the impact of hospital volume on the outcomes of patients who underwent lymph node dissection (54% underwent D0 lymph node dissection and 46% underwent D1 or D2 lymph node dissection).<sup>210</sup> High-volume centers had no effect on OS or disease-free survival (DFS) for patients who underwent D0 lymph node dissection. However, there was a trend toward improved OS among patients who underwent D1 or D2 lymph node dissection at moderate- to high-volume cancer centers. In a randomized phase II trial of D1 versus D2 lymph node dissection conducted by the Italian Gastric Cancer Study Group involving 267 patients (133 patients allocated to D1 lymph node dissection and 134 patients allocated to D2 lymph node dissection), the 30-day postoperative morbidity and mortality rates were not significantly different between the two groups.<sup>211,212</sup> After a median follow-up of 8.8 years, the 5-year OS rates were 66.5% and 64.2% after D1 and D2 lymph node dissections, respectively, although this difference was not significant ( $P = .695$ ).<sup>212</sup>

Investigators have long argued that D2 lymph node dissection may be beneficial in select patients if the complication rate is decreased. Although pancreatectomy and splenectomy have been widely performed with D2 lymph node dissections in Japan, both of these procedures have been

shown to increase postoperative mortality and morbidity.<sup>207,208,214,215</sup> In a prospective, randomized, phase II study conducted by the Italian Gastric Cancer Study Group, pancreas-preserving D2 lymph node dissection was associated with a survival benefit and lower complication rate in patients with advanced gastric cancer.<sup>214,215</sup> Pancreatectomy was performed only when T4 tumor involvement was suspected. Postoperative complications were higher after D2 gastrectomy (16.3% vs. 10.5% after D1), but the difference was not significant ( $P = .29$ ). Postoperative mortality rates were 0% and 1.3%, respectively, in the D1 and D2 groups. The overall 5-year morbidity rate was 20.9% and the postoperative in-hospital mortality rate was 3.1% for D2 lymph node dissection without pancreatectomy.<sup>215</sup> These rates are comparable with the rates for D1 lymph node dissections in the Dutch and United Kingdom trials.<sup>207,208</sup> Meta-analyses have confirmed that among patients who underwent D2 lymph node dissections, there was a trend toward improved survival and lower gastric cancer-related mortality in patients who did not undergo resection of the spleen or pancreas.<sup>216-218</sup>

For patients with localized resectable gastric cancer, the NCCN Guidelines for Gastric Cancer recommend gastrectomy with a D1 or a modified D2 lymph node dissection, with a goal of examining  $\geq 16$  lymph nodes.<sup>205,209,214,215</sup> The guidelines emphasize that D2 lymph node dissections should be performed by experienced surgeons in high-volume centers. Routine or prophylactic pancreatectomy is not recommended with D2 lymph node dissection,<sup>200,219</sup> and splenectomy is acceptable only when the spleen is involved or extensive hilar adenopathy is noted.

### Laparoscopic Resection

Laparoscopic resection is an emerging surgical approach that offers several potential advantages (less blood loss, reduced postoperative pain, accelerated recovery, early return to normal bowel function, and reduced hospital stay) when compared to open surgical procedures for gastric cancer.<sup>220-222</sup> In a propensity score-matched analysis of 692 patients who



## NCCN Guidelines Version 3.2025

# Gastric Cancer

underwent total gastrectomy for gastric cancer, patients who received laparoscopic resection had less blood loss, shorter mean operation time, and a higher number of retrieved lymph nodes compared to patients who received an open procedure.<sup>223</sup> The 3-year cumulative survival rates after a median follow-up of 45 months were similar between the two groups. Results of a meta-analysis involving 9337 patients with advanced gastric cancer (5000 received laparoscopic gastrectomy and 4337 received open gastrectomy) showed that the laparoscopic procedure resulted in less intraoperative blood loss and faster recovery times.<sup>224</sup> However, there was no difference in operative time, number of harvested lymph nodes, postoperative mortality, or 5-year OS.

The safety and efficacy of laparoscopic resection versus standard open resection have been evaluated in several clinical trials in Asia. In the phase III CLASS-01 trial, 1056 Chinese patients with locally advanced gastric cancer (cT2 to cT4a) were randomized to receive laparoscopic or open distal gastrectomy, both with D2 lymph node dissection.<sup>225</sup> After 3 years, the DFS rate was 76.5% in the laparoscopic group and 77.8% in the open group (hazard ratio [HR] for recurrence = 1.069). The 3-year OS rates and cumulative incidence of recurrence were also similar between the two groups (83.1% and 18.8%, respectively, in the laparoscopic group and 85.2% and 16.5% in the open group), suggesting that the long-term oncologic outcomes of laparoscopic distal gastrectomy were noninferior to those of the conventional open surgery for patients with advanced gastric cancer. The randomized CLASS-02 trial compared the safety of laparoscopic and open total gastrectomy with lymphadenectomy in 277 patients with early-stage gastric cancer.<sup>226</sup> The rates of overall morbidity and mortality, intraoperative complications, and overall postoperative complications were not significantly different between the groups. Although one patient in the laparoscopic group died from intra-abdominal bleeding secondary to splenic artery hemorrhage, there was no significant difference in mortality between the laparoscopic and open groups. These

results showed that the safety of laparoscopic total gastrectomy with lymphadenectomy by experienced surgeons for early-stage gastric cancer was comparable to that of an open procedure.

The randomized phase III KLASS-01 trial reported the long-term outcomes of 1416 Korean patients with stage I gastric cancer randomized to receive laparoscopic or open gastrectomy.<sup>227</sup> The 5-year OS rates were 94.2% in the laparoscopic group and 93.3% in the open surgery group ( $P = .64$ ), and 5-year cancer-specific survival rates were 97.1% and 97.2%, respectively ( $P = .91$ ). Intention-to-treat analysis confirmed the noninferiority of laparoscopic gastrectomy compared with the open approach. Although these results suggest that laparoscopic resection may be a feasible surgical strategy, the role of this approach in the treatment of gastric cancer in Western countries requires further investigation. The randomized phase III KLASS-02 trial reported the long-term outcomes of laparoscopic or open subtotal distal gastrectomy with D2 lymphadenectomy in 974 Korean patients with locally advanced gastric cancer.<sup>228</sup> Compared to the open surgery group, the laparoscopy group suffered fewer early complications (15.7% vs. 23.4%;  $P = .0027$ ) and late complications (4.7% vs. 9.5%;  $P = .0038$ ). The 3-year relapse-free survival rate was 80.3% for the laparoscopy group and 81.3% for the open group ( $P = .726$ ). Therefore, the outcomes of laparoscopic distal gastrectomy with D2 lymphadenectomy were comparable to those of open surgery in patients with locally advanced gastric cancer.

Based on these and other data suggesting equivalent oncologic outcomes in the East and West, the Panel suggests that minimally invasive approaches may be considered for selected cases provided that the surgeon has experience in performing laparoscopic or robotic foregut procedures and has experience in lymphadenectomy.<sup>229</sup> Minimally invasive approaches are generally not recommended for T4b or N2 bulky gastric cancer.



## NCCN Guidelines Version 3.2025

# Gastric Cancer

### Principles of Radiation Therapy

RT has been assessed in randomized trials in both the preoperative and postoperative settings in patients with resectable gastric cancer. Smalley et al have reviewed clinical and anatomic issues related to RT and offer detailed recommendations for the application of RT to the comprehensive care of patients with gastric cancer.<sup>230</sup>

RT as a single modality has minimal value in patients with unresectable gastric cancer.<sup>231</sup> However, early studies showed that RT improved survival when used concurrently with chemotherapy. Moertel et al assessed fluorouracil plus RT compared with RT alone in the treatment of locally advanced unresectable gastric cancer.<sup>56</sup> Patients receiving combined modality treatment had significantly better median OS (13 vs. 6 months) and 5-year OS (12% vs. 0%) rates compared to those receiving RT alone. In another study by the Gastrointestinal Tumor Study Group, 90 patients with locally advanced gastric cancer were randomized to receive either combination chemotherapy with fluorouracil and lomustine or split-course RT with concurrent bolus fluorouracil followed by maintenance with fluorouracil and lomustine.<sup>232</sup> At 3 years, the survival curve reached a plateau in the combined modality arm while tumor-related deaths continued to occur in the chemotherapy-alone arm, suggesting that a small fraction of patients can be cured with combined modality therapy.

Randomized clinical trials have also been conducted to compare surgery alone to surgery plus RT in patients with resectable gastric cancer. In a trial conducted by the British Stomach Cancer Group, 432 patients were randomized to undergo surgery alone or surgery followed by either RT or chemotherapy.<sup>233</sup> At the 5-year follow-up, no survival benefit was seen for patients receiving postoperative RT or chemotherapy compared with those who underwent surgery alone. However, there was a significant reduction in locoregional recurrence with the addition of RT to surgery (27% for surgery vs. 10% for surgery plus RT and 19% for surgery plus

chemotherapy). The results from a systematic review and meta-analysis also showed a significant 5-year survival benefit with the addition of RT to surgery in patients with resectable gastric cancer.<sup>234</sup>

The addition of chemotherapy to RT in the preoperative setting has also been studied in this patient population. In the global, randomized phase II/III TOPGEAR trial ( $n = 574$ ), patients with resectable gastric or EGJ cancer received either preoperative chemoradiation plus perioperative chemotherapy or perioperative chemotherapy only.<sup>235</sup> More patients who underwent resection in the preoperative chemoradiation therapy arm had a pathologic CR (17%) compared to perioperative chemotherapy (8%). However, at median 67-month follow-up, survival outcomes were not significantly different between the two treatment arms, and no survival benefit was reported for a specific subgroup in their analyses.<sup>235</sup> Median OS was 46 months with preoperative chemoradiation compared to 49 months with perioperative chemotherapy only (HR for death, 1.05). Similarly, median PFS with preoperative chemoradiation was not significantly different than with perioperative chemotherapy (31 vs. 32 months; HR for progression or death, 0.98).<sup>235</sup> Therefore, the Panel does not recommend preoperative chemoradiation for resectable gastric cancer.

Intensity-modulated RT (IMRT) has the potential to reduce radiation-related toxicity by delivering large doses of RT to target tissues while sparing adjacent organs. Retrospective studies have shown that IMRT can lead to improved organ sparing and lower toxicity, compared to 3D conformal techniques.<sup>236-239</sup>

Over time, the role of radiation has been limited for palliation of symptoms (bleeding, pain, dysphagia).

### General Guidelines

RT treatment recommendations should be made after joint consultation and/or discussion by a multidisciplinary team, which should include



# NCCN Guidelines Version 3.2025

## Gastric Cancer

medical oncologists, radiation oncologists, surgical oncologists, radiologists, gastroenterologists, and pathologists. Imaging studies and endoscopy reports should be reviewed by this multidisciplinary team to ensure an informed determination of treatment volume and field borders prior to simulation. All available information from pretreatment diagnostic studies should be used to determine the target volume. Image guidance may be used appropriately to enhance clinical targeting. In general, Siewert Type I and II tumors should be managed with RT guidelines applicable to esophageal and EGJ cancers (see the NCCN Guidelines for Esophageal and EGJ Cancers [available at [www.nccn.org](http://www.nccn.org)]). Depending on the clinical situation, Siewert Type III tumors may be appropriately managed with RT guidelines applicable to either esophageal and EGJ cancers or gastric cancer. These recommendations may be modified depending on the location of the bulk of the tumor.

A dose range of 45 to 50.4 Gy delivered in fractions of 1.8 Gy per day is recommended by the Panel. Higher doses may be used as a boost for positive surgical margins in select patients.

### Simulation and Treatment Planning

CT simulation and conformal treatment planning should be used. IV and/or oral contrast may be used for CT simulation to aid in target localization when clinically appropriate. It is optimal to treat patients in the supine position, as this setup is generally more stable and reproducible. The use of an immobilization device is strongly recommended for reproducibility. Motion management techniques, such as 4D-CT planning, may be appropriately utilized in select circumstances where organ motion with respiration may be significant.

IMRT may be used in clinical settings where dose reduction to organs at risk is required.<sup>236-239</sup> Target volumes need to be carefully defined and encompassed when designing IMRT plans. Uncertainties from variations in stomach filling and respiratory motion should be considered. In

designing IMRT for organs at risk, attention should be given to the volume receiving low to moderate doses, as well as the volume receiving high doses.

### Target Volume

In the postoperative setting, clip placement should be performed in addition to pretreatment diagnostic studies to identify the tumor/gastric bed, the anastomosis or stumps, and pertinent nodal groups.<sup>58,230</sup> Treatment of the remaining stomach should depend on a balance of the normal tissue morbidity and the risk of local recurrence in the residual stomach.

The relative risk of nodal metastases at a specific location is dependent on the site of the primary tumor and other factors including the depth of invasion into the gastric wall. Nodal areas at risk include the perigastric, celiac, left gastric artery, splenic artery, splenic hilar, hepatic artery, porta hepatic, suprapyloric, subpyloric, and pancreaticoduodenal lymph nodes. Coverage of nodal areas may be modified based on clinical circumstances and the risks of toxicity. See *Principles of Radiation Therapy - Target Volume* in the algorithm for more information.

### Normal Tissue Tolerance and Dose Limits

Treatment planning is essential to reduce unnecessary RT doses to organs at risk (liver, kidneys, small bowel, spinal cord, heart, and lungs) and to limit the volume of organs at risk receiving high RT doses. Particular effort should be made to keep RT doses to the left ventricle of the heart to a minimum. Additionally, lung dose-volume histogram (DVH) parameters can be used as predictors of pulmonary complications in patients treated with concurrent chemoradiation. Although every effort should be made to minimize RT doses to organs at risk, it is recognized that these dose guidelines may be appropriately exceeded based on clinical circumstances.



# NCCN Guidelines Version 3.2025

## Gastric Cancer

### Supportive Care

Careful monitoring and management of acute toxicities with aggressive supportive care is essential to avoid treatment interruptions or dose reductions. During an RT treatment course, patients' vital signs, weight, and blood counts should be measured at least once per week.

Prophylactic antiemetics should be given when appropriate. Additionally, antacid and antidiarrheal medications may be prescribed when needed. If the estimated caloric intake is inadequate (<1500 kcal/day), oral and/or enteral nutrition should be considered. Feeding jejunostomy tubes or nasogastric feeding tubes may be placed to ensure adequate caloric intake. Adequate enteral and/or IV hydration is necessary throughout chemoradiation and recovery.

### Combined Modality Therapy

Combined modality therapy has been shown to significantly increase survival in patients with gastric cancer with locoregional disease.<sup>240-242</sup> Perioperative systemic therapy is recommended for localized resectable disease (category 1).<sup>52,54,55,241,243,244</sup> Postoperative chemoradiation is recommended for patients who received less than a D2 lymph node dissection.<sup>58,59,245</sup> Other treatment options include postoperative chemotherapy for patients who have undergone primary D2 lymph node dissection.<sup>60,62,63</sup> Chemoradiation alone should be reserved for patients with unresectable disease or those who decline surgery. Preoperative or perioperative ICIs can be considered for certain patients with an MSI-H/dMMR gastric tumor. Importantly, for MSI-H/dMMR tumors, a multidisciplinary team should be consulted for perioperative immunotherapy. The role of surgery following biopsy proven and confirmed radiologic/metabolic CR after preoperative immunotherapy is unclear.

### Perioperative Systemic Therapy

The survival benefit of perioperative chemotherapy in gastric cancer was first demonstrated in the landmark phase III MAGIC trial.<sup>244</sup> This study, which compared perioperative chemotherapy with epirubicin, cisplatin, and fluorouracil (ECF) to surgery alone, established that perioperative chemotherapy improves progression-free survival (PFS) and OS in patients with non-metastatic stage II and higher gastric or EGJ adenocarcinoma. In the randomized controlled phase II/III FLOT4 trial, Al-Batran et al compared perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) to the standard ECF regimen in patients with resectable non-metastatic gastric or EGJ adenocarcinoma ( $\geq$ cT2 and/or N+).<sup>54,246</sup> In the phase II part of the study, 265 patients were randomized to receive either three preoperative and postoperative cycles of ECF (n = 137) or four preoperative and postoperative cycles of FLOT (n = 128). Results showed that FLOT was associated with significantly higher proportions of patients achieving pathologic CR than was ECF (16%; 95% CI, 10–23 vs. 6%; 95% CI, 3–11; P = .02).<sup>246</sup> Additionally, FLOT was associated with a reduction in the percentage of patients experiencing at least one grade 3–4 adverse event (AE), including neutropenia, leucopenia, nausea, infection, fatigue, and vomiting (40% of patients in the ECF group vs. 25% of patients in the FLOT group). In the phase III part of the trial, 716 patients were randomized to receive FLOT (n = 356) or ECF (n = 360).<sup>54</sup> Results showed that median OS was increased in the FLOT group compared with the ECF group (50 vs. 35 months; HR, 0.77; 95% CI, 0.63–0.94). The percentage of patients with serious chemotherapy-related AEs was the same in the two groups (27% in the ECF group vs. 27% in the FLOT group). Therefore, ECF should no longer be recommended in this setting. However, because of considerable toxicity associated with the FLOT regimen, the Panel recommends its use in select patients with good performance status (category 1). The perioperative regimen for most



## NCCN Guidelines Version 3.2025

# Gastric Cancer

patients who have good to moderate performance status is fluorouracil and oxaliplatin (FOLFOX).

In the FNCLCC ACCORD 07 trial ( $n = 224$  patients; 25% had gastric adenocarcinoma), Ychou et al reported that perioperative chemotherapy with fluorouracil and cisplatin significantly increased the curative resection rate, DFS, and OS in patients with resectable cancer.<sup>52</sup> At a median follow-up of 5.7 years, the 5-year OS rate was 38% for patients in the perioperative chemotherapy group and 24% for patients in the surgery alone group ( $P = .02$ ). The corresponding 5-year DFS rates were 34% and 19%, respectively. Although this trial was prematurely terminated due to low accrual, the Panel feels that perioperative fluorouracil and cisplatin is a viable treatment option for patients with locally advanced resectable gastric cancer (category 1).

The phase III randomized CRITICS trial, which compared perioperative chemotherapy with preoperative chemotherapy followed by postoperative chemoradiation in 788 patients with resectable gastric adenocarcinoma, found that postoperative chemoradiation did not improve OS compared with postoperative chemotherapy.<sup>243</sup> Patients were randomized to receive either three preoperative and three postoperative cycles of modified ECF regimens (chemotherapy group;  $n = 393$ ) or capecitabine and cisplatin with concurrent RT (chemoradiation group;  $n = 395$ ). At a median follow-up of 61.4 months, median OS was 43 months (95% CI, 31–57) in the chemotherapy group and 37 months (95% CI, 30–48) in the chemoradiation group (HR, 1.01; 95% CI, 0.84–1.22;  $P = .90$ ). After a median follow-up of 6.7 years, the 5-year OS was 58% in the chemotherapy group versus 46% in the chemoradiation group (HR, 1.62;  $P = .0004$ ).<sup>247</sup> Therefore, adding RT to postoperative chemotherapy confers no survival benefit following adequate preoperative chemotherapy and surgery. Since there was poor postoperative adherence in both treatment groups, optimization of preoperative treatment strategies is integral. An ongoing phase II trial (CRITICS II) is comparing three

preoperative strategies (chemotherapy, concurrent chemoradiation, and sequential chemotherapy and chemoradiation) in participants with resectable gastric cancer (Clinical Trial ID: [NCT02931890](#)).<sup>248</sup>

In this setting, the use of the monoclonal PD-L1 antibody durvalumab in combination with FLOT is also a category 1, preferred option for certain patients. MATTERHORN was a global, randomized phase III trial investigating durvalumab with FLOT given perioperatively to patients with untreated resectable gastric or EGJ adenocarcinoma compared to placebo plus FLOT ( $n = 948$ ).<sup>55</sup> Event-free survival (EFS) was the primary endpoint. In all patients at 24 months, the EFS rate was 67.4% in the durvalumab arm versus 58.5% in the placebo arm (HR for event or death, 0.71;  $P < .001$ ). Subgroup analyses were performed based on PD-L1 TAP  $< 1\%$  ( $n = 95$ ) and PD-L1 TAP  $\geq 1\%$  ( $n = 853$ ). In the PD-L1 TAP  $\geq 1\%$  cohort, the HR for EFS with durvalumab versus placebo was 0.70 (95% CI: 0.57–0.87), and the HR in the PD-L1 TAP  $< 1\%$  cohort was 0.77 (95% CI: 0.40–1.46).<sup>55</sup> Notably, other studies evaluating an ICI in localized gastroesophageal cancers have reported non-significant or worse survival outcomes in cohorts with negative PD-L1 expression,<sup>249–252</sup> suggesting the benefit of ICIs in this setting is associated with PD-L1 positive tumors. Therefore, the Panel recommends this regimen for patients whose tumors are PD-L1 CPS  $\geq 1$  or TAP  $\geq 1\%$ . An analysis based on histologic type showed no EFS benefit of adding durvalumab to FLOT for patients with a diffuse type tumor (HR, 0.93).<sup>55</sup> Additionally, pathologic CR rate favored the addition of durvalumab compared to placebo. Delayed surgery was reported for ~10% of patients in each treatment arm and a similar percentage of patients in the durvalumab or placebo cohort had an R0 resection (80% vs 78%, respectively). Similar incidence of grade 3 and 4 AEs was observed between durvalumab and placebo (72% vs. 71%, respectively). Immune-related AEs were reported in a higher percentage of patients in the durvalumab arm, with grade 3 or 4 immune-related AEs observed in 7% of patients with durvalumab versus 4% with placebo.<sup>55</sup>

# NCCN Guidelines Version 3.2025

## Gastric Cancer

### Preoperative or Perioperative Immunotherapy

For certain patients with MSI-H/dMMR gastric tumors, immunotherapy in the neoadjuvant or perioperative setting may be an option. The GERCOR NEONIPIGA phase II trial investigated the use of neoadjuvant nivolumab (monoclonal PD-1 antibody) plus ipilimumab (monoclonal CTLA-4 antibody) followed by adjuvant nivolumab in 32 patients with locally advanced gastric or EGJ adenocarcinoma and confirmed MSI-H/dMMR.<sup>253</sup> Following neoadjuvant therapy, 29 patients underwent R0 resection and a little more than half (~59%) had a pathologic CR. Of the 31 patients evaluated for survival, 97% had a survival benefit.<sup>253</sup> The Panel recommends nivolumab plus ipilimumab followed by nivolumab as a category 2A option useful in certain circumstances for patients with MSI-H/dMMR gastric tumors in the neoadjuvant or perioperative settings.

In another phase II trial, 35 patients with locally advanced MSI-H/dMMR solid tumors (most with stage III colorectal cancer) received neoadjuvant pembrolizumab (monoclonal PD-1 antibody).<sup>254</sup> Among 33 patients assessed, the overall response rate (ORR) was 82% and CR was observed in 30% of patients. Out of 17 patients whose tumors were surgically resected, 65% had a pathologic CR.<sup>254</sup> Individual case reports have also shown certain patients with MSI-H/dMMR gastric cancer may benefit from neoadjuvant pembrolizumab.<sup>255</sup> Based on these data, the Panel recommends pembrolizumab as a category 2A option useful in certain circumstances for patients with MSI-H/dMMR gastric tumors in the neoadjuvant or perioperative settings.

The combination of tremelimumab, a CTLA-4 inhibitor, and durvalumab, a PD-L1 inhibitor, was previously approved by the FDA for unresectable hepatocellular carcinoma and for certain patients with metastatic non-small cell lung cancer (NSCLC). These ICIs have also been investigated in combination in gastric cancer. In a randomized phase Ib/II trial, previously treated patients with gastric or EGJ cancer received either tremelimumab

monotherapy, durvalumab monotherapy, or the combination.<sup>256</sup> There was no significant difference in ORR and PFS between the combination and either durvalumab or tremelimumab monotherapy, and median OS between the same treatment arms was 9.2, 3.4, and 7.7 months, respectively. The most common AEs regardless of treatment were fatigue, decreased appetite, diarrhea, and pruritis.<sup>256</sup> In the ongoing phase II INFINITY trial, patients with resectable MSI-H/dMMR gastric or EGJ adenocarcinoma received preoperative or definitive tremelimumab/durvalumab. Primary endpoint analysis showed a pathologic CR rate of 60% in the preoperative arm, and those who had pathologic CR were negative for ctDNA prior to surgery.<sup>257</sup> The Panel recommends tremelimumab and durvalumab as preoperative therapy only (category 2A, useful in certain circumstances).

### Postoperative Chemoradiation Therapy

The landmark INT-0116 trial investigated the effectiveness of surgery followed by postoperative chemotherapy plus chemoradiation on the survival of patients with resectable gastric or EGJ adenocarcinoma.<sup>58,59</sup> In this trial, 556 patients (stage IB to IV, M0) who had not received preoperative therapy were randomized to receive surgery followed by postoperative chemotherapy plus chemoradiation ( $n = 281$ ; bolus fluorouracil and leucovorin before and after concurrent chemoradiation with the same regimen) or surgery alone ( $n = 275$ ).<sup>58</sup> The majority of patients had T3 or T4 tumors (69%) and node-positive disease (85%). After a median follow-up of 5 years, median OS in the surgery-only group was 27 months compared to 36 months in the postoperative chemotherapy plus chemoradiation group ( $P = .005$ ). The postoperative chemotherapy plus chemoradiation group also had better 3-year OS (50% vs. 41%) and RFS rates (48% vs. 31%) than the surgery-only group. There was also a significant decrease in local failure as the first site of failure in the chemoradiation group (19% vs. 29%). After a median follow-



## NCCN Guidelines Version 3.2025

# Gastric Cancer

up of >10 years, survival remained improved in patients treated with postoperative chemoradiation.<sup>59</sup>

The results of the INT-0116 trial established the efficacy of postoperative chemoradiation in patients with completely resected gastric or EGJ adenocarcinoma who have not received preoperative therapy. However, the dosing and schedule of chemotherapy agents used in this trial were associated with high rates of grade 3–4 hematologic and GI toxicities (54% and 33%, respectively). Among the 281 patients assigned to the chemoradiation group, 17% discontinued treatment and three patients died as a result of chemoradiation-related toxicities, including pulmonary fibrosis, cardiac events, and myelosuppression. Therefore, the doses and schedule of chemotherapy agents used in the INT-0116 trial are not recommended by the Panel due to concerns regarding toxicity. See *Principles of Systemic Therapy—Regimens and Dosing Schedules* in the algorithm for recommended modifications to this regimen.

The degree of lymph node dissection during gastrectomy may influence the efficacy of postoperative chemoradiation. A retrospective analysis that compared the outcomes of patients treated with surgery alone to patients treated with postoperative fluoropyrimidine-based chemoradiation reported that postoperative chemoradiation was associated with significantly lower recurrence rates after D1 lymph node dissection. However, there was no significant difference in recurrence rates between the two groups following D2 lymph node dissection.<sup>245</sup> The results of the phase III ARTIST trial confirmed that postoperative chemoradiation did not significantly reduce recurrence rates after D2 lymph node dissection in patients with curatively resected gastric cancer compared to postoperative chemotherapy.<sup>60,258</sup> Interestingly, postoperative chemoradiation was associated with a significant prolongation of 3-year DFS compared to postoperative chemotherapy in a subgroup (ad-hoc) of patients with positive lymph nodes (78% vs. 72%;  $P = .0365$ ).<sup>258</sup> However, the phase III ARTIST II trial demonstrated no survival benefit for the addition of radiation to

postoperative chemotherapy in 546 patients with node-positive, D2-resected gastric cancer (3-year DFS of 74.3% vs. 72.8% for postoperative chemotherapy and postoperative chemoradiation, respectively; HR, .971;  $P = .879$ ).<sup>259</sup> Therefore, postoperative chemoradiation is recommended for patients who received less than a D2 lymph node dissection while patients who received a D2 lymph node dissection should be treated with postoperative chemotherapy.

### Postoperative Chemotherapy

The phase III CLASSIC trial (conducted in South Korea, China, and Taiwan) evaluated postoperative chemotherapy with capecitabine and oxaliplatin after curative gastrectomy with D2 lymph node dissection in 1035 patients with stage II or IIIB gastric cancer.<sup>62,63</sup> In this study, patients were randomized to receive either surgery alone ( $n = 515$ ) or surgery followed by postoperative chemotherapy ( $n = 520$ ). After a median follow-up of 34.2 months, postoperative chemotherapy with capecitabine and oxaliplatin significantly improved 3-year DFS (74%) compared to surgery alone (59%) for all disease stages ( $P < .0001$ ).<sup>62</sup> After a median follow-up of 62.4 months, the estimated 5-year DFS rate was 68% for the postoperative chemotherapy group compared to 53% for the surgery alone group; the corresponding estimated 5-year OS rates were 78% and 69%, respectively.<sup>63</sup> Therefore, the Panel supports the use of postoperative chemotherapy with capecitabine and oxaliplatin after D2 lymph node dissection in patients with advanced resectable gastric cancer (category 1). The Panel also endorses the use of FOLFOX in this setting. However, it should be noted that the benefit of postoperative chemotherapy following a D1 or D0 lymph node dissection has not been documented in randomized clinical trials. Thus, postoperative chemoradiation remains the treatment of choice for this patient population.<sup>58,59,245</sup>



# NCCN Guidelines Version 3.2025

## Gastric Cancer

### Peritoneal Carcinoma as Only Disease

For many patients with locally advanced or metastatic gastric cancer, there is a high risk of peritoneal disease, which confers a poor prognosis. The blood-peritoneal barrier presents challenges in effectively treating the disease.<sup>260,261</sup> For selected patients with only peritoneal metastatic disease, see *Peritoneal Carcinoma As Only Disease* in the algorithm for Panel recommendations. Briefly, following workup (if not previously done), selected patients should be given systemic therapy for a minimum of 3 months. Before considering further therapy, patients should undergo restaging. Multidisciplinary discussion is then recommended for patients with low peritoneal cancer index (PCI) ( $\leq 10$ ), improved or stable disease, and no metastasis/extraperitoneal disease to determine status for cytoreduction. Regardless of whether complete or incomplete cytoreduction is predicted, these patients have the option of clinical trial participation or continuing systemic therapy. Only patients who are likely to have complete cytoreduction of all visible nodes/plaques have the option of gastrectomy with cytoreductive surgery and intraperitoneal chemotherapy (IC)/hyperthermic intraperitoneal chemotherapy (HIPEC). For patients with high PCI ( $> 10$ ) and disease progression or extraperitoneal disease, the Panel recommends systemic therapy, clinical trial participation, or best supportive care.

### IC/HIPEC

Only case reports and small series are available to support the use of IC/HIPEC/pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in resectable gastric tumors. The HIPEC procedure involves the continuous circulation of a heated sterile chemotherapy-containing solution throughout the peritoneal cavity following cytoreductive surgery. HIPEC enables the infusion of high doses of chemotherapy directly into the abdominal cavity, where traditional methods of chemotherapy cannot effectively reach. Similarly, PIPAC is the introduction of chemotherapy

directly to the abdomen but via aerosol. Note that PIPAC is considered investigational and should only be performed in the context of a clinical trial. Therefore, the focus of this section is on HIPEC and the Panel's recommendations.

HIPEC can potentially improve long-term outcomes and provide more treatment options for certain patients with advanced gastric cancer. This technique is currently under investigation in clinical trials. In the CYTO-CHIP study, which included 277 patients with peritoneal metastases from gastric cancer who underwent cytoreductive surgery with HIPEC ( $n = 180$ ) or cytoreductive surgery alone ( $n = 97$ ), the addition of HIPEC improved OS and recurrence-free survival, without increasing morbidity or mortality.<sup>262</sup> However, the median PCI remained higher in the HIPEC group following treatment. Therefore, cytoreductive surgery with HIPEC may be effective for strictly selected patients with limited peritoneal metastases.

In a phase II trial, 20 patients with gastric adenocarcinoma and positive peritoneal cytology or carcinomatosis who completed systemic chemotherapy and laparoscopic HIPEC underwent cytoreduction, gastrectomy, and HIPEC. The 90-day morbidity and mortality rates were 70% and 0%, respectively. A median OS of 16.1 months was observed from the time of cytoreduction, gastrectomy, and HIPEC. The OS rates for 1, 2, and 3 years from the diagnosis of metastatic disease were 90%, 50%, and 28%, respectively.<sup>263</sup> In a phase III trial, 68 patients with gastric cancer and peritoneal carcinomatosis were randomized to receive cytoreductive surgery alone or cytoreductive surgery with HIPEC.<sup>264</sup> At a median follow-up of 32 months, death occurred in 97% of cases in the surgery alone group and 85% of cases in the surgery plus HIPEC group. The median survival was 6.5 months and 11 months, respectively ( $P = .046$ ). Four patients (11.7%) in the surgery alone group and 5 (14.7%) in the HIPEC group developed serious AEs ( $P = .839$ ). Multivariate analysis

## NCCN Guidelines Version 3.2025

# Gastric Cancer

found that the addition of HIPEC to cytoreductive surgery is an independent predictor for better survival.

A recent phase III trial, GASTRIPEC-I, investigated cytoreductive surgery with and without HIPEC following preoperative chemotherapy in patients with gastric or EGJ cancers and peritoneal metastasis. No significant differences were observed in OS between the two approaches (HR, 0.72;  $P = .1647$ ).<sup>265</sup> Median PFS (7.1 vs. 3.5 months;  $P = .0472$ ) and other distant metastasis-free survival (10.2 vs. 9.2 months;  $P = .0286$ ) were improved with the addition of HIPEC. Of note, some patients were excluded from further treatment and complete cytoreduction after initial preoperative chemotherapy due to disease progression, among other causes, and almost half had a PCI of  $\geq 7$ .<sup>265</sup> Additionally, an ongoing Dutch study, PERISCOPE II, is investigating gastrectomy followed by cytoreductive surgery plus HIPEC versus systemic treatment in resectable cT3–cT4 gastric cancer with limited peritoneal carcinoma (PCI <7). The primary endpoint is OS and secondary endpoints are PFS, toxicity, and quality of life.<sup>266</sup>

Due to limited evidence and a lack of appropriate randomized clinical trials to support the use of these methods in resectable tumors, the Panel recommends that IC/HIPEC should be pursued only in select circumstances and after multidisciplinary discussion. Any patient considered for IC/HIPEC should undergo pretreatment evaluation as described in the algorithm for those with documented peritoneal carcinoma as the only disease. This includes staging with chest/abdomen/pelvis CT, diagnostic laparoscopy with washings for PCI and/or cytology-positive disease evaluation, and consideration of a PET scan to rule out distant metastases. For certain patients with PCI  $\leq 10$  and candidates for complete cytoreduction, IC/HIPEC in conjunction with cytoreductive surgery is an option. For certain patients with PCI  $> 10$ , IC/HIPEC may be considered in a clinical trial. All treatment decisions should be made in the context of a multidisciplinary tumor board.

### Unresectable Locally Advanced, Recurrent, or Metastatic Disease

When locoregional recurrence develops after prior therapy, the clinician should determine whether surgery is an appropriate option. Surgery should be considered in patients who are medically fit with isolated resectable recurrences. Palliative management, which may include chemoradiation (only if locally unresectable and not previously received), systemic therapy, and/or best supportive care, is recommended for patients with unresectable or metastatic recurrence. If not done previously, HER2, PD-L1, CLDN18.2, and MSI/MMR testing should be performed. NGS should be considered via a validated assay.

Management of unresectable or metastatic disease may include either systemic therapy and/or chemoradiation, with the goal of providing symptom relief and delaying progression and should incorporate symptom-directed best supportive care (See *Palliative/Best Supportive Care* below). The decision to offer palliative/best supportive care alone or with systemic therapy is dependent upon the patient's performance status.

The [Eastern Cooperative Oncology Group Performance Status Scale](#) (ECOG PS) and the [Karnofsky Performance Status Scale](#) (KPS) are commonly used to assess the performance status of patients with cancer.<sup>267–269</sup> Patients with higher ECOG PS scores are considered to have worse performance status while lower KPS scores are associated with worse survival for most serious illnesses. Patients with a KPS score <60% or an ECOG PS score  $\geq 3$  should be offered palliative/best supportive care only. Systemic therapy or chemoradiation (only if locally unresectable and not previously received) can be offered in addition to palliative/best supportive care for patients with better performance status (KPS score of  $\geq 60\%$  or ECOG PS score  $\leq 2$ ).

The survival benefit of systemic therapy compared to palliative/best supportive care alone for patients with advanced gastric cancer has been demonstrated in several randomized trials.<sup>270–273</sup> In an early comparison

# NCCN Guidelines Version 3.2025

## Gastric Cancer

between chemotherapy and best supportive care versus best supportive care alone, OS (8 vs. 5 months) and time to progression (5 vs. 2 months) were longer in patients receiving chemotherapy in addition to best supportive care for advanced gastric cancer.<sup>270</sup> More patients in the chemotherapy group (45%) had an improved or prolonged quality of life for a minimum of 4 months compared to those who received best supportive care alone (20%). In a randomized phase III study, the addition of second-line chemotherapy with irinotecan significantly prolonged OS compared to best supportive care alone in patients with metastatic or locally advanced gastric or EGJ adenocarcinoma (n = 40).<sup>271</sup> Median survival was 4 months in the irinotecan and best supportive care group compared to 2.4 months in the best supportive care alone group. However, the study was closed prematurely due to poor accrual. In a larger randomized trial (n = 193), second-line chemotherapy with irinotecan (or docetaxel) was also found to significantly improve OS compared to best supportive care alone (5.1 vs. 3.8 months) in patients with advanced gastric cancer.<sup>272</sup> In another phase III randomized trial, the addition of docetaxel to best supportive care was associated with a survival benefit for patients with advanced adenocarcinoma of the esophagus (n = 33), EGJ (n = 59), or stomach (n = 76) that had progressed on or within 6 months of treatment with platinum and fluoropyrimidine-based combination chemotherapy.<sup>273</sup> After a median follow-up of 12 months, the median OS was 5.2 months for patients in the docetaxel and best supportive care group compared to 3.6 months for those in the best supportive care alone group ( $P = .01$ ). Therefore, the addition of systemic therapy to best supportive care can improve the quality of life and may prolong survival in patients with advanced gastric cancer.

See *Principles of Systemic Therapy* in the algorithm for a full list of specific regimens for unresectable locally advanced, recurrent, or metastatic disease. Some of the regimens and dosing schedules included in the

guidelines are based on extrapolations from published literature and clinical practice.

### Chemoradiation for Unresectable Disease

Chemoradiation alone may be offered to certain patients who are medically fit with unresectable disease and if not received previously. Since there are limited data in gastric cancer, the Panel recommends extrapolation of fluorouracil-based chemoradiation regimens with proven efficacy in esophageal carcinoma. Preferred regimens in this setting include FOLFOX as well as fluorouracil and cisplatin. Another recommended regimen is fluoropyrimidine (fluorouracil or capecitabine) and paclitaxel (category 2B). Chemoradiation with either FOLFOX or fluorouracil and cisplatin were shown to be effective in a randomized phase III trial of patients with unresectable esophageal cancer.<sup>274</sup> In a randomized phase III trial (PRODIGE5/ACCORD17), 267 patients with unresectable esophageal cancer or those medically unfit for surgery were randomized to receive chemoradiation with either FOLFOX or fluorouracil and cisplatin. The median PFS was 9.7 months in the FOLFOX group compared to 9.4 months in the fluorouracil and cisplatin group ( $P = .64$ ). Although FOLFOX was not associated with a PFS benefit compared to fluorouracil and cisplatin, the investigators suggest that FOLFOX might be a more convenient option for patients who may not be candidates for surgery.<sup>274</sup> A trial of patients with stage II–IV esophageal carcinoma confirmed the safety and efficacy of FOLFOX combined with RT with or without surgery.<sup>275</sup> In the FFCD 9102 trial, survival was similar for patients with esophageal cancer receiving fluorouracil and cisplatin-based chemoradiation with or without surgery.<sup>276</sup> Additionally, patients may receive a fluoropyrimidine combined with paclitaxel, which has proven efficacy in yielding a pathologic response in resectable gastric cancer.<sup>277</sup> Following primary treatment, patients should be restaged to determine whether surgery is an option. Surgery is preferred if appropriate for patients with resectable and medically operable disease



# NCCN Guidelines Version 3.2025

## Gastric Cancer

after chemoradiation, while those found to still have unresectable or medically inoperable and/or metastatic disease should receive palliative management.

### First-Line Therapy

Systemic therapy can provide palliation, improved survival, and enhanced quality of life in patients with locally advanced or metastatic gastric cancer.<sup>270-273</sup> First-line systemic therapy regimens with two cytotoxic drugs are preferred for patients with advanced disease because of their lower toxicity. The use of three cytotoxic drugs in a regimen should be reserved for patients who are medically fit with excellent PS and easy access to frequent toxicity evaluations.<sup>278</sup> Oxaliplatin is generally preferred over cisplatin due to lower toxicity.

For HER2 overexpression-positive disease, the addition of trastuzumab to chemotherapy with or without pembrolizumab is a treatment option for certain patients in this setting. Preferred regimens for HER2 overexpression-negative disease include certain ICIs combined with fluoropyrimidine and platinum-based therapies. Specifically, an ICI should be added to first-line chemotherapy for patients with PD-L1 CPS  $\geq 1$ . CPS and TAP score have high concordance and appear interchangeable.<sup>171,172</sup> For MSI-H/dMMR tumors, treatment options also include certain ICIs. See *Targeted Therapies* below for more information and specific Panel recommendations.

The preferred regimens for HER2-negative disease also include a fluoropyrimidine (fluorouracil or capecitabine) combined with either oxaliplatin<sup>279-281</sup> or cisplatin.<sup>279,282-284</sup> A phase III trial conducted by the German Study Group compared treatment with fluorouracil and cisplatin to FOLFOX in patients ( $n = 220$ ) with previously untreated advanced adenocarcinoma of the stomach or EGJ.<sup>279</sup> Results showed that FOLFOX (referred to as FLO) was associated with significantly less toxicity and showed a trend towards improved median PFS (5.8 vs. 3.9 months;  $P =$

.77) compared to fluorouracil, leucovorin, and cisplatin (FLP).<sup>279</sup> However, there was no significant difference in median OS (10.7 vs. 8.8 months, respectively) between the two groups. FOLFOX resulted in significantly superior response rates (41.3% vs. 16.7%;  $P = .12$ ), time to treatment failure (5.4 vs. 2.3 months;  $P < .001$ ), PFS (6.0 vs. 3.1 months;  $P = .029$ ), and improved OS (13.9 vs. 7.2 months) compared with FLP in patients  $>65$  years ( $n = 94$ ). Therefore, FOLFOX offers reduced toxicity and similar efficacy compared to fluorouracil plus cisplatin and may also be associated with improved efficacy in older adult patients. The safety and efficacy of FOLFOX have also been demonstrated in other studies.<sup>280,285,286</sup>

Regimens combining a platinum agent with capecitabine have also been evaluated in several studies for patients with advanced gastric cancer.<sup>284,287,288</sup> A phase III randomized trial (ML 17032) that evaluated the efficacy of combined capecitabine and cisplatin compared to fluorouracil and cisplatin found that capecitabine was noninferior to fluorouracil as first-line therapy in patients with advanced gastric cancer.<sup>284</sup> Two phase II trials concluded that capecitabine in combination with oxaliplatin is active and well-tolerated as first-line therapy for advanced gastric cancer.<sup>287,288</sup> Furthermore, results of a meta-analysis suggest that OS was superior in patients with advanced gastroesophageal cancer treated with capecitabine-based combinations compared to patients treated with fluorouracil-based combinations, although no significant difference in PFS between treatment groups was seen.<sup>289</sup> Another meta-analysis reported that treatment with oxaliplatin-based regimens significantly improved the partial response rate, disease progression rate, and 1-year OS rate of patients with gastric cancer as compared to cisplatin-based regimens.<sup>290</sup> Therefore, capecitabine and oxaliplatin is also a preferred regimen for first-line treatment of patients with advanced gastric cancers. The GO2 phase III trial demonstrated that a low-dose capecitabine and oxaliplatin regimen (60% of the standard dose) was noninferior in terms of PFS and resulted



## NCCN Guidelines Version 3.2025

# Gastric Cancer

in significantly lower toxicities and better overall treatment utility in patients who are older and/or frail with advanced gastroesophageal cancers ( $n = 514$ ).<sup>291</sup> Therefore, this low-dose regimen is recommended as an alternative to standard-dose capecitabine and oxaliplatin for patients who are older and/or frail with advanced or metastatic disease. See *Principles of Systemic Therapy—Regimens and Dosing Schedules* in the algorithm for recommended modifications to this regimen.

First-line treatment with irinotecan-based regimens has been explored extensively in clinical trials involving patients with advanced or metastatic gastroesophageal cancers.<sup>283,292-303</sup> The results of a randomized phase III study comparing irinotecan and fluorouracil (FOLFIRI) to cisplatin and fluorouracil (CF) in patients with advanced gastric or EGJ adenocarcinoma ( $n = 337$ ) showed that FOLFIRI was noninferior to CF in terms of PFS, but not in terms of OS or time to progression.<sup>298</sup> FOLFIRI was also associated with a more favorable safety profile. A phase III trial (French Intergroup Study) compared FOLFIRI with ECF as first-line treatment in patients ( $n = 416$ ) with advanced or metastatic gastric or EGJ adenocarcinoma.<sup>303</sup> After a median follow-up of 31 months, median time to treatment failure was significantly longer with FOLFIRI than with ECF (5.1 vs. 4.2 months;  $P = .008$ ).<sup>303</sup> However, there were no significant differences in median PFS (5.3 vs. 5.8 months;  $P = .96$ ), median OS (9.5 vs. 9.7 months;  $P = .95$ ), or response rate (39.2% vs. 37.8%). Importantly, FOLFIRI was less toxic and better tolerated than ECF. Therefore, FOLFIRI may be recommended as an option for first-line therapy in patients with advanced or metastatic gastric cancer.

Docetaxel, cisplatin, and fluorouracil (DCF) has also demonstrated activity in patients with locally advanced or metastatic gastric cancer.<sup>304,305</sup> An international phase III study (V325) that randomized 445 patients with untreated advanced gastric or EGJ cancer to receive either DCF or CF found that the addition of docetaxel to CF significantly improved time to progression, OS, and ORR.<sup>304</sup> However, DCF was associated with

increased toxicities including myelosuppression and infectious complications. Various modifications of the DCF regimen have demonstrated improved safety in clinical trials of patients with advanced gastric cancer compared to the DCF regimen evaluated in the V325 study.<sup>306-311</sup> Therefore, due to concerns regarding toxicity, dose-modified DCF or other DCF modifications should be used as alternative options to the standard DCF regimen for first-line therapy.<sup>307,310,311</sup> Other recommended regimens for first-line therapy include fluorouracil plus irinotecan,<sup>303</sup> paclitaxel with either cisplatin or carboplatin,<sup>312-314</sup> docetaxel with cisplatin,<sup>315,316</sup> docetaxel plus oxaliplatin and fluorouracil,<sup>317</sup> and single-agent fluoropyrimidine (fluorouracil or capecitabine),<sup>283,318,319</sup> docetaxel,<sup>273,320</sup> or paclitaxel.<sup>321,322</sup>

### Second-Line and Subsequent Therapy

The selection of regimens for second-line or subsequent therapy is dependent upon prior therapy and performance status. Ramucirumab plus paclitaxel,<sup>323</sup> as well as single-agent docetaxel,<sup>273,320</sup> paclitaxel,<sup>321,322,324</sup> and irinotecan<sup>271,324-326</sup> are category 1 preferred options for second-line or subsequent therapy. Fam-trastuzumab deruxtecan-nxki is an option for HER2 overexpression-positive adenocarcinoma. See *Targeted Therapies* below for more information on and specific recommendations for ramucirumab and fam-trastuzumab deruxtecan-nxki. In a randomized phase III trial (COUGAR-02) single-agent docetaxel was shown to significantly increase 12-month OS compared to active symptom control alone (5.2 vs. 3.6 months, respectively; HR, 0.67;  $P = .01$ ).<sup>273</sup> A randomized phase III trial comparing second-line therapy with paclitaxel to irinotecan in patients with advanced gastric cancer found similar OS between the two groups (9.5 months in the paclitaxel group vs. 8.4 months in the irinotecan group; HR, 1.13;  $P = .38$ ).<sup>324</sup>

FOLFIRI is a preferred treatment option that can be safely used in the second-line setting if it was not previously used in first-line therapy.<sup>294,326</sup>



# NCCN Guidelines Version 3.2025

## Gastric Cancer

<sup>329</sup> A phase II trial investigating the efficacy and toxicity of FOLFIRI in patients (n = 40) with recurrent or metastatic gastric cancer reported an ORR of 29% and median OS of 6.4 months.<sup>329</sup> Another phase II trial reported similar results with an ORR of 20% and OS of 6.7 months in patients with advanced gastric cancer (n = 59) treated with FOLFIRI in the second-line setting.<sup>326</sup> Additionally, FOLFIRI was shown to be an effective and safe treatment option in a cohort of patients with metastatic gastric or EGJ cancers refractory to docetaxel-based chemotherapy.<sup>327</sup> In this study, the ORR was 22.8% and median PFS and OS were 3.8 and 6.2 months, respectively. The most common grade 3–4 toxicities were neutropenia (28.5%) and diarrhea (14.5%).

The trifluridine and tipiracil regimen was approved by the FDA in 2019 for previously treated recurrent or metastatic gastric and EGJ adenocarcinoma, based on results from the global phase III TAGS trial, in which 507 patients with heavily pretreated metastatic gastric or EGJ cancer were randomized 2:1 to receive trifluridine and tipiracil plus best supportive care (n = 337) or placebo plus best supportive care (n = 170).<sup>330</sup> This study reported an improvement in median OS by 2.1 months (5.7 vs. 3.6 months) with the trifluridine and tipiracil regimen compared to placebo (HR, 0.69; 95% CI, 0.56–0.85;  $P = .0003$ ). PFS was significantly longer in the trifluridine and tipiracil group (2.0 vs. 1.8 months; HR, 0.57; 95% CI, 0.47–0.70;  $P < .0001$ ).<sup>330,331</sup> The efficacy benefits of trifluridine and tipiracil were observed regardless of whether or not the patient had undergone previous gastrectomy.<sup>332</sup> The most frequently reported grade 3–4 toxicities were neutropenia (38%), leukopenia (21%), anemia (19%), and lymphocytopenia (19%).<sup>330</sup> Patients ≥65 years had a higher incidence of moderate renal impairment compared to the overall study population (31% vs. 17%).<sup>331</sup> In the trifluridine and tipiracil arm versus the placebo arm, the ORR was 4.5% versus 2.1%, respectively, and the disease control rate was 44.1% versus 14.5%.<sup>330</sup> However, trifluridine and tipiracil produced substantial grade 3–4 toxicities. Therefore, this treatment should

be considered for a very select population of patients with low-volume gastric cancer who have minimal or no symptoms and the ability to swallow pills. Trifluridine and tipiracil is recommended as a preferred category 1 treatment option for patients with recurrent or metastatic gastric cancer in the third-line or subsequent setting.

Other recommended regimens for second-line or subsequent therapy include single-agent ramucirumab (category 1),<sup>333</sup> irinotecan and cisplatin,<sup>280,334</sup> ramucirumab combined with irinotecan<sup>335</sup> or FOLFIRI,<sup>336</sup> and irinotecan and docetaxel (category 2B).<sup>337</sup> Options that are useful in certain circumstances include pembrolizumab,<sup>159,338,339</sup> nivolumab and ipilimumab,<sup>340</sup> or dostarlimab-gxly<sup>341</sup> for MSI-H/dMMR tumors; pembrolizumab for TMB-H ( $\geq 10$  mutations/megabase) tumors<sup>342</sup>; entrectinib, larotrectinib, or repotrectinib for *NTRK* gene fusion-positive tumors<sup>343–345</sup>; dabrafenib and trametinib for *BRAF* V600E-mutated tumors<sup>346</sup>; and selpercatinib for *RET* gene fusion-positive tumors.<sup>347</sup> See *Targeted Therapies* below for more information on these agents.

### Targeted Therapies

At present, several targeted therapeutic agents, including HER2-directed therapies, ICIs, and various kinase inhibitors, have been approved by the FDA for advanced gastric cancer. See *Principles of Biomarker Testing* above for details on testing recommendations.

### Trastuzumab

The ToGA trial was the first randomized prospective phase III trial that evaluated the efficacy and safety of trastuzumab in patients with HER2 overexpression-positive advanced gastric or EGJ adenocarcinoma.<sup>146</sup> In this trial, 594 patients with HER2 overexpression-positive, locally advanced, recurrent, or metastatic gastric or EGJ adenocarcinoma were randomized to receive trastuzumab plus chemotherapy (cisplatin plus fluorouracil or capecitabine) or chemotherapy alone.<sup>146</sup> The majority of



## NCCN Guidelines Version 3.2025

# Gastric Cancer

patients had gastric cancer (80% in the trastuzumab group and 83% in the chemotherapy group). Median follow-up was 19 months and 17 months, respectively, in the two groups. Results showed significant improvement in median OS with the addition of trastuzumab to chemotherapy in patients with HER2 overexpression-positive disease (13.8 vs. 11 months, respectively;  $P = .046$ ). This study established trastuzumab in combination with cisplatin and a fluoropyrimidine as a treatment option for patients with HER2 overexpression-positive advanced gastroesophageal adenocarcinoma. In a post-hoc subgroup analysis, the addition of trastuzumab to chemotherapy further improved OS in patients whose tumors were IHC 2+ and FISH positive or IHC 3+ ( $n = 446$ ; 16 vs. 11.8 months; HR, 0.65) compared to those with tumors that were IHC 0 or 1+ and FISH positive ( $n = 131$ ; 10 vs. 8.7 months; HR, 1.07).

The phase II HERXO trial assessed the combination of trastuzumab with capecitabine and oxaliplatin in the first-line treatment of patients with HER2 overexpression-positive advanced gastric or EGJ adenocarcinoma ( $n = 45$ ).<sup>348</sup> At a median follow-up of 13.7 months, PFS and OS were 7.1 and 13.8 months, respectively, and 8.9%, 37.8%, and 31.1% of patients achieved a CR, partial response, and stable disease. The most frequently reported grade 3 or higher AEs were diarrhea (26.6%), fatigue (15.5%), nausea (20%), and vomiting (13.3%). In a retrospective study of 34 patients with HER2 overexpression-positive metastatic gastric or EGJ adenocarcinoma, the combination of trastuzumab with a modified FOLFOX regimen (mFOLFOX6) improved tolerability compared with the cisplatin plus fluorouracil regimen in previously untreated patients with HER2 overexpression-positive tumors.<sup>349</sup> The ORR with this regimen was 41% and median PFS and OS were 9.0 months and 17.3 months, respectively. The most frequent grade 3–4 toxicities were neutropenia (8.8%) and neuropathy (17.6%). These results suggest that the combinations of trastuzumab with capecitabine and oxaliplatin or with mFOLFOX are effective regimens with acceptable safety profiles in

patients with HER2 overexpression-positive gastroesophageal cancers. Trastuzumab should be added to first-line chemotherapy for patients with advanced HER2 overexpression-positive adenocarcinoma (combination with a fluoropyrimidine and a platinum agent is preferred [category 1 for cisplatin<sup>146</sup>; category 2A for oxaliplatin]). Pembrolizumab can also be added to this regimen for treatment of advanced HER2 overexpression-positive adenocarcinoma<sup>350</sup> (see *Pembrolizumab* below). Trastuzumab may be combined with other chemotherapy agents for first-line therapy, but should not be continued in second-line therapy.<sup>351</sup>

### Pembrolizumab

#### *HER2 Overexpression-Positive Tumors*

Pembrolizumab is a PD-1 antibody that can be added to first-line fluoropyrimidine, platinum, and trastuzumab therapy for patients with advanced HER2 overexpression-positive gastric cancer. The phase III KEYNOTE-811 trial compared pembrolizumab to placebo in combination with trastuzumab and the investigator's choice of chemotherapy with fluorouracil and cisplatin or capecitabine and oxaliplatin in patients with previously untreated advanced HER2-positive gastric or EGJ adenocarcinoma.<sup>352</sup> Median PFS in patients in the pembrolizumab arm was longer than in the placebo arm (10 vs. 8.1 months;  $P = .0002$ ).<sup>353</sup> In the subgroup analyses at the second interim (median ~28 months), patients with PD-L1 CPS  $\geq 1$  treated in the pembrolizumab arm had longer median PFS compared to placebo (10.8 vs. 7.2 months; HR, 0.70), which was not observed in patients with PD-L1 CPS < 1 (9.5 vs. 9.6 months; HR, 1.17). Median OS was 20 months in the pembrolizumab arm compared to 16.9 months in the placebo arm (HR, 0.87; 95% CI, 0.72–1.06;  $P = .084$ ), with the PD-L1 subgroup analysis following a similar trend to the PFS analysis.<sup>353</sup> The third interim analysis was consistent with the second. Improved ORR (72.6% vs. 59.8%) and median duration of response (11.2 vs. 9 months) was observed with the addition of pembrolizumab compared



# NCCN Guidelines Version 3.2025

## Gastric Cancer

to placebo. CRs were also more frequent in the pembrolizumab group compared to placebo (14% vs. 11%).<sup>353</sup> Similar incidence of AEs was observed in the pembrolizumab and placebo groups, the most common being diarrhea, nausea, and anemia.<sup>352,353</sup> Based on KEYNOTE-811, in 2021 the FDA approved pembrolizumab in combination with trastuzumab plus fluoropyrimidine- and platinum-containing chemotherapy for locally advanced, unresectable or metastatic HER2-positive gastric or EGJ adenocarcinoma in first-line. The approval was modified in 2023 for patients in this setting whose tumor has PD-L1 CPS  $\geq 1$ . Therefore, pembrolizumab combined with trastuzumab and fluoropyrimidine and platinum-based chemotherapy is a category 1 preferred first-line therapy option for treatment of patients with advanced HER2 overexpression-positive adenocarcinoma and PD-L1 CPS  $\geq 1$ .

### ***HER2 Overexpression-Negative Tumors***

The randomized phase III KEYNOTE-859 trial investigated pembrolizumab plus chemotherapy versus placebo plus chemotherapy in treatment-naïve patients with advanced HER2-negative gastric or EGJ adenocarcinoma.<sup>354</sup> At a median 31-month follow-up, OS and PFS were favorable for the pembrolizumab combination versus placebo. More specifically, in the PD-L1 CPS  $\geq 10$  subgroup, median OS was significantly longer with pembrolizumab compared with placebo (15.7 vs. 11.8 months; HR, 0.65;  $P < .0001$ ), and median PFS was also longer with pembrolizumab (8.1 vs. 5.6 months; HR, 0.62;  $P < .0001$ ). Objective responses were observed in 61% of patients with pembrolizumab versus 43% with placebo.<sup>354</sup> In the PD-L1 CPS  $\geq 1$  subgroup, median OS was 13 months versus 11.4 months (HR, 0.74;  $P < .0001$ ) and median PFS was 6.9 months versus 5.6 months (HR, 0.72;  $P < .0001$ ) for pembrolizumab versus placebo, respectively. Objective responses were observed in 52% compared to 43%. Incidence of AEs were similar between the two treatment arms, with the most common grade 3–5 AEs being anemia and decreased neutrophils.<sup>354</sup> Based on this study, the FDA granted approval for pembrolizumab in

combination with fluoropyrimidine- and platinum-based chemotherapy for locally advanced, unresectable, or metastatic HER2-negative gastric or EGJ cancer in first-line therapy.

The Panel includes pembrolizumab in combination with fluoropyrimidine- and platinum-based chemotherapy as a preferred option for first-line treatment of advanced HER2 overexpression-negative gastric cancer with PD-L1 CPS  $\geq 1$  if no prior ICI therapy or no tumor progression while on an ICI. This is a category 1 preferred option when PD-L1 CPS is  $\geq 5$ .

### ***MSI-H/dMMR Tumors***

Pembrolizumab was FDA approved in 2017 for the treatment of patients with unresectable or metastatic MSI-H or dMMR solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. This first-ever tissue- and site-agnostic approval was based on data from 149 patients with MSI-H/dMMR cancers (90 patients had colorectal cancer) enrolled across five multicenter single-arm clinical trials.<sup>159,338,339</sup> The ORR was 39.6% and responses lasted  $\geq 6$  months for 78% of those whose disease responded to pembrolizumab. There were 11 CRs and 48 partial responses, and the ORR was similar irrespective of cancer type. In an updated analysis of cohort K in KEYNOTE-158, 351 patients were enrolled with 28 tumor types represented.<sup>355</sup> By independent central radiologic review, the ORR was 30.8%, with 27 patients having a CR, and median duration of response (DOR) was 47.5 months. Among the 42 patients with gastric cancer, the ORR was 31%.<sup>355</sup>

A few studies investigating pembrolizumab monotherapy and/or plus chemotherapy in advanced gastric or EGJ adenocarcinoma included patients whose tumors were MSI-H. In the phase II KEYNOTE-059 trial of a cohort of previously treated recurrent or metastatic gastric and EGJ cancers, four out of seven patients with an MSI-H tumor obtained an objective response with pembrolizumab monotherapy, with an ORR of

# NCCN Guidelines Version 3.2025

## Gastric Cancer

57.1%. Median OS and PFS were not reached among these same patients.<sup>156,356</sup> Previously treated patients in the phase III KEYNOTE-061 trial received either pembrolizumab or paclitaxel.<sup>357</sup> Among the 5.3% of patients with MSI-H tumors, median OS was not reached with pembrolizumab compared to 8.1 months with paclitaxel only. Median PFS was 17.8 months and ORR was 46.7% in patients with MSI-H tumor who received pembrolizumab versus 3.5 months and 16.7%, respectively, with paclitaxel alone.<sup>156,357</sup> In the phase III KEYNOTE-062 trial, treatment-naïve patients received pembrolizumab ± chemotherapy.<sup>358</sup> Similar to the other trials, median OS was not reached in the 7% of patients with MSI-H untreated locally advanced/unresectable or metastatic disease who received pembrolizumab ± chemotherapy versus 8.5 months with chemotherapy. Median PFS was 11.2 months among these patients with pembrolizumab and not reached with pembrolizumab plus chemotherapy versus 6.6 months with chemotherapy alone.<sup>156,358</sup> ORR was 57.1% and 64.7% with pembrolizumab and pembrolizumab plus chemotherapy, respectively, compared to 36.8% with chemotherapy alone.<sup>156</sup> Similar incidences of treatment-related all-grade or grade 3–5 AEs were observed with pembrolizumab and were lower than chemotherapy in the two phase III trials.<sup>357–359</sup>

Both pembrolizumab monotherapy and pembrolizumab in combination with fluoropyrimidine and oxaliplatin are recommended as category 2A preferred first-line therapy options for patients with advanced MSI-H/dMMR gastric cancer, independent of PD-L1 expression.

Pembrolizumab monotherapy is also a category 2A option useful in certain circumstances for MSI-H/dMMR tumors in second- and subsequent-line.

### TMB-H Tumors

In June 2020, the FDA approved pembrolizumab for the treatment of patients with metastatic TMB-H solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. This approval was

based on a prospective analysis of 102 patients enrolled in the KEYNOTE-158 trial who had tumors identified as TMB-H.<sup>342</sup> The ORR for these patients was 29%, with a 4% CR rate. The median duration of response was not reached, with 50% of patients having response duration for ≥24 months.<sup>342</sup> Based on these data, pembrolizumab may be used for the second-line or subsequent treatment of TMB-H gastroesophageal tumors. However, it should be noted that no patients with gastroesophageal cancer were included in this TMB analysis from the KEYNOTE-158 trial.

### Nivolumab

#### *HER2 Overexpression-Negative Tumors*

As mentioned, nivolumab is a monoclonal PD-1 antibody. It was approved by the FDA in April 2021, in combination with fluoropyrimidine- and platinum-based chemotherapy, for the first-line treatment of patients with advanced or metastatic gastric cancer. This approval was based on results from the phase III Checkmate-649 trial, which randomized 1581 patients with previously untreated, HER2-negative, unresectable gastric, EGJ, or esophageal adenocarcinoma to receive chemotherapy alone or nivolumab plus chemotherapy (capecitabine and oxaliplatin or mFOLFOX).<sup>360</sup> The 3-year follow-up was consistent with initial efficacy results. At 3 years, median OS was 14.4 months for those with PD-L1 CPS ≥5 treated with nivolumab plus chemotherapy compared to 11.1 months with chemotherapy alone (HR, 0.70).<sup>361</sup> Median PFS was 8.3 months with nivolumab plus chemotherapy versus 6.1 months with chemotherapy (HR, 0.70) in the same patient population. OS and PFS benefit was maintained with nivolumab plus chemotherapy compared to chemotherapy alone in the 5-year follow-up.<sup>362</sup> These patients also had an ORR of 60%, and 13% achieved CR with nivolumab plus chemotherapy compared to an ORR of 45% and CR rate of 7% with chemotherapy.<sup>361</sup> In the PD-L1 CPS ≥1 cohort, median OS for nivolumab plus chemotherapy was 13.8 versus 11.3 months with chemotherapy (HR, 0.75) and median

# NCCN Guidelines Version 3.2025

## Gastric Cancer

PFS was 7.5 versus 6.9 months (HR, 0.77), respectively.<sup>361,362</sup> Among all patients, 59% of those in the nivolumab plus chemotherapy group and 44% of those in the chemotherapy alone group experienced grade 3–4 treatment-related AEs, remaining consistent in the 3-year follow-up.<sup>360,361</sup> The most common any-grade treatment-related AEs were nausea, diarrhea, and peripheral neuropathy across both groups. Sixteen treatment-related deaths occurred in the nivolumab plus chemotherapy group compared to four in the chemotherapy alone group.<sup>360</sup> Therefore, nivolumab plus fluoropyrimidine- and oxaliplatin-based chemotherapy is a preferred first-line treatment option for patients with HER2-negative gastric tumors with PD-L1 expression levels by CPS  $\geq 1$  if no prior ICI therapy or no tumor progression while on an ICI. This combination is a category 1 preferred option when CPS is  $\geq 5$ .

### **MSI-H/dMMR Tumors**

About 3% of patients enrolled in Checkmate-649 had MSI-H tumors.<sup>360,361</sup> In the 3-year follow-up, the OS benefit observed with nivolumab plus chemotherapy was better for those with MSI-H tumors than chemotherapy alone. This was true in patients who had MSI-H tumors with PD-L1 CPS  $\geq 5$  ( $n = 34$ ; 44.8 vs. 8.8 months; HR, 0.29) and in all randomized patients with MSI-H tumors ( $n = 44$ ; 38.7 vs. 12.3 months; HR, 0.34).<sup>361</sup>

The Checkmate-649 trial also randomized some patients to nivolumab plus ipilimumab or chemotherapy. At a minimum 24-month follow-up, patients with tumors having PD-L1 CPS  $\geq 5$  and all randomized patients did not have improved OS, PFS, or ORR with nivolumab plus ipilimumab versus chemotherapy alone.<sup>340</sup> However, patients with MSI-H tumors treated with nivolumab plus ipilimumab had improved median OS versus chemotherapy (not reached vs. 10 months; HR, 0.28). ORR was also improved with the combination versus chemotherapy (70% vs. 57%) in

those with an MSI-H tumor. There was no survival benefit in the microsatellite stable cohort.<sup>340</sup>

For MSI-H/dMMR tumors, independent of PD-L1 status, the Panel recommends nivolumab plus fluoropyrimidine and oxaliplatin as a category 2A preferred option in first-line. The Panel also recommends nivolumab plus ipilimumab as a category 2A preferred option in first-line and a category 2A option useful in certain circumstances in second- and subsequent-line for patients with MSI-H/dMMR tumors.

### **Tislelizumab-jsgc**

Another PD-1 inhibitor, tislelizumab, was recently approved by the FDA in combination with fluoropyrimidine- and platinum-based chemotherapy for the treatment of unresectable or metastatic HER2-negative gastric or EGJ adenocarcinoma with PD-L1 CPS  $\geq 1$ . The randomized, global multicenter phase III trial RATIONALE-305 investigated the use of tislelizumab plus chemotherapy (investigator's choice, capecitabine plus oxaliplatin or fluorouracil plus cisplatin) in the first-line setting for unresectable locally advanced or metastatic gastric or EGJ adenocarcinoma.<sup>171</sup> Patients received either tislelizumab plus chemotherapy ( $n = 501$ ) or placebo plus chemotherapy ( $n = 496$ ). In all randomized patients, median OS for tislelizumab was 15 months versus 12.9 months with placebo (HR, 0.80;  $P = .001$ ). Median PFS was 6.9 months versus 6.2 months with tislelizumab versus placebo, respectively (HR, 0.78). In the interim analysis, in patients whose tumors had a PD-L1 TAP of  $\geq 5\%$ , median OS for tislelizumab was 17.2 months versus 12.6 months with placebo (HR, 0.74;  $P = .006$ ) and PFS was 7.2 months versus 5.9 months, respectively (HR, 0.67;  $P < .001$ ).<sup>171</sup> The authors found concordance between the TAP score and CPS and reported similar OS in each treatment arm in a post hoc analysis of PD-L1 CPS of  $\geq 5$ . AEs of grade 3 or higher were observed in 54% of patients treated with tislelizumab compared to 50% with placebo. Common grade 3 or 4 AEs included decreased neutrophil and platelet counts,



## NCCN Guidelines Version 3.2025

# Gastric Cancer

anemia, and neutropenia. In the tislelizumab arm, 23% experienced serious treatment-related AEs and 31% experienced immune-related AEs, compared to 15% and 12% with placebo, respectively.<sup>171</sup> Based on these data, the Panel recommends tislelizumab in combination with fluoropyrimidine (fluorouracil or capecitabine) and platinum (oxaliplatin or cisplatin) as a first-line treatment option for patients whose tumors are HER2-negative and PD-L1 CPS  $\geq 1$ , if no prior ICI therapy or no tumor progression while on an ICI. For tumors with PD-L1 CPS  $\geq 5$ , this is a category 1, preferred option.

### Zolbetuximab-clzb

The FDA recently approved zolbetuximab combined with fluoropyrimidine- and platinum-based therapy for patients with HER2-negative, CLDN18.2-positive, unresectable locally advanced or metastatic gastric or EGJ adenocarcinoma in the first-line setting. Zolbetuximab is a novel monoclonal antibody targeting the tight junction protein, CLDN18.2, that demonstrated significant survival benefit in two global, randomized, multicenter phase III trials in this setting.<sup>173,183</sup>

In the SPOTLIGHT trial, 565 treatment-naïve patients with HER2-negative, CLDN18.2-positive, unresectable locally advanced or metastatic gastric or EGJ tumors received either zolbetuximab plus mFOLFOX6 (n = 283) or placebo plus mFOLFOX6 (n = 282).<sup>173</sup> Median PFS was 10.61 months with zolbetuximab compared to 8.67 months with placebo, with the HR for disease progression or death being 0.75 ( $P = .0066$ ). Median OS was also longer with zolbetuximab at 18.23 months versus placebo at 15.54 months (HR for risk of death, 0.75;  $P = .0053$ ). ORR and median DOR were similar between treatment groups.<sup>173</sup> In the GLOW trial, 507 untreated patients with unresectable locally advanced or metastatic HER2-negative, CLDN18.2-positive gastric or EGJ adenocarcinoma received either zolbetuximab plus CAPOX (n = 254) or placebo plus CAPOX (n = 253).<sup>183</sup> Median PFS was longer in the zolbetuximab arm versus the placebo arm

(8.21 vs. 6.8 months; HR, 0.687;  $P = .0007$ ). Median OS was also improved with zolbetuximab compared to placebo (14.39 vs. 12.16 months; HR, 0.771;  $P = .0118$ ). In the zolbetuximab group, ORR and DOR were 42.5% and 6.14 months versus placebo, which was 40.3% and 6.08 months, respectively.<sup>183</sup>

In both studies, treatment-emergent all grade AEs with a >10% difference between zolbetuximab and placebo arms were nausea and vomiting. These events were also accounted for in the most frequent AEs of grade 3 or higher. Other AEs of grade 3 or higher in the GLOW trial were anemia and neutropenia, while decreased appetite was also observed in the SPOTLIGHT trial.<sup>173,183</sup> Based on these data, fluoropyrimidine-based chemotherapy plus oxaliplatin and zolbetuximab is a category 1, preferred first-line therapy option for patients with unresectable locally advanced, recurrent or metastatic gastric cancer whose tumors are HER2-negative and CLDN18.2-positive.

### Ramucirumab

Ramucirumab, a vascular endothelial growth factor receptor (VEGFR)-2 antibody, has shown favorable results in patients with previously treated advanced or metastatic gastroesophageal cancers in two phase III clinical trials.<sup>333,363</sup> An international randomized multicenter phase III trial (REGARD) demonstrated a survival benefit for ramucirumab in patients with advanced gastric or EGJ adenocarcinoma progressing after first-line chemotherapy.<sup>333</sup> In this study, 355 patients were randomized to receive ramucirumab (n = 238) or placebo (n = 117). Median OS was 5.2 months in patients treated with ramucirumab compared to 3.8 months for those in the placebo group ( $P = .047$ ). Ramucirumab was associated with higher rates of hypertension than placebo (16% vs. 8%), whereas rates of other AEs were similar.<sup>333</sup>

An international phase III randomized trial (RAINBOW) evaluated paclitaxel with or without ramucirumab in patients (n = 665) with metastatic



# NCCN Guidelines Version 3.2025

## Gastric Cancer

gastric or EGJ adenocarcinoma progressing on first-line chemotherapy.<sup>363</sup> Patients randomized to receive ramucirumab plus paclitaxel (n = 330) had significantly longer median OS (9.63 months) compared to patients receiving paclitaxel alone (n = 335; 7.36 months; P < .0001). The median PFS was 4.4 months and 2.86 months, respectively, and the ORR was 28% for ramucirumab plus paclitaxel compared to 6% for paclitaxel alone (P = .0001). Neutropenia and hypertension were more common with ramucirumab plus paclitaxel. An exposure-response analysis revealed that ramucirumab was a significant predictor of OS and PFS in both studies.<sup>364</sup> Based on these results, ramucirumab (as a single agent or in combination with paclitaxel) was approved by the FDA for the treatment of patients with advanced gastric or EGJ adenocarcinoma refractory to or progressive following first-line therapy with platinum- or fluoropyrimidine-based chemotherapy. The guidelines recommend ramucirumab as a single agent (category 1, other recommended) or in combination with paclitaxel (category 1; preferred) as treatment options for second-line or subsequent therapy in patients with advanced or metastatic gastric adenocarcinoma.

Ramucirumab combined with FOLFIRI is a category 2A other recommended option for second-line or subsequent therapy. In a multi-institutional retrospective analysis of 29 patients with advanced gastric or EGJ adenocarcinoma who received FOLFIRI plus ramucirumab in the second-line setting, the ORR was 23% with a disease control rate of 79%.<sup>336</sup> Median PFS was 6 months and median OS was 13.4 months. Six- and 12-month OS were 90% and 41%, respectively. No new safety signals were observed with the combination treatment, making FOLFIRI plus ramucirumab a safe, non-neurotoxic alternative to ramucirumab plus paclitaxel. Ramucirumab combined with irinotecan is also a category 2A other recommended option for second-line or subsequent therapy for patients with advanced gastric cancer.<sup>335</sup>

Due to the results of the international phase III RAINFALL trial, in which treatment with ramucirumab did not reduce the risk of disease progression

or death in treatment-naïve patients with metastatic gastroesophageal adenocarcinoma, the addition of ramucirumab to first-line chemotherapy is not recommended at this time.<sup>365</sup>

### Fam-trastuzumab deruxtecan-nxki

Fam-trastuzumab deruxtecan-nxki is an antibody-drug conjugate consisting of trastuzumab and a cytotoxic topoisomerase I inhibitor connected by a cleavable tetrapeptide-based linker. The efficacy and safety of fam-trastuzumab deruxtecan-nxki in advanced or metastatic gastric or EGJ adenocarcinoma was evaluated in the phase II DESTINY-Gastric01 trial, which included 188 patients with progressive disease following at least two prior lines of therapy, including trastuzumab.<sup>366</sup> Patients were randomized 2:1 to receive either fam-trastuzumab deruxtecan-nxki or physician's choice of chemotherapy (paclitaxel or irinotecan). The confirmed ORR for patients on fam-trastuzumab deruxtecan-nxki was 40.5% compared to 11% for those on chemotherapy. OS (12.5 vs. 8.4 months; P = .0097), median PFS (5.6 vs. 3.5 months), and DOR (11.3 vs. 3.9 months) were also higher in the fam-trastuzumab deruxtecan-nxki group compared to the chemotherapy group. Fam-trastuzumab deruxtecan-nxki resulted in more toxicities than systemic chemotherapy in this trial. The most common AEs (grade 3 or higher) were a decreased neutrophil count (51% of the fam-trastuzumab deruxtecan-nxki group and 24% of the chemotherapy group), anemia (38% and 23%, respectively), and decreased white blood cell count (21% and 11%). Fam-trastuzumab deruxtecan-nxki-related interstitial lung disease (ILD) or pneumonitis occurred in 12 patients resulting in 1 drug-related death (due to pneumonia). No drug-related deaths occurred in the physician's choice group.<sup>366</sup>

The single-arm, multicenter, phase II trial, DESTINY-Gastric02 investigated fam-trastuzumab deruxtecan-nxki in patients in Western countries with unresectable or metastatic HER2-positive gastric or EGJ

# NCCN Guidelines Version 3.2025

## Gastric Cancer

cancer who progressed on or after first-line therapy.<sup>367</sup> Based on HER2 status, the ORR was 47.1% in patients whose tumor was IHC 3+ compared to 10 months for IHC 2+/ISH+. Patients had a median DOR of 8.1 months, as well as median PFS and OS of 5.6 months and 12.1 months, respectively. The most common grade 3 or higher AEs were similar to DESTINY-Gastric01 and also included nausea. ILD/pneumonitis occurred in eight patients, and for two patients it was a grade 5 event.<sup>367</sup>

The FDA has approved fam-trastuzumab deruxtecan-nxki to treat patients with unresectable or metastatic HER2 overexpression-positive solid tumors in second-line or subsequent therapy. Therefore, fam-trastuzumab deruxtecan-nxki is a category 2A preferred second-line or subsequent treatment option for patients with HER2 overexpression-positive adenocarcinoma following disease progression on prior treatment with a trastuzumab-based regimen. However, careful selection of patients and close monitoring of patients for excessive toxicity is recommended.

### Entrectinib, Larotrectinib, and Repotrectinib

Gene fusions involving *NTRK1*, *NTRK2*, or *NTRK3* encode TRK fusion proteins (TRKA, TRKB, TRKC), which have increased kinase function and are implicated in the oncogenesis of many solid tumors including head and neck, thyroid, soft tissue, lung, and colon.<sup>344,368</sup> Although believed to be extremely rare in gastroesophageal cancers, one case report provides evidence that *NTRK* gene fusions do occur in gastric adenocarcinoma and may be associated with an aggressive phenotype.<sup>369-371</sup>

In 2018, the FDA granted accelerated approval of the TRK inhibitor larotrectinib for the treatment of adult and pediatric patients (aged ≥12 years) with solid tumors that have an *NTRK* gene fusion without a known acquired resistance mutation, that are either metastatic or where surgical resection is likely to result in severe morbidity, and who have no

satisfactory alternative treatments or whose cancer has progressed following treatment. This second-ever tissue-agnostic FDA approval for the treatment of patients with cancer was based on data from three multicenter, single-arm clinical trials. Patients with prospectively identified *NTRK* gene fusion-positive cancers were enrolled into one of three protocols: a phase I trial involving adults (LOXO-TRK-14001), a phase I-II trial involving children (SCOUT), and a phase II trial involving adolescents and adults (NAVIGATE).<sup>344</sup> A total of 55 patients with unresectable or metastatic solid tumors harboring an *NTRK* gene fusion who experienced disease progression following systemic therapy were enrolled across the three trials and treated with larotrectinib. The most common cancer types represented were salivary gland tumors, soft tissue sarcoma, infantile fibrosarcoma, and thyroid cancer. In an updated pooled analysis of the 3 trials (n = 153), the ORR was 79%, with a CR rate of 16%.<sup>372</sup> At a median follow-up of 12.9 months, 23% of patients who had responses experienced a progression event. Median DOR, PFS, and OS were 35.2 months, 28.3 months, and 44.4 months, respectively. AEs were predominantly grade 1–2, the most common being fatigue, increased aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, vomiting, constipation, and dizziness.<sup>372</sup> The SCOUT (Clinical Trial ID: [NCT02637687](#)) and NAVIGATE (Clinical Trial ID: [NCT02576431](#)) trials are ongoing.

In 2019, the FDA approved the second TRK inhibitor, entrectinib, for the same indications as larotrectinib, as well as for adult patients with metastatic NSCLC whose tumors are *ROS1* positive. The approval of entrectinib for the treatment of *NTRK* gene fusion-positive tumors was based on data from three multicenter, single-arm phase I and phase II clinical trials. A total of 54 patients aged ≥18 years with metastatic or locally advanced *NTRK* gene fusion-positive solid tumors were enrolled into one of the three protocols (ALK-372-001, STARTRK-1, and STARTRK-2).<sup>343</sup> The most common cancer types represented were



## NCCN Guidelines Version 3.2025

# Gastric Cancer

sarcoma, NSCLC, mammary analogue secretory carcinoma, breast, thyroid, and colorectal. The ORR across the three trials was 57%, with a CR rate of 7%. Response duration was ≥6 months for 68% of patients and ≥12 months for 45% of patients. The median duration of response was 10 months. The most common grade 3–4 treatment-related AEs were increased weight and anemia while the most common serious treatment-related AEs were nervous system disorders. STARTRK-2 (Clinical Trial ID: [NCT02568267](#)) is ongoing.

Repotrectinib was FDA approved in 2023 for patients with locally advanced or metastatic *ROS1*-positive NSCLC. It was given accelerated approval by the FDA in 2024 for similar indications to larotrectinib and entrectinib in patients with *NTRK* gene fusion-positive solid tumors. This was based on data from the phase I/II TRIDENT-1 trial investigating repotrectinib in previously tyrosine kinase inhibitor (TKI)-treated and TKI-treatment-naïve patients with NSCLC and *NTRK+* solid tumors (ongoing, Clinical Trial ID: [NCT03093116](#)).<sup>345</sup> The most common tumor types were NSCLC, salivary gland, thyroid, and soft tissue sarcoma. Confirmed ORR was 58% in the TKI-naïve group and 50% in the previously treated group. The 12-month DOR and PFS were 86% and 56% for the TKI-naïve patients, respectively, and 39% and 22%, respectively, for the previously treated patients. Dizziness was the most common treatment-emergent AE of any grade, and AEs grade 3 or higher were observed in 51% of patients.<sup>345</sup>

These data demonstrate that these *NTRK* inhibitors induce durable and clinically meaningful responses in patients with *NTRK* gene fusion-positive tumors with manageable safety profiles. Entrectinib, larotrectinib, or repotrectinib are recommended as first-line (category 2B) and second-line or subsequent treatment options (category 2A) for patients with *NTRK* gene fusion-positive gastric tumors.

### Dostarlimab-gxly

Dostarlimab-gxly, an anti-PD-1 antibody, was approved by the FDA in August 2021 for the treatment of patients with dMMR recurrent or advanced solid tumors that have progressed on or following prior treatment, who have no satisfactory alternative treatment options, and who had not previously received a PD-1 or PD-L1 inhibitor. This approval was based on data from the nonrandomized phase 1 multi-cohort GARNET trial that evaluated the safety and antitumor activity of dostarlimab-gxly in patients with dMMR solid tumors who had not received prior PD-1, PDL-1, or CTLA4 inhibitors.<sup>373,374</sup> The majority of patients had endometrial or GI cancers. At median follow-up of 27.7 months, the ORR was 44% and DOR was not reached.<sup>374</sup> Median PFS and OS were 6.9 months and not reached, respectively. The most common treatment-related AEs of any grade were fatigue, diarrhea, asthenia, pruritus, and hypothyroidism. Immune-related AEs that occurred in 34% of patients included hypothyroidism, elevated ALT, and arthralgia.<sup>374</sup> Based on these data, dostarlimab-gxly is a category 2A, preferred option for first-line therapy for MSI-H/dMMR tumors. It is also useful in certain circumstances for second-line therapy in patients with MSI-H/dMMR gastric tumors whose disease is progressing on or following prior treatment that does not include immunotherapy and who have no satisfactory alternatives.

### Dabrafenib and Trametinib

In June 2022, the FDA granted tumor-agnostic approval for the combination of dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, for treatment of patients with unresectable or metastatic solid tumors with *BRAF* V600E mutations who have progressed following prior treatment and have no satisfactory alternative treatment options. This approval was based in part on data from the phase II BRF117019 and NCI-MATCH trials, which enrolled a combined 131 adult patients with various *BRAF* V600E-mutated tumor types.<sup>346</sup> In subprotocol H (EAY131-

# NCCN Guidelines Version 3.2025

## Gastric Cancer

H) of the NCI-MATCH platform trial, patients with *BRAF* V600E-mutated solid tumors (except for melanoma, thyroid cancer, or colorectal cancer) received combined dabrafenib and trametinib continuously until disease progression or intolerable toxicity. The ORR was 38% ( $P < .0001$ ) and PFS was 11.4 months.<sup>346</sup> The median OS in this cohort was 29 months. For the 131 patients across both trials, the ORR was 41%. The most common treatment-related AEs included pyrexia, fatigue, nausea, rash, chills, headache, hemorrhage, cough, and vomiting.<sup>346</sup> Based on these data, dabrafenib and trametinib may be used for second-line or subsequent therapy (category 2A) for patients with *BRAF* V600E-mutated gastroesophageal tumors.

### Selpercatinib

In September 2022, the FDA granted tumor-agnostic approval for selpercatinib, a TKI, for treatment of patients with locally advanced or metastatic solid tumors with *RET* gene fusions who have progressed following prior treatment and have no satisfactory alternative treatment options. This approval was based on an interim analysis of data from the ongoing phase I/II LIBRETTO-001 trial, which evaluated 41 patients with *RET* fusion-positive tumors (other than NSCLC and thyroid cancer) who received selpercatinib until disease progression or unacceptable toxicity.<sup>347</sup> The ORR was 44% with a duration of response of 25 months. The most common treatment-related AEs included edema, diarrhea, fatigue, dry mouth, hypertension, and abdominal pain. The most common grade 3 or higher treatment-related AEs were hypertension, increased ALT, and increased AST.<sup>347</sup> Based on these data, selpercatinib may be used for second-line or subsequent therapy (category 2A) for patients with *RET* gene fusion-positive gastroesophageal tumors.

### Leucovorin Shortage

Leucovorin is indicated with certain fluorouracil-based regimens. However, there is currently a shortage of leucovorin in the United States.<sup>375</sup> There

are no specific data to guide management under these circumstances, and all proposed strategies are empiric. One is the use of levoleucovorin, which is commonly used in Europe. A levoleucovorin dose of 200 mg/m<sup>2</sup> is equivalent to 400 mg/m<sup>2</sup> of standard leucovorin. Another option is to use lower doses of leucovorin in all patients, since lower doses are likely to be as efficacious as higher doses, based on several studies in patients with colorectal cancer.<sup>376-378</sup> However, the Panel recommends use of these regimens without leucovorin in situations where leucovorin is not available.

### Survivorship

In addition to survivorship care relevant to all survivors of cancer (see NCCN Guidelines for Survivorship [available at [www.nccn.org](http://www.nccn.org)]), survivors of gastric cancer have special long-term care needs due to the nature of their illness and treatments. Therefore, screening and management of long-term sequelae are important for all survivors of gastric cancer. However, due to a lack of large randomized trials, the survivorship management recommendations provided by the Panel are based on smaller studies, clinical experience, and other consensus recommendations and guidelines.<sup>379-382</sup> Survivorship care planning should include appropriate timing of transfer of care to a primary care physician and maintenance of a therapeutic relationship with the primary care physician throughout life. The oncology team and primary care physician should have clearly delineated roles in survivorship care, with these roles communicated to the patient. In general, routine gastric cancer-specific surveillance is not recommended for more than 5 years following the end of treatment. Surveillance should be performed in conjunction with good routine medical care, including routine health maintenance, preventive care, and cancer screening. Survivors of gastric cancer should be counseled to maintain a healthy body weight, adopt a physically active lifestyle, consume a healthy diet with an emphasis on plant-based sources, and limit alcohol intake. Smoking cessation should also be



## NCCN Guidelines Version 3.2025

# Gastric Cancer

encouraged, as appropriate. Additional preventive health measures and immunizations should be performed as indicated under the care of or in conjunction with a primary care physician.

Common issues facing survivors of gastric cancer include weight loss, diarrhea, chemotherapy-induced neuropathy, and fatigue. Weight loss and fatigue can be effectively managed by monitoring patients' weight regularly, encouraging more frequent consumption of smaller meals without fluid intake, and encouraging physical activity and energy conservation measures. Anti-diarrheal medications, bulk-forming agents, or diet manipulation can be considered to treat diarrhea. Duloxetine can be considered to treat painful chemotherapy-induced neuropathy but is ineffective for numbness or tingling. Referral to occupational, rehabilitation, and/or physical therapy should be considered for patients with chemotherapy-induced neuropathy who are at risk for falls.

Osteopenia/osteoporosis is another common long-term sequelae in survivors of gastric cancer, caused by deficiencies in vitamin D, calcium, phosphorus, and other vitamins and minerals. Supplementation with vitamin D, and treatment with other therapies, has been shown to improve bone health in these patients.<sup>383,384</sup> Therefore, bone density should be screened at regular intervals and low bone density should be managed as per established national guidelines.<sup>385</sup>

In addition to the issues discussed above, survivors of gastric cancer who underwent gastrectomy face other long-term health issues (usually lifetime) including postprandial fullness, nutritional deficiencies (including vitamins B<sub>12</sub> and D, calcium, iron, and zinc), dumping syndrome, and bacterial overgrowth in the small intestine (blind loop). See *Principles of Survivorship* in the algorithm for specific management recommendations. Lifelong monitoring and management of nutritional sequelae of gastrectomy should be established with appropriate practitioners and specialists.

Survivors who undergo gastrectomy are at risk for long-term health issues, as they have been shown to have greater restrictions and a significantly worse quality of life compared to those who receive partial gastrectomy.<sup>386-388</sup> A prospective study of 254 patients who were followed for 5 years following gastrectomy (partial or total) as treatment for gastric cancer found that symptoms including diarrhea, dysphagia, reflux, eating restrictions, physical functioning, cognitive functioning, and fatigue negatively impacted the patients' long-term quality of life.<sup>389</sup> Survivors of gastrectomy also have unique nutritional needs due to frequent vitamin and mineral deficiencies and other GI dysfunctions.<sup>390</sup> Studies have shown that long-term anemia and deficiencies in nutrients such as iron, vitamin B<sub>12</sub>, vitamin D, and zinc can occur in patients treated with gastrectomy for gastric cancer.<sup>391-394</sup> Supplementation of nutrients such as vitamin B<sub>12</sub><sup>395</sup> and iron<sup>396</sup> is safe and effective for reversing these deficiencies. It is recommended to supplement and monitor levels of vitamin B<sub>12</sub> and D, iron, and calcium. Daily multivitamin and mineral complexes that include other vitamins and nutrients, as listed in the algorithm, are recommended as clinically indicated.

Dumping syndrome, which results from rapid emptying of the stomach into the small bowel, is another concern for survivors of total gastrectomy. Patients suffering from early dumping syndrome (within 30 minutes of eating a meal) may experience palpitations, diarrhea, nausea, and cramps while those with late dumping syndrome (within 2–3 hours of eating a meal) may experience dizziness, hunger, cold sweats, and faintness. A large study of 1153 total survivors of gastrectomy reported that 67.6% and 38.4% of patients experienced early and late dumping, respectively.<sup>397</sup> To help manage the symptoms of dumping syndrome, the Panel recommends making dietary changes including frequent eating throughout the day, avoiding fluid intake with meals, and consuming a diet high in protein and fiber and low in simple carbohydrates and sugars.



# NCCN Guidelines Version 3.2025

## Gastric Cancer

Patients who undergo gastrectomy can experience small intestinal bacterial overgrowth, a shift in the microbiome of the small intestine.<sup>398,399</sup> Small intestinal bacterial overgrowth (blind loop) can have nonspecific symptoms and lead to maldigestion and malabsorption.<sup>399,400</sup> Modifications to diet<sup>399</sup> and use of antibiotics such as rifaximin can be effective in treating certain patients.<sup>401,402</sup> The Panel recommends consideration of antibiotic treatment and a diet high in protein and low in carbohydrates.

The Panel recommends the development of a survivorship care plan that includes information on treatments received (surgeries, RT, and systemic therapies), follow-up care, surveillance, screening recommendations, and post-treatment needs regarding acute, late, and long-term treatment-related effects and health risks. The roles of oncologists, primary care physicians, and subspecialty care physicians in the survivorship care plan should be clearly delineated. Long-term survivorship care plans should also include a periodic assessment of ongoing needs and identification of appropriate resources, including timing of transfer of care, if appropriate.

### Palliative/Best Supportive Care

The goals of palliative/best supportive care are to prevent, reduce, and relieve suffering and improve the quality of life for patients and their caregivers, regardless of the stage of the disease or the need for other therapies. In patients with advanced or metastatic gastric cancer, palliative/best supportive care provides symptom relief and improvement in overall quality of life and may result in prolongation of life. This is especially true when a multimodality interdisciplinary approach is pursued. Therefore, a multimodality interdisciplinary approach to palliative/best supportive care of patients with gastric cancer is encouraged.

### Bleeding

Acute bleeding is common in patients with gastric cancer and may be tumor-related or a consequence of therapy. Patients with acute severe

bleeding (hematemesis or melena) should undergo prompt endoscopic assessment.<sup>403</sup> The efficacy of endoscopic treatment for bleeding in patients with gastric cancer is not well-studied, but limited available data suggest that while endoscopic therapies may be effective as initial treatment, the rate of recurrent bleeding is very high.<sup>404,405</sup> Widely available options for endoscopic therapies include injection therapy, mechanical therapy (eg, endoscopic clip placement), ablative therapy (eg, argon plasma coagulation or other laser therapy), or a combination of modalities.<sup>404</sup> Interventional radiology with angiographic embolization techniques may be useful in situations where endoscopy is not helpful.<sup>406</sup> Additionally, external beam RT (EBRT) has been shown to effectively manage acute and chronic GI bleeding.<sup>407,408</sup> Palliative gastrectomy is also an option in select patients. Proton pump inhibitors can also be prescribed to reduce the risk of bleeding from gastric cancer; however, there are no definitive data supporting their use at this time.

### Obstruction

The primary goals of palliation for patients with malignant gastric obstruction are to reduce nausea and vomiting and, when possible, allow resumption of an oral diet. Management of malignant gastric obstruction should be individualized, and treatment options should be selected as clinically appropriate. Treatment options used to alleviate or bypass obstruction include surgery (gastrojejunostomy<sup>409</sup> or gastrectomy in select patients<sup>202</sup>), EBRT, chemotherapy, and endoscopic placement of an enteral stent for relief of gastric outlet obstruction<sup>409</sup> or esophageal stent for EGJ/cardia obstruction. Endoscopic placement of a SEMS is a safe and effective minimally invasive palliative treatment for patients with luminal obstruction due to advanced gastric cancer.<sup>410-413</sup> In a systematic review, patients treated with endoscopic placement of a SEMS were more likely to tolerate oral intake and had shorter hospital stays than patients treated with gastrojejunostomy.<sup>414</sup> The results of another systematic review suggest that SEMS placement may be associated with more



# NCCN Guidelines Version 3.2025

## Gastric Cancer

favorable results in patients with a relatively short life expectancy, whereas gastrojejunostomy is preferable in patients with a more prolonged prognosis.<sup>409</sup> A randomized trial also reported similar findings.<sup>203</sup> However, these results need to be confirmed in larger randomized trials.

When obstruction cannot be alleviated or bypassed, the primary goal is to reduce the symptoms of obstruction via venting gastrostomy.<sup>415</sup> Percutaneous, endoscopic, surgical, or interventional radiology gastrostomy tube placement may be performed for gastric decompression, if tumor location permits. Percutaneous decompressive gastrostomy has been associated with palliative benefit for patients with gastric outlet obstruction.<sup>416,417</sup> Ascites, if present, should be drained prior to venting gastrostomy tube placement to reduce the risk of infectious complications.<sup>418,419</sup> Feeding gastrostomy tubes for patients with EGJ/gastric cardia obstruction or jejunal feeding tubes for patients with mid and distal gastric obstruction may be necessary to provide adequate hydration and nutritional support for patients who cannot tolerate an oral diet. Nutritional counseling may also be valuable.

### Pain

Pain control may be achieved with the use of EBRT or chemotherapy. If the patient is experiencing tumor-related pain, then pain should be assessed and treated according to the NCCN Guidelines for Adult Cancer Pain (available at [www.nccn.org](http://www.nccn.org)). Severe, uncontrolled pain following gastric stent placement should be treated with immediate endoscopic removal of the stent.

### Nausea and Vomiting

Patients experiencing nausea and vomiting should be treated according to the NCCN Guidelines for Antiemesis (available at [www.nccn.org](http://www.nccn.org)). Nausea and vomiting may be associated with luminal obstruction, so endoscopic

or fluoroscopic evaluation should be performed to determine if obstruction is present.

### Summary

Gastric cancer is rampant in many parts of the world and is often diagnosed at an advanced stage. Risk factors for gastric cancer include *H. pylori* infection, smoking, and high salt intake. Some gastric cancers are associated with inherited gastric cancer predisposition syndromes. See the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric (available at [www.nccn.org](http://www.nccn.org)) for more information. The NCCN Panel strongly recommends multidisciplinary team management as essential for treating localized gastric cancer. Best supportive care is an integral part of treatment, especially in patients with unresectable locally advanced, recurrent, or metastatic disease.

ER (EMR or ESD) is the primary treatment option for patients with early-stage (Tis or T1a) tumors. Patients who are medically fit with resectable T1b or higher, any N tumors can receive surgery with D2 lymph node dissection. Perioperative systemic therapy is a category 1 recommendation for patients with resectable T2 or higher, any N tumors or neoadjuvant/perioperative ICI can be considered for certain patients with MSI-H/dMMR tumors (category 2A). Patients who are medically fit with surgically unresectable tumors have the option of chemoradiation or systemic therapy. Nonsurgical candidates (patients who cannot tolerate surgery or decline surgery) and patients with metastatic disease should receive palliative management.

Following an R0 resection, observation is an option for patients with Tis or T1,N0 tumors who did not receive previous systemic therapy.

Postoperative chemoradiation is recommended for patients with T3–T4, any N tumors or any T, N+ tumors in patients who had received less than a D2 lymph node dissection and had not received previous systemic therapy (category 1). Selected patients with T2, N0 tumors and high-risk



## NCCN Guidelines Version 3.2025

# Gastric Cancer

features can also be considered for postoperative chemoradiation. Postoperative chemotherapy should be reserved for patients with T3–T4, any N and or any T, N+ tumors who received D2 lymph node dissection (category 1). Postoperative chemoradiation is recommended for all patients with residual disease at surgical margins if it was not received previously. Palliative management is also an option for certain patients following R2 resection. Options for patients who have received previous systemic therapy include systemic therapy (category 1) following R0 resection. Patients with R1 or R2 resection have the option of chemoradiation. Patients with R1 resection can also be considered for re-resection, while patients with R2 resection can receive palliative management. Palliative management is an option for patients with M1 disease, regardless of whether they received preoperative therapy.

Histologic subtype and molecular characteristics have important implications in diagnosing and treating gastric cancer. The list of biomarkers that will characterize more subsets will continue to evolve. Several targeted therapeutic agents, including HER2-directed therapies, ICIs, and various kinase inhibitors, have been approved by the FDA for advanced gastric cancer. Targeted therapies have produced encouraging results in the treatment of patients with advanced gastric cancer. The NCCN Guidelines for Gastric Cancer are based on evidence- and consensus-based treatment approaches for the comprehensive care of patients with gastric cancer. The Panel encourages patients with gastric cancer to participate in well-designed clinical trials investigating novel therapeutic strategies to enable further advances in the management of this disease.



# NCCN Guidelines Version 3.2025

## Gastric Cancer

### References

1. Sitarz R, Skierucha M, Mielko J, et al. Gastric cancer: epidemiology, prevention, classification, and treatment. *Cancer Manag Res* 2018;10:239–248. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29445300>.
2. Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. *Nat Rev Clin Oncol* 2023;20:338–349. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36959359>.
3. Ma J, Shen H, Kapesa L, Zeng S. Lauren classification and individualized chemotherapy in gastric cancer. *Oncol Lett* 2016;11:2959–2964. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27123046>.
4. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: stomach cancer. 2024. Available at: <https://seer.cancer.gov/statfacts/html/stomach.html>. Accessed May 6, 2024.
5. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. *Cancer Epidemiol Biomarkers Prev* 2016;25:16–27. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26667886>.
6. Etemadi A, Safiri S, Sepanlou SG, et al. The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. *Lancet Gastroenterol Hepatol* 2020;5:42–54. Available at: <https://pubmed.ncbi.nlm.nih.gov/31648970/>.
7. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2024;74:229–263. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/38572751>.
8. World Health Organization. International Agency for Research on Cancer. GLOBOCAN 2022: stomach cancer fact sheet. 2024. Available at: <https://qco.iarc.who.int/media/globocan/factsheets/cancers/7-stomach-fact-sheet.pdf>. Accessed May 8, 2024.
9. Zhao JK, Wu M, Kim CH, et al. Jiangsu Four Cancers Study: a large case-control study of lung, liver, stomach, and esophageal cancers in Jiangsu Province, China. *Eur J Cancer Prev* 2017;26:357–364. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27275735>.
10. Siegel RL, Kratzer TB, Giaquinto AN, et al. Cancer statistics, 2025. *CA Cancer J Clin* 2025;75:10–45. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/39817679>.
11. Bergquist JR, Leiting JL, Habermann EB, et al. Early-onset gastric cancer is a distinct disease with worrisome trends and oncogenic features. *Surgery* 2019;166:547–555. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31331685>.
12. Arnold M, Park JY, Camargo MC, et al. Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035. *Gut* 2020;69:823–829. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32001553>.
13. Li Y, Hahn AI, Laszkowska M, et al. Clinicopathological characteristics and risk factors of young-onset gastric carcinoma: A systematic review and meta-analysis. *Clin Transl Gastroenterol* 2024;15:e1. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/38717039>.
14. Karimi P, Islami F, Anandasabapathy S, et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. *Cancer Epidemiol Biomarkers Prev* 2014;23:700–713. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24618998>.
15. Yusefi AR, Bagheri Lankarani K, Bastani P, et al. Risk factors for gastric cancer: a systematic review. *Asian Pac J Cancer Prev* 2018;19:591–603. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29579788>.



## NCCN Guidelines Version 3.2025

# Gastric Cancer

16. Hu B, El Hajj N, Sittler S, et al. Gastric cancer: classification, histology and application of molecular pathology. *J Gastrointest Oncol* 2012;3:251–261. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22943016>.
17. Tramacere I, Negri E, Pelucchi C, et al. A meta-analysis on alcohol drinking and gastric cancer risk. *Ann Oncol* 2012;23:28–36. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21536659>.
18. He Z, Zhao TT, Xu HM, et al. Association between alcohol consumption and the risk of gastric cancer: a meta-analysis of prospective cohort studies. *Oncotarget* 2017;8:84459–84472. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29137439>.
19. Wang PL, Xiao FT, Gong BC, Liu FN. Alcohol drinking and gastric cancer risk: a meta-analysis of observational studies. *Oncotarget* 2017;8:99013–99023. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29228746>.
20. Deng W, Jin L, Zhuo H, et al. Alcohol consumption and risk of stomach cancer: A meta-analysis. *Chem Biol Interact* 2021;336:109365. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33412155>.
21. Falk J, Carstens H, Lundell L, Albertsson M. Incidence of carcinoma of the oesophagus and gastric cardia. Changes over time and geographical differences. *Acta Oncol* 2007;46:1070–1074. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17851842>.
22. Powell J, McConkey CC, Gillison EW, Spychal RT. Continuing rising trend in oesophageal adenocarcinoma. *Int J Cancer* 2002;102:422–427. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12402314>.
23. Crew KD, Neugut AI. Epidemiology of gastric cancer. *World J Gastroenterol* 2006;12:354–362. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16489633>.
24. Freedman-Cass DA, Fischer T, Alpert AB, et al. The value and process of inclusion: Using sensitive, respectful, and inclusive language and images in NCCN content. *J Natl Compr Canc Netw* 2023;21:434–441. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37156485>.
25. Amin MB, Edge SB, Greene FL. AJCC cancer staging manual (ed 8). New York, NY: Springer; 2017.
26. Bando E, Makuuchi R, Irino T, et al. Validation of the prognostic impact of the new tumor-node-metastasis clinical staging in patients with gastric cancer. *Gastric Cancer* 2019;22:123–129. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29357013>.
27. Sano T, Coit DG, Kim HH, et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. *Gastric Cancer* 2017;20:217–225. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26897166>.
28. In H, Solsky I, Palis B, et al. Validation of the 8th edition of the AJCC TNM staging system for gastric cancer using the National Cancer Database. *Ann Surg Oncol* 2017;24:3683–3691. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28895113>.
29. Huang SF, Chien TH, Fang WL, et al. The 8th edition American Joint Committee on gastric cancer pathological staging classification performs well in a population with high proportion of locally advanced disease. *Eur J Surg Oncol* 2018;44:1634–1639. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29941227>.
30. Abdalla EK, Pisters PWT. Staging and preoperative evaluation of upper gastrointestinal malignancies. *Semin Oncol* 2004;31:513–529. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15297943>.
31. Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. *J Clin Oncol* 2007;25:2107–2116. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17513817>.
32. Weber WA, Ott K. Imaging of esophageal and gastric cancer. *Semin Oncol* 2004;31:530–541. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15297944>.
33. Matsumoto Y, Yanai H, Tokiyama H, et al. Endoscopic ultrasonography for diagnosis of submucosal invasion in early gastric



# NCCN Guidelines Version 3.2025

## Gastric Cancer

cancer. *J Gastroenterol* 2000;35:326–331. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10832666>.

34. Cardoso R, Coburn N, Seeveratnam R, et al. A systematic review and meta-analysis of the utility of EUS for preoperative staging for gastric cancer. *Gastric Cancer* 2012;15 Suppl 1:S19–26. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22237654>.

35. Spolverato G, Ejaz A, Kim Y, et al. Use of endoscopic ultrasound in the preoperative staging of gastric cancer: a multi-institutional study of the US gastric cancer collaborative. *J Am Coll Surg* 2015;220:48–56. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25283742>.

36. Tsendsuren T, Jun S-M, Mian X-H. Usefulness of endoscopic ultrasonography in preoperative TNM staging of gastric cancer. *World J Gastroenterol* 2006;12:43–47. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16440415>.

37. Stahl A, Ott K, Weber WA, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. *Eur J Nucl Med Mol Imaging* 2003;30:288–295. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12552348>.

38. Wieder HA, Krause BJ, Herrmann K. PET and PET-CT in esophageal and gastric cancer. *Methods Mol Biol* 2011;727:59–76. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21331929>.

39. Chen J, Cheong J-H, Yun MJ, et al. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. *Cancer* 2005;103:2383–2390. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15856477>.

40. Rosenbaum SJ, Stergar H, Antoch G, et al. Staging and follow-up of gastrointestinal tumors with PET/CT. *Abdom Imaging* 2006;31:25–35. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16333707>.

41. Dassen AE, Lips DJ, Hoekstra CJ, et al. FDG-PET has no definite role in preoperative imaging in gastric cancer. *Eur J Surg Oncol* 2009;35:449–455. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19147324>.

42. Lim JS, Yun MJ, Kim M-J, et al. CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy. *Radiographics* 2006;26:143–156. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16418249>.

43. Sarela AI, Lefkowitz R, Brennan MF, Karpeh MS. Selection of patients with gastric adenocarcinoma for laparoscopic staging. *Am J Surg* 2006;191:134–138. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16399124>.

44. Bentrem D, Wilton A, Mazumdar M, et al. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. *Ann Surg Oncol* 2005;12:347–353. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15915368>.

45. Mezhir JJ, Shah MA, Jacks LM, et al. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. *Ann Surg Oncol* 2010;17:3173–3180. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20585870>.

46. De Andrade JP, Mezhir JJ. The critical role of peritoneal cytology in the staging of gastric cancer: an evidence-based review. *J Surg Oncol* 2014;110:291–297. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24850538>.

47. Chau I, Norman AR, Cunningham D, et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. *J Clin Oncol* 2004;22:2395–2403. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15197201>.

48. Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than number? An analysis of 1,038 patients. *Ann Surg* 2000;232:362–371. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10973386>.

49. Brar SS, Mahar AL, Helyer LK, et al. Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA



## NCCN Guidelines Version 3.2025

# Gastric Cancer

expert panel. JAMA Surg 2014;149:18–25. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24225775>.

50. Siewert JR. Carcinoma of the cardia: carcinoma of the gastroesophageal junction classification, pathology, and extent of resection. Dis Esophagus 1996;9:173–182. Available at: <https://academic.oup.com/dote/article-abstract/9/3/173/2798630>.

51. Siewert JR, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000;232:353–361. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10973385>.

52. Ychou M, Boige V, Pignon J-P, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1715–1721. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21444866>.

53. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851–856. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19139439>.

54. Al-Batran S-E, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019;393:1948–1957. Available at: <https://pubmed.ncbi.nlm.nih.gov/30982686/>.

55. Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med 2025;393:217–230. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/40454643>.

56. Moertel CG, Childs DS, Reitemeier RJ, et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969;2:865–867. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/4186452>.

57. The Gastrointestinal Tumor Study Group. The concept of locally advanced gastric cancer. Effect of treatment on outcome. Cancer 1990;66:2324–2330. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1700927>.

58. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–730. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11547741>.

59. Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed Intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012;30:2327–2333. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22585691>.

60. Park SH, Sohn TS, Lee J, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the Adjuvant Chemoradiotherapy In Stomach Tumors trial, including survival and subset analyses. J Clin Oncol 2015;33:3130–3136. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25559811>.

61. Du C, Zhou Y, Huang K, et al. Defining a high-risk subgroup of pathological T2N0 gastric cancer by prognostic risk stratification for adjuvant therapy. J Gastrointest Surg 2011;15:2153–2158. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21938559>.

62. Bang Y-J, Kim Y-W, Yang H-K, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315–321. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22226517>.



## NCCN Guidelines Version 3.2025

### Gastric Cancer

63. Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:1389–1396. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25439693>.
64. Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med 2018;378:1085–1095. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29562147>.
65. Youn HG, An JY, Choi MG, et al. Recurrence after curative resection of early gastric cancer. Ann Surg Oncol 2010;17:448–454. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19904573>.
66. Yoo CH, Noh SH, Shin DW, et al. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000;87:236–242. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10671934>.
67. Song J, Lee HJ, Cho GS, et al. Recurrence following laparoscopy-assisted gastrectomy for gastric cancer: a multicenter retrospective analysis of 1,417 patients. Ann Surg Oncol 2010;17:1777–1786. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20151217>.
68. Lee JH, Kim HI, Kim MG, et al. Recurrence of gastric cancer in patients who are disease-free for more than 5 years after primary resection. Surgery 2016;159:1090–1098. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26747230>.
69. Jin LX, Moses LE, Squires MH, 3rd, et al. Factors associated with recurrence and survival in lymph node-negative gastric adenocarcinoma: a 7-institution study of the US Gastric Cancer Collaborative. Ann Surg 2015;262:999–1005. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25607760>.
70. Honda M, Hiki N, Kinoshita T, et al. Long-term outcomes of laparoscopic versus open surgery for clinical stage I gastric cancer: the LOC-1 study. Ann Surg 2016;264:214–222. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27115899>.
71. Fields RC, Strong VE, Gonen M, et al. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastroesophageal adenocarcinoma. Br J Cancer 2011;104:1840–1847. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21610705>.
72. D'Angelica M, Gonen M, Brennan MF, et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004;240:808–816. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15492562>.
73. Cao L, Selby LV, Hu X, et al. Risk factors for recurrence in T1-2N0 gastric cancer in the United States and China. J Surg Oncol 2016;113:745–749. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27040753>.
74. Baiocchi GL, Marrelli D, Verlato G, et al. Follow-up after gastrectomy for cancer: an appraisal of the Italian Research Group for Gastric Cancer. Ann Surg Oncol 2014;21:2005–2011. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24526547>.
75. Hatfield AR, Slavin G, Segal AW, Levi AJ. Importance of the site of endoscopic gastric biopsy in ulcerating lesions of the stomach. Gut 1975;16:884–886. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1193417>.
76. Graham DY, Schwartz JT, Cain GD, Gyorkey F. Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. Gastroenterology 1982;82:228–231. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/7054024>.
77. Akiyama M, Ota M, Nakajima H, et al. Endoscopic mucosal resection of gastric neoplasms using a ligating device. Gastrointest Endosc 1997;45:182–186. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9041007>.
78. Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011;14:113–123. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21573742>.



## NCCN Guidelines Version 3.2025

# Gastric Cancer

79. Botet JF, Lightdale CJ, Zauber AG, et al. Preoperative staging of gastric cancer: comparison of endoscopic US and dynamic CT. *Radiology* 1991;181:426–432. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1924784>.
80. Bentrem D, Gerdes H, Tang L, et al. Clinical correlation of endoscopic ultrasonography with pathologic stage and outcome in patients undergoing curative resection for gastric cancer. *Ann Surg Oncol* 2007;14:1853–1859. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17357856>.
81. Okada K, Fujisaki J, Kasuga A, et al. Endoscopic ultrasonography is valuable for identifying early gastric cancers meeting expanded-indication criteria for endoscopic submucosal dissection. *Surg Endosc* 2011;25:841–848. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20734082>.
82. Keswani RN, Early DS, Edmundowicz SA, et al. Routine positron emission tomography does not alter nodal staging in patients undergoing EUS-guided FNA for esophageal cancer. *Gastrointest Endosc* 2009;69:1210–1217. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19012886>.
83. Soetikno R, Kaltenbach T, Yeh R, Gotoda T. Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. *J Clin Oncol* 2005;23:4490–4498. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16002839>.
84. Bonenkamp JJ, van de Velde CJ, Kampschoer GH, et al. Comparison of factors influencing the prognosis of Japanese, German, and Dutch gastric cancer patients. *World J Surg* 1993;17:410–414. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8337889>.
85. Uedo N, Iishi H, Tatsuta M, et al. Longterm outcomes after endoscopic mucosal resection for early gastric cancer. *Gastric Cancer* 2006;9:88–92. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16767363>.
86. Youn JC, Youn YH, Kim TI, et al. Factors affecting long-term clinical outcomes of endoscopic mucosal resection of early gastric cancer. *Hepatogastroenterology* 2006;53:643–647. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16995480>.
87. Kim JJ, Lee JH, Jung H-Y, et al. EMR for early gastric cancer in Korea: a multicenter retrospective study. *Gastrointest Endosc* 2007;66:693–700. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17905010>.
88. Choi KS, Jung HY, Choi KD, et al. EMR versus gastrectomy for intramucosal gastric cancer: comparison of long-term outcomes. *Gastrointest Endosc* 2011;73:942–948. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21392757>.
89. Chung I-K, Lee JH, Lee S-H, et al. Therapeutic outcomes in 1000 cases of endoscopic submucosal dissection for early gastric neoplasms: Korean ESD Study Group multicenter study. *Gastrointest Endosc* 2009;69:1228–1235. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19249769>.
90. Isomoto H, Shikuwa S, Yamaguchi N, et al. Endoscopic submucosal dissection for early gastric cancer: a large-scale feasibility study. *Gut* 2009;58:331–336. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19001058>.
91. Akasaka T, Nishida T, Tsutsui S, et al. Short-term outcomes of endoscopic submucosal dissection (ESD) for early gastric neoplasm: multicenter survey by osaka university ESD study group. *Dig Endosc* 2011;23:73–77. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21198921>.
92. Farhat S, Chaussade S, Ponchon T, et al. Endoscopic submucosal dissection in a European setting. A multi-institutional report of a technique in development. *Endoscopy* 2011;43:664–670. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21623560>.
93. Sugimoto T, Okamoto M, Mitsuno Y, et al. Endoscopic submucosal dissection is an effective and safe therapy for early gastric neoplasms: a multicenter feasible study. *J Clin Gastroenterol* 2012;46:124–129. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21959325>.
94. Chaves DM, Moura EGH, Milhomem D, et al. Initial experience of endoscopic submucosal dissection in Brazil to treat early gastric and esophagheal cancer: a multi-institutional analysis. *Arq Gastroenterol*



## NCCN Guidelines Version 3.2025

# Gastric Cancer

2013;50:148–152. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23903626>.

95. Abe S, Oda I, Suzuki H, et al. Short- and long-term outcomes of endoscopic submucosal dissection for undifferentiated early gastric cancer. *Endoscopy* 2013;45:703–707. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23990481>.

96. Repici A, Zullo A, Hassan C, et al. Endoscopic submucosal dissection of early gastric neoplastic lesions: a western series. *Eur J Gastroenterol Hepatol* 2013;25:1261–1264. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23925276>.

97. Oda I, Saito D, Tada M, et al. A multicenter retrospective study of endoscopic resection for early gastric cancer. *Gastric Cancer* 2006;9:262–270. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17235627>.

98. Hoteya S, Izuka T, Kikuchi D, Yahagi N. Benefits of endoscopic submucosal dissection according to size and location of gastric neoplasm, compared with conventional mucosal resection. *J Gastroenterol Hepatol* 2009;24:1102–1106. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19383079>.

99. Nakamoto S, Sakai Y, Kasanuki J, et al. Indications for the use of endoscopic mucosal resection for early gastric cancer in Japan: a comparative study with endoscopic submucosal dissection. *Endoscopy* 2009;41:746–750. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19681023>.

100. Watanabe T, Kume K, Taip M, et al. Gastric mucosal cancer smaller than 7mm can be treated with conventional endoscopic mucosal resection as effectively as with endoscopic submucosal dissection. *Hepatogastroenterology* 2010;57:668–673. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20698247>.

101. Park YM, Cho E, Kang HY, Kim JM. The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis.

Surg Endosc 2011;25:2666–2677. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21424201>.

102. Lian J, Chen S, Zhang Y, Qiu F. A meta-analysis of endoscopic submucosal dissection and EMR for early gastric cancer. *Gastrointest Endosc* 2012;76:763–770. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22884100>.

103. Zhao Y, Wang C. Long-term clinical efficacy and perioperative safety of endoscopic submucosal dissection versus endoscopic mucosal resection for early gastric cancer: An updated meta-analysis. *Biomed Res Int* 2018;2018:3152346. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/29568748>.

104. Yahagi N, Fujishiro M, Kakushima N, et al. Endoscopic submucosal dissection for early gastric cancer using the tip of an electrosurgical snare (thin type). *Digestive Endoscopy* 2004;16:34–38. Available at:

<https://doi.org/10.1111/j.1443-1661.2004.00313.x>.

105. Facciorusso A, Antonino M, Di Maso M, Muscatiello N. Endoscopic submucosal dissection vs endoscopic mucosal resection for early gastric cancer: a meta-analysis. *World J Gastrointest Endosc* 2014;6:555–563. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25400870>.

106. Ono H, Kondo H, Gotoda T, et al. Endoscopic mucosal resection for treatment of early gastric cancer. *Gut* 2001;48:225–229. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11156645>.

107. committee Asop, Forbes N, Elhanafi SE, et al. American Society for Gastrointestinal Endoscopy guideline on endoscopic submucosal dissection for the management of early esophageal and gastric cancers: summary and recommendations. *Gastrointest Endosc* 2023;98:271–284. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37498266>.

108. Pimentel-Nunes P, Libanio D, Bastiaansen BAJ, et al. Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2022. *Endoscopy* 2022;54:591–622. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/35523224>.



## NCCN Guidelines Version 3.2025

### Gastric Cancer

109. Ahn JY, Jung HY, Choi KD, et al. Endoscopic and oncologic outcomes after endoscopic resection for early gastric cancer: 1370 cases of absolute and extended indications. *Gastrointest Endosc* 2011;74:485–493. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21741645>.
110. Schmidt C, Gerdes H, Hawkins W, et al. A prospective observational study examining quality of life in patients with malignant gastric outlet obstruction. *Am J Surg* 2009;198:92–99. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19482259>.
111. Vakil N, Morris AI, Marcon N, et al. A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. *Am J Gastroenterol* 2001;96:1791–1796. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11419831>.
112. Shike M, Latkany L, Gerdes H, Bloch AS. Direct percutaneous endoscopic jejunostomies for enteral feeding. *Gastrointest Endosc* 1996;44:536–540. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8934158>.
113. Lightdale CJ, Botet JF, Kelsen DP, et al. Diagnosis of recurrent upper gastrointestinal cancer at the surgical anastomosis by endoscopic ultrasound. *Gastrointest Endosc* 1989;35:407–412. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2676688>.
114. Park SR, Lee JS, Kim CG, et al. Endoscopic ultrasound and computed tomography in restaging and predicting prognosis after neoadjuvant chemotherapy in patients with locally advanced gastric cancer. *Cancer* 2008;112:2368–2376. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18404697>.
115. Sarkaria IS, Rizk NP, Bains MS, et al. Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. *Ann Surg* 2009;249:764–767. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19387328>.
116. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* 2014;513:202–209. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25079317>.
117. Nemtsova MV, Kuznetsova EB, Bure IV. Chromosomal Instability in Gastric Cancer: Role in Tumor Development, Progression, and Therapy. *Int J Mol Sci* 2023;24:16961. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/38069284>.
118. Supek F, Lehner B. Differential DNA mismatch repair underlies mutation rate variation across the human genome. *Nature* 2015;521:81–84. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25707793>.
119. Puliga E, Corso S, Pietrantonio F, Giordano S. Microsatellite instability in gastric cancer: Between lights and shadows. *Cancer Treat Rev* 2021;95:102175. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33721595>.
120. Wang L, Zhang Q, Ni S, et al. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status. *Cancer Med* 2018;7:2612–2620. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29673110>.
121. Morihiro T, Kuroda S, Kanaya N, et al. PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer. *Sci Rep* 2019;9:4633. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30874607>.
122. Lowy AM, Mansfield PF, Leach SD, et al. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. *Ann Surg* 1999;229:303–308. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10077040>.
123. Mansour JC, Tang L, Shah M, et al. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? *Ann Surg Oncol* 2007;14:3412–3418. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17909917>.



## NCCN Guidelines Version 3.2025

### Gastric Cancer

124. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. *Cancer* 2003;98:1521–1530. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14508841>.
125. Smyth EC, Fassan M, Cunningham D, et al. Effect of pathologic tumor response and nodal status on survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy trial. *J Clin Oncol* 2016;34:2721–2727. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27298411>.
126. Ryan R, Gibbons D, Hyland JM, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. *Histopathology* 2005;47:141–146. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16045774>.
127. Burgart LJ, Chopp WV, Jain D. Protocol for the examination of specimens from patients with carcinoma of the stomach. *Cancer Protocol Templates*. Northfield, IL: College of American Pathologists; 2021.
128. Naffouje SA, Salti GI. Extensive lymph node dissection improves survival among American patients with gastric adenocarcinoma treated surgically: analysis of the National Cancer Database. *J Gastric Cancer* 2017;17:319–330. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29302372>.
129. Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. *J Clin Oncol* 2005;23:7114–7124. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16192595>.
130. Yuan SQ, Chen YT, Huang ZP. Equipping the 8th edition American Joint Committee on Cancer staging for gastric cancer with the 15-node minimum: a population-based study using recursive partitioning analysis. *J Gastrointest Surg* 2017;21:1591–1598. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28752402>.
131. Hechtman JF, Polydorides AD. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. *Arch Pathol Lab Med* 2012;136:691–697. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22646280>.
132. Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes—a systematic review. *Int J Cancer* 2012;130:2845–2856. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21780108>.
133. Gomez-Martin C, Garralda E, Echarri MJ, et al. HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. *J Clin Pathol* 2012;65:751–757. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22569536>.
134. Jorgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer—a systematic analysis of data from the literature. *J Cancer* 2012;3:137–144. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22481979>.
135. Kato S, Okamura R, Baumgartner JM, et al. Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma. *Clin Cancer Res* 2018;24:6248–6256. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30348637>.
136. Cho JH, Lim JY, Cho JY. Survival analysis based on human epidermal growth factor 2 status in stage II–III gastric cancer. *World J Gastroenterol* 2017;23:7407–7414. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29151694>.
137. Lei YY, Huang JY, Zhao QR, et al. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature. *World J Surg Oncol* 2017;15:68. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28327158>.
138. Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value—conclusions from 924 cases of two independent series. *Cell Oncol* 2010;32:57–65. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20208134>.



## NCCN Guidelines Version 3.2025

# Gastric Cancer

139. Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA international collaborative analysis. *Ann Oncol* 2012;23:2656–2662. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22689179>.
140. Kunz PL, Mojtahehd A, Fisher GA, et al. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. *Appl Immunohistochem Mol Morphol* 2012;20:13–24. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21617522>.
141. Scheck MK, Hofheinz RD, Lorenzen S. HER2-positive gastric cancer and antibody treatment: State of the art and future developments. *Cancers (Basel)* 2024;16. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/38611014>.
142. Tanner M, Hollmen M, Junnila TT, et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. *Ann Oncol* 2005;16:273–278. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15668283>.
143. Yan B, Yau EX, Bte Omar SS, et al. A study of HER2 gene amplification and protein expression in gastric cancer. *J Clin Pathol* 2010;63:839–842. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20696687>.
144. Kim WH, Gomez-Izquierdo L, Vilardell F, et al. HER2 status in gastric and gastroesophageal junction cancer: results of the large, multinational HER-EAGLE study. *Appl Immunohistochem Mol Morphol* 2018;26:239–245. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27490762>.
145. Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. *Gastric Cancer* 2015;18:476–484. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25038874>.
146. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010;376:687–697. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20728210>.
147. Bartley AN, Washington MK, Colasacco C, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. *J Clin Oncol* 2017;35:446–464. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28129524>.
148. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. *Histopathology* 2008;52:797–805. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18422971>.
149. Ruschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing. *Virchows Arch* 2010;457:299–307. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20665045>.
150. Wu H, Ma W, Jiang C, et al. Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy. *Ann Surg Oncol* 2023;30:8572–8587. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37667098>.
151. Polom K, Marano L, Marrelli D, et al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. *Br J Surg* 2018;105:159–167. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29091259>.
152. Bermúdez A, Arranz-Salas I, Mercado S, et al. Her2-positive and microsatellite instability status in gastric cancer—clinicopathological implications. *Diagnostics* Vol. 11; 2021:944. Available at: <https://pubmed.ncbi.nlm.nih.gov/34070574/>.



## NCCN Guidelines Version 3.2025

### Gastric Cancer

153. Mathiak M, Warneke VS, Behrens HM, et al. Clinicopathologic characteristics of microsatellite unstable gastric carcinomas revisited: Urgent need for standardization. *Appl Immunohistochem Mol Morphol* 2017;25:12–24. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26371427>.
154. Bonneville R, Krook MA, Kutto EA, et al. Landscape of Microsatellite Instability Across 39 Cancer Types. *JCO Precis Oncol* 2017;2017. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29850653>.
155. Pietrantonio F, Miceli R, Raimondi A, et al. Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. *J Clin Oncol* 2019;37:3392–3400. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31513484>.
156. Chao J, Fuchs CS, Shitara K, et al. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. *JAMA Oncol* 2021;7:895–902. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33792646>.
157. Zhuo ZG, Deng HY, Song TN, et al. Predictors for the clinical benefit of anti-PD-1/PD-L1 therapy in advanced gastroesophageal cancer: a meta-analysis of clinical trials. *Ann Palliat Med* 2020;9:2524–2537. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33065778>.
158. Ratti M, Lampis A, Hahne JC, et al. Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. *Cell Mol Life Sci* 2018;75:4151–4162. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30173350>.
159. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science* 2017;357:409–413. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28596308>.
160. Bartley AN, Fitzgibbons PL, Broaddus RR, Shi C. Template for reporting results of DNA mismatch repair testing in patients being considered for checkpoint inhibitor immunotherapy. College of American Pathologists 2018. Available at: <https://documents.cap.org/protocols/cp-general-dnamismatchrepair-18biomarker-1001.pdf>.
161. Gou Q, Dong C, Xu H, et al. PD-L1 degradation pathway and immunotherapy for cancer. *Cell Death Dis* 2020;11:955. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33159034>.
162. Cha JH, Chan LC, Li CW, et al. Mechanisms controlling PD-L1 expression in cancer. *Mol Cell* 2019;76:359–370. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31668929>.
163. Lin X, Kang K, Chen P, et al. Regulatory mechanisms of PD-1/PD-L1 in cancers. *Mol Cancer* 2024;23:108. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/38762484>.
164. Liu X, Choi MG, Kim K, et al. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. *Pathol Res Pract* 2020;216:152881. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32089413>.
165. Boger C, Behrens HM, Mathiak M, et al. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. *Oncotarget* 2016;7:24269–24283. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27009855>.
166. Chen XJ, Wei CZ, Lin J, et al. Prognostic significance of PD-L1 expression in gastric cancer patients with peritoneal metastasis. *Biomedicines* 2023;11:2003. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37509642>.
167. Gu L, Chen M, Guo D, et al. PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. *PLoS One* 2017;12:e0182692. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28796808>.
168. Kawazoe A, Kuwata T, Kuboki Y, et al. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric



## NCCN Guidelines Version 3.2025

### Gastric Cancer

cancer patients. *Gastric Cancer* 2017;20:407–415. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/27629881>.

169. Chang H, Jung WY, Kang Y, et al. Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group. *Oncotarget* 2016;7:80426–80434. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27741514>.

170. Liu C, Fang F, Kong Y, ElGabry EA. Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring. *Diagn Pathol* 2023;18:48. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37076889>.

171. Qiu MZ, Oh DY, Kato K, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. *BMJ* 2024;385:e078876. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/38806195>.

172. Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. *Lancet Oncol* 2023;24:483–495. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/37080222>.

173. Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. *Lancet* 2023;401:1655–1668. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37068504>.

174. Angerilli V, Ghelardi F, Nappo F, et al. Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with expert opinion. *Pathol Res Pract* 2024;254:155145. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/38277741>.

175. Pellino A, Brignola S, Riello E, et al. Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. *J Pers Med* 2021;11:1095. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34834447>.

176. Coati I, Lotz G, Fanelli GN, et al. Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. *Br J Cancer* 2019;121:257–263. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31235864>.

177. Kubota Y, Kawazoe A, Mishima S, et al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. *ESMO Open* 2023;8:100762. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36610262>.

178. Shitara K, Xu RH, Ajani JA, et al. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. *Gastric Cancer* 2024;27:1058–1068. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/38954176>.

179. Cao W, Xing H, Li Y, et al. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. *Biomark Res* 2022;10:38. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35642043>.

180. Rohde C, Yamaguchi R, Mukhina S, et al. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. *Jpn J Clin Oncol* 2019;49:870–876. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31087075>.

181. Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. *Clin Cancer Res* 2008;14:7624–7634. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19047087>.



## NCCN Guidelines Version 3.2025

### Gastric Cancer

182. Inamoto R, Takahashi N, Yamada Y. Claudin18.2 in advanced gastric cancer. *Cancers (Basel)* 2023;15:5742. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/38136288>.
183. Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. *Nat Med* 2023;29:2133–2141. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37524953>.
184. Willis J, Lefterova MI, Artyomenko A, et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel. *Clin Cancer Res* 2019;25:7035–7045. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31383735>.
185. Sousa H, Pinto-Correia AL, Medeiros R, Dinis-Ribeiro M. Epstein-Barr virus is associated with gastric carcinoma: the question is what is the significance? *World J Gastroenterol* 2008;14:4347–4351. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18666324>.
186. Jacome AA, Lima EM, Kazzi AI, et al. Epstein-Barr virus-positive gastric cancer: a distinct molecular subtype of the disease? *Rev Soc Bras Med Trop* 2016;49:150–157. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27192582>.
187. Sohn BH, Hwang JE, Jang HJ, et al. Clinical significance of four molecular subtypes of gastric cancer identified by the Cancer Genome Atlas project. *Clin Cancer Res* 2017;23:4441–4449. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28747339>.
188. Hewitt LC, Inam IZ, Saito Y, et al. Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: a large multi-centre study. *Eur J Cancer* 2018;94:104–114. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29550565>.
189. Camargo MC, Murphy G, Koriyama C, et al. Determinants of Epstein-Barr virus-positive gastric cancer: an international pooled analysis. *Br J Cancer* 2011;105:38–43. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21654677>.
190. van Beek J, zur Hausen A, Klein Kranenborg E, et al. EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. *J Clin Oncol* 2004;22:664–670. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/14966089>.
191. Cho J, Kang MS, Kim KM. Epstein-Barr virus-associated gastric carcinoma and specific features of the accompanying immune response. *J Gastric Cancer* 2016;16:1–7. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27104020>.
192. Ma C, Patel K, Singh AD, et al. Programmed death-ligand 1 expression is common in gastric cancer associated with Epstein-Barr virus or microsatellite instability. *Am J Surg Pathol* 2016;40:1496–1506. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27465786>.
193. Derk S, Liao X, Chiaravalli AM, et al. Abundant PD-L1 expression in Epstein-Barr virus-infected gastric cancers. *Oncotarget* 2016;7:32925–32932. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27147580>.
194. Cho J, Lee J, Bang H, et al. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. *Oncotarget* 2017;8:13320–13328. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28076847>.
195. Ajani JA, Mayer RJ, Ota DM, et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. *J Natl Cancer Inst* 1993;85:1839–1844. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8230264>.
196. Leichman L, Silberman H, Leichman CG, et al. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. *J Clin Oncol* 1992;10:1933–1942. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1453207>.
197. Hermanek P, Wittekind C. Residual tumor (R) classification and prognosis. *Semin Surg Oncol* 1994;10:12–20. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8115781>.



## NCCN Guidelines Version 3.2025

### Gastric Cancer

198. Ito H, Clancy TE, Osteen RT, et al. Adenocarcinoma of the gastric cardia: what is the optimal surgical approach? *J Am Coll Surg* 2004;199:880–886. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15555971>.
199. Bozzetti F, Marubini E, Bonfanti G, et al. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. *Italian Gastrointestinal Tumor Study Group*. *Ann Surg* 1999;230:170–178. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10450730>.
200. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. *Br J Surg* 2006;93:559–563. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16607678>.
201. Marano L, Rondelli F, Bartoli A, et al. Oncologic effectiveness and safety of splenectomy in total gastrectomy for proximal gastric carcinoma: meta-analysis of randomized controlled trials. *Anticancer Res* 2018;38:3609–3617. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29848717>.
202. Lim S, Muhs BE, Marcus SG, et al. Results following resection for stage IV gastric cancer; are better outcomes observed in selected patient subgroups? *J Surg Oncol* 2007;95:118–122. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17262741>.
203. Jeurnink SM, Steyerberg EW, van Hooft JE, et al. Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial. *Gastrointest Endosc* 2010;71:490–499. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20003966>.
204. Halpern AL, McCarter MD. Palliative Management of Gastric and Esophageal Cancer. *Surg Clin North Am* 2019;99:555–569. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31047042>.
205. Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. *Ann Surg Oncol* 2007;14:317–328. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17094022>.
206. Seevaratnam R, Bocicariu A, Cardoso R, et al. How many lymph nodes should be assessed in patients with gastric cancer? A systematic review. *Gastric Cancer* 2012;15 Suppl 1:S70–88. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22895615>.
207. Hartgrink HH, van de Velde CJH, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. *J Clin Oncol* 2004;22:2069–2077. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15082726>.
208. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. *Surgical Co-operative Group*. *Br J Cancer* 1999;79:1522–1530. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10188901>.
209. Songun I, Putter H, Kranenborg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. *Lancet Oncol* 2010;11:439–449. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20409751>.
210. Enzinger PC, Benedetti JK, Meyerhardt JA, et al. Impact of hospital volume on recurrence and survival after surgery for gastric cancer. *Ann Surg* 2007;245:426–434. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17435550>.
211. Degiuli M, Sasako M, Ponti A. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. *Br J Surg* 2010;97:643–649. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20186890>.
212. Degiuli M, Sasako M, Ponti A, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. *Br J Surg* 2014;101:23–31. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24375296>.



## NCCN Guidelines Version 3.2025

### Gastric Cancer

213. Mogal H, Fields R, Maithel SK, Votanopoulos K. In patients with localized and resectable gastric cancer, what is the optimal extent of lymph node dissection-D1 Versus D2 Versus D3? Ann Surg Oncol 2019;26:2912–2932. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31076930>.
214. Degiuli M, Sasako M, Calgaro M, et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol 2004;30:303–308. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15028313>.
215. Degiuli M, Sasako M, Ponti A, Calvo F. Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer 2004;90:1727–1732. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15150592>.
216. Seevaratnam R, Bocicariu A, Cardoso R, et al. A meta-analysis of D1 versus D2 lymph node dissection. Gastric Cancer 2012;15 Suppl 1:S60–69. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22138927>.
217. Jiang L, Yang KH, Chen Y, et al. Systematic review and meta-analysis of the effectiveness and safety of extended lymphadenectomy in patients with resectable gastric cancer. Br J Surg 2014;101:595–604. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24668465>.
218. El-Sedfy A, Dixon M, Seevaratnam R, et al. Personalized surgery for gastric adenocarcinoma: a meta-analysis of D1 versus D2 lymphadenectomy. Ann Surg Oncol 2015;22:1820–1827. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25348779>.
219. Csendes A, Burdiles P, Rojas J, et al. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery 2002;131:401–407. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11935130>.
220. Reyes CD, Weber KJ, Gagner M, Divino CM. Laparoscopic vs open gastrectomy. A retrospective review. Surg Endosc 2001;15:928–931. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11605108>.
221. Jiang L, Yang KH, Guan QL, et al. Laparoscopy-assisted gastrectomy versus open gastrectomy for resectable gastric cancer: an update meta-analysis based on randomized controlled trials. Surg Endosc 2013;27:2466–2480. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23361259>.
222. Wang W, Li Z, Tang J, et al. Laparoscopic versus open total gastrectomy with D2 dissection for gastric cancer: a meta-analysis. J Cancer Res Clin Oncol 2013;139:1721–1734. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23990014>.
223. Lin JX, Lin JL, Zheng CH, et al. Short- and long-term outcomes of laparoscopy-assisted versus open total gastrectomy for gastric cancer: a propensity score-matched analysis. Oncotarget 2017;8:80029–80038. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29108385>.
224. Wei Y, Yu D, Li Y, et al. Laparoscopic versus open gastrectomy for advanced gastric cancer: a meta-analysis based on high-quality retrospective studies and clinical randomized trials. Clin Res Hepatol Gastroenterol 2018;42:577–590. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30146236>.
225. Yu J, Huang C, Sun Y, et al. Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial. JAMA 2019;321:1983–1992. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31135850>.
226. Liu F, Huang C, Xu Z, et al. Morbidity and mortality of laparoscopic vs open total gastrectomy for clinical stage I gastric cancer: The CLASS02 multicenter randomized clinical trial. JAMA Oncol 2020;6:1590–1597. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32815991>.
227. Kim HH, Han SU, Kim MC, et al. Effect of laparoscopic distal gastrectomy vs open distal gastrectomy on long-term survival among



# NCCN Guidelines Version 3.2025

## Gastric Cancer

patients with stage I gastric cancer: the KLAFF-01 randomized clinical trial. *JAMA Oncol* 2019;5:506–513. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/30730546>.

228. Hyung WJ, Yang HK, Park YK, et al. Long-term outcomes of laparoscopic distal gastrectomy for locally advanced gastric cancer: The KLAFF-02-RCT randomized clinical trial. *J Clin Oncol* 2020;38:3304–3313. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32816629>.

229. Huscher CGS, Mingoli A, Sgarzini G, et al. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial. *Ann Surg* 2005;241:232–237. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15650632>.

230. Smalley SR, Gunderson L, Tepper J, et al. Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. *Int J Radiat Oncol Biol Phys* 2002;52:283–293. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11872272>.

231. Hazard L, O'Connor J, Scaife C. Role of radiation therapy in gastric adenocarcinoma. *World J Gastroenterol* 2006;12:1511–1520. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16570342>.

232. Schein PS. A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. *Cancer* 1982;49:1771–1777. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/6176313>.

233. Hallissey MT, Dunn JA, Ward LC, Allum WH. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. *Lancet* 1994;343:1309–1312. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7910321>.

234. Valentini V, Cellini F, Minsky BD, et al. Survival after radiotherapy in gastric cancer: systematic review and meta-analysis. *Radiother Oncol* 2009;92:176–183. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19586672>.

235. Leong T, Smithers BM, Michael M, et al. Preoperative chemoradiotherapy for resectable gastric cancer. *N Engl J Med* 2024;391:1810–1821. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/39282905>.

236. Moninger S, Ajani JA, Badgwell BD, et al. IMRT reduces acute toxicity in patients treated with preoperative chemoradiation for gastric cancer. *Adv Radiat Oncol* 2020;5:369–376. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32529130>.

237. Trip AK, Nijkamp J, van Tinteren H, et al. IMRT limits nephrotoxicity after chemoradiotherapy for gastric cancer. *Radiother Oncol* 2014;112:289–294. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25241995>.

238. Ringash J, Perkins G, Brierley J, et al. IMRT for adjuvant radiation in gastric cancer: a preferred plan? *Int J Radiat Oncol Biol Phys* 2005;63:732–738. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15978742>.

239. Ren F, Li S, Zhang Y, et al. Efficacy and safety of intensity-modulated radiation therapy versus three-dimensional conformal radiation treatment for patients with gastric cancer: a systematic review and meta-analysis. *Radiat Oncol* 2019;14:84. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31118042>.

240. Al-Batran SE, Lorenzen S. Management of locally advanced gastroesophageal cancer: still a multidisciplinary global challenge? *Hematol Oncol Clin North Am* 2017;31:441–452. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28501086>.

241. Cai Z, Yin Y, Shen C, et al. Comparative effectiveness of preoperative, postoperative and perioperative treatments for resectable gastric cancer: a network meta-analysis of the literature from the past 20 years. *Surg Oncol* 2018;27:563–574. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30217320>.

242. Coccolini F, Nardi M, Montori G, et al. Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of



## NCCN Guidelines Version 3.2025

# Gastric Cancer

randomized trials. *Int J Surg* 2018;51:120–127. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29413875>.

243. Cats A, Jansen EPM, van Grieken NCT, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. *Lancet Oncol* 2018;19:616–628. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29650363>.

244. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 2006;355:11–20. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16822992>.

245. Dikken JL, Jansen EP, Cats A, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. *J Clin Oncol* 2010;28:2430–2436. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20368551>.

246. Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. *Lancet Oncol* 2016;17:1697–1708. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27776843>.

247. de Steur WO, van Amelsvoort RM, Hartgrink HH, et al. Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial. *Ann Oncol* 2021;32:360–367. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33227408>.

248. Slagter AE, Jansen EPM, van Laarhoven HWM, et al. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. *BMC*

Cancer 2018;18:877. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/30200910>.

249. Kang YK, Terashima M, Kim YW, et al. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. *Lancet Gastroenterol Hepatol* 2024;9:705–717. Available at:

250. Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577. *Journal of Clinical Oncology* 2025;43:4000–4000. Available at: [https://doi.org/10.1200/JCO.2025.43.16\\_suppl.4000](https://doi.org/10.1200/JCO.2025.43.16_suppl.4000).

251. Lorenzen S, Gotze TO, Thuss-Patience P, et al. Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: Interim results from the randomized, multicenter, phase II/III DANTE/IKF-s633 Trial. *J Clin Oncol* 2024;42:410–420. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37963317>.

252. Shitara K, Rha SY, Wyrwicz LS, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. *Lancet Oncol* 2024;25:212–224. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/38134948>.

253. Andre T, Tougeron D, Piessen G, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: The GERCOR NEONIPIGA phase II study. *J Clin Oncol* 2023;41:255–265. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35969830>.

254. Ludford K, Ho WJ, Thomas JV, et al. Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid



# NCCN Guidelines Version 3.2025

## Gastric Cancer

tumors. *J Clin Oncol* 2023;41:2181–2190. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36623241>.

255. Liu L, Woo Y, D'Apuzzo M, et al. Immunotherapy-based neoadjuvant treatment of advanced microsatellite instability-high gastric cancer: A case series. *J Natl Compr Canc Netw* 2022;20:857–865. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35948034>.

256. Kelly RJ, Lee J, Bang YJ, et al. Safety and efficacy of durvalumab and tremelimumab alone or in combination in patients with advanced gastric and gastroesophageal junction adenocarcinoma. *Clin Cancer Res* 2020;26:846–854. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31676670>.

257. Pietrantonio F, Raimondi A, Lonardi S, et al. INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC). *Journal of Clinical Oncology* 2023;41:358–358. Available at: [https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.4\\_suppl.358](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.4_suppl.358).

258. Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. *J Clin Oncol* 2012;30:268–273. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22184384>.

259. Park SH, Lim DH, Sohn TS, et al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial(). *Ann Oncol* 2021;32:368–374. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33278599>.

260. Brandl A, van Sandick JW. Treatment of gastric cancer peritoneal metastases: role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Br J Surg* 2024;111. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/38953711>.

261. Manzanedo I, Pereira F, Perez-Viejo E, Serrano A. Gastric cancer with peritoneal metastases: Current status and prospects for treatment. *Cancers (Basel)* 2023;15:1777. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36980663>.

262. Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): A propensity score analysis. *J Clin Oncol* 2019;37:2028–2040. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31084544>.

263. Badgwell B, Ikoma N, Murphy MB, et al. A phase II trial of cytoreduction, gastrectomy, and hyperthermic intraperitoneal perfusion with chemotherapy for patients with gastric cancer and carcinomatosis or positive cytology. *Ann Surg Oncol* 2021;28:258–264. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32556731>.

264. Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. *Ann Surg Oncol* 2011;18:1575–1581. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21431408>.

265. Rau B, Lang H, Koenigsrainer A, et al. Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: The phase III Gastripec-I trial. *J Clin Oncol* 2024;42:146–156. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37906724>.

266. Sarvestani AL, Gregory SN, Akmal SR, et al. Gastrectomy + cytoreductive surgery + hipec for gastric cancer with peritoneal dissemination (PERISCOPE II). *Ann Surg Oncol* 2024;31:28–30. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37947975>.

267. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. *Evaluation of Chemotherapeutic Agents*. New York Columbia University Press; 1949:199–205.



## NCCN Guidelines Version 3.2025

# Gastric Cancer

268. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol* 1982;5:649–655. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7165009>.
269. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. *J Clin Oncol* 1984;2:187–193. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/6699671>.
270. Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. *Ann Oncol* 1997;8:163–168. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9093725>.
271. Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). *Eur J Cancer* 2011;47:2306–2314. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21742485>.
272. Kang JH, Lee SI, Lim do H, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. *J Clin Oncol* 2012;30:1513–1518. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22412140>.
273. Ford ER, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. *Lancet Oncol* 2014;15:78–86. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24332238>.
274. Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. *Lancet Oncol* 2014;15:305–314. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24556041>.
275. Khushalani NI, Leichman CG, Proulx G, et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. *J Clin Oncol* 2002;20:2844–2850. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12065561>.
276. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. *J Clin Oncol* 2007;25:1160–1168. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17401004>.
277. Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. *J Clin Oncol* 2006;24:3953–3958. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16921048>.
278. Al-Batran SE, Pauligk C, Homann N, et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). *Eur J Cancer* 2013;49:835–842. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23063354>.
279. Al-Batran S-E, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. *J Clin Oncol* 2008;26:1435–1442. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18349393>.
280. Enzinger PC, Burtness BA, Niedzwiecki D, et al. CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. *J Clin Oncol* 2016;34:2736–2742. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27382098>.
281. Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. *Eur J Cancer* 2012;48:518–526. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22243774>.



## NCCN Guidelines Version 3.2025

# Gastric Cancer

282. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009;20:1667–1673. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19549707>.
283. Bouche O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803. J Clin Oncol 2004;22:4319–4328. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15514373>.
284. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666–673. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19153121>.
285. Louvet C, Andre T, Tigaud JM, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002;20:4543–4548. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12454110>.
286. Al-Batran S-E, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004;22:658–663. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14966088>.
287. Park YH, Lee JL, Ryoo BY, et al. Capecitabine in combination with oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemother Pharmacol 2008;61:623–629. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17522863>.
288. Luo HY, Xu RH, Wang F, et al. Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer. Chemotherapy 2010;56:94–100. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20357440>.
289. Okines AFC, Norman AR, McCloud P, et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009;20:1529–1534. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19474114>.
290. Wang G, Yang B, Fu Z, et al. Efficacy and safety of oxaliplatin-based regimen versus cisplatin-based regimen in the treatment of gastric cancer: a meta-analysis of randomized controlled trials. Int J Clin Oncol 2019;24:614–623. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30919257>.
291. Hall PS, Swinson D, Cairns DA, et al. Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer: The go2 phase 3 randomized clinical trial. JAMA Oncol 2021;7:869–877. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33983395>.
292. Enzinger PC, Kulke MH, Clark JW, et al. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci 2005;50:2218–2223. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16416165>.
293. Ajani JA, Baker J, Pisters PWT, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 2002;94:641–646. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11857295>.
294. Moehler M, Haas U, Siebler J, et al. Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer. Anticancer Drugs 2003;14:645–650. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14501387>.



## NCCN Guidelines Version 3.2025

# Gastric Cancer

295. Pozzo C, Barone C, Szanto J, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. *Ann Oncol* 2004;15:1773–1781. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15550582>.
296. Moehler M, Eimermacher A, Siebler J, et al. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. *Br J Cancer* 2005;92:2122–2128. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15942629>.
297. Beretta E, Di Bartolomeo M, Buzzoni R, et al. Irinotecan, fluorouracil and folinic acid (FOLFIRI) as effective treatment combination for patients with advanced gastric cancer in poor clinical condition. *Tumori* 2006;92:379–383. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17168428>.
298. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. *Ann Oncol* 2008;19:1450–1457. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18558665>.
299. Brell JM, Krishnamurthi SS, Javle M, et al. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. *Cancer Chemother Pharmacol* 2009;63:851–857. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18670776>.
300. Enzinger PC, Ryan DP, Clark JW, et al. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. *Ann Oncol* 2009;20:475–480. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19139178>.
301. Lustberg MB, Bekaii-Saab T, Young D, et al. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. *J Thorac Oncol* 2010;5:713–718. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20354452>.
302. Moehler M, Kanzler S, Geissler M, et al. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. *Ann Oncol* 2010;21:71–77. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19605504>.
303. Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French Intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. *J Clin Oncol* 2014;32:3520–3526. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25287828>.
304. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. *J Clin Oncol* 2006;24:4991–4997. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17075117>.
305. Roth AD, Fazio N, Stupp R, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. *J Clin Oncol* 2007;25:3217–3223. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17664469>.
306. Al-Batran SE, Hartmann JT, Hofheinz R, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. *Ann Oncol* 2008;19:1882–1887. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18669868>.



## NCCN Guidelines Version 3.2025

### Gastric Cancer

307. Elsaid AA, Elkerm Y. Final results of a randomized phase III trial of docetaxel, carboplatin and 5FU versus epirubicin, cisplatin and 5FU for locally advanced gastric cancer. *J Clin Oncol* 2005;23:4014. Available at: [http://ascopubs.org/doi/abs/10.1200/jco.2005.23.16\\_suppl.4014](http://ascopubs.org/doi/abs/10.1200/jco.2005.23.16_suppl.4014).
308. Inal A, Kaplan MA, Kucukoner M, Isikdogan A. Docetaxel and cisplatin plus fluorouracil compared with modified docetaxel, cisplatin, and 5-fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution. *Neoplasma* 2012;59:233–236. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22248282>.
309. Di Lauro L, Vici P, Belli F, et al. Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer. *Gastric Cancer* 2014;17:718–724. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24318671>.
310. Van Cutsem E, Boni C, Tabernero J, et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. *Ann Oncol* 2015;26:149–156. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25416687>.
311. Shah MA, Janjigian YY, Stoller R, et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium. *J Clin Oncol* 2015;33:3874–3879. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26438119>.
312. Ilson DH, Forastiere A, Arquette M, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. *Cancer J* 2000;6:316–323. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11079171>.
313. Petrasch S, Welt A, Reinacher A, et al. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. *Br J Cancer* 1998;78:511–514. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9716036>.
314. Gadgeel SM, Shields AF, Heilbrun LK, et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. *Am J Clin Oncol* 2003;26:37–41. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12576922>.
315. Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. *J Clin Oncol* 2005;23:5660–5667. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16110025>.
316. Kim JY, Do YR, Park KU, et al. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. *Cancer Chemother Pharmacol* 2010;66:31–36. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19763571>.
317. Blum Murphy MA, Qiao W, Mewada N, et al. A phase I/II study of docetaxel, oxaliplatin, and fluorouracil (D-FOX) chemotherapy in patients with untreated locally unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction. *Am J Clin Oncol* 2018;41:321–325. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26908161>.
318. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). *J Clin Oncol* 2003;21:54–59. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12506170>.
319. Hong YS, Song SY, Lee SI, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. *Ann Oncol* 2004;15:1344–1347. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15319239>.
320. Albertsson M, Johansson B, Friesland S, et al. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or



## NCCN Guidelines Version 3.2025

# Gastric Cancer

recurrent esophageal cancer. *Med Oncol* 2007;24:407–412. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17917090>.

321. Ajani JA, Ilson DH, Daugherty K, et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. *J Natl Cancer Inst* 1994;86:1086–1091. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7912736>.

322. Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. *Ann Oncol* 2007;18:898–902. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17351256>.

323. Cascinu S, Bodoky G, Muro K, et al. Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. *Oncologist* 2021;26:e414–e424. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33274542>.

324. Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. *J Clin Oncol* 2013;31:4438–4444. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24190112>.

325. Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. *J Clin Oncol* 2003;21:807–814. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12610178>.

326. Sym SJ, Hong J, Park J, et al. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. *Cancer Chemother Pharmacol* 2013;71:481–488. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23192279>.

327. Maugeri-Sacca M, Pizzuti L, Sergi D, et al. FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. *J Exp Clin Cancer Res* 2013;32:67. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24330513>.

328. Sym SJ, Ryu MH, Lee JL, et al. Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane. *Am J Clin Oncol* 2008;31:151–156. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18391599>.

329. Assersohn L, Brown G, Cunningham D, et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. *Ann Oncol* 2004;15:64–69. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/14679122>.

330. Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2018;19:1437–1448. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30355453>.

331. Shitara K, Doi T, Hosaka H, et al. Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): subgroup analysis from TAGS. *J Clin Oncol* 2019;37:4037. Available at: [https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15\\_suppl.4037](https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.4037).

332. Ilson DH, Tabernero J, Prokharau A, et al. Efficacy and safety of trifluridine/tipiracil treatment in patients with metastatic gastric cancer who had undergone gastrectomy: subgroup analyses of a randomized clinical trial. *JAMA Oncol* 2020;61:e193531. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31600365>.

333. Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre,



## NCCN Guidelines Version 3.2025

# Gastric Cancer

placebo-controlled, phase 3 trial. Lancet 2014;383:31–39. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24094768>.

334. Ilson DH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park) 2004;18:22–25. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15685830>.

335. Sakai D, Boku N, Kodera Y, et al. An intergroup phase III trial of ramucirumab plus irinotecan in third or more line beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial). J Clin Oncol 2018;36:TPS4138. Available at:

[https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15\\_suppl.TPS4138](https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.TPS4138).

336. Klempner SJ, Maron SB, Chase L, et al. Initial report of second-line FOLFIRI in combination with ramucirumab in advanced gastroesophageal adenocarcinomas: a multi-institutional retrospective analysis. Oncologist 2019;24:475–482. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/30470690>.

337. Burtness B, Gibson M, Egleston B, et al. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Ann Oncol 2009;20:1242–1248. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19429872>.

338. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509–2520. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26028255>.

339. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1–10. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/31682550>.

340. Shitara K, Ajani JA, Moehler M, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 2022;603:942–948. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35322232>.

341. Berton D, Banerjee SN, Curigliano G, et al. Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability-high tumors: A combined analysis of two cohorts in the GARNET study. J Clin Oncol 2021;39:2564. Available at: [https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15\\_suppl.2564](https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.2564).

342. Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21:1353–1365. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32919526>.

343. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271–282. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31838007>.

344. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731–739. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/29466156>.

345. Solomon BJ, Drilon A, Lin JJ, et al. 1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial. Annals of Oncology 2023;34:S787–S788. Available at: <https://doi.org/10.1016/j.annonc.2023.09.2405>.

346. Salama AKS, Li S, Macrae ER, et al. Dabrafenib and trametinib in patients with tumors with BRAF(V600E) mutations: Results of the NCI-MATCH trial subprotocol H. J Clin Oncol 2020;38:3895–3904. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32758030>.

347. Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selretinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol 2022;23:1261–1273. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36108661>.



## NCCN Guidelines Version 3.2025

### Gastric Cancer

348. Rivera F, Romero C, Jimenez-Fonseca P, et al. Phase II study to evaluate the efficacy of trastuzumab in combination with capecitabine and oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. *Cancer Chemother Pharmacol* 2019;83:1175–1181. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30927036>.
349. Soularue E, Cohen R, Tournigand C, et al. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. *Bull Cancer* 2015;102:324–331. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25744576>.
350. Chung HC, Bang YJ, C SF, et al. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. *Future Oncol* 2021;17:491–501. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33167735>.
351. Makiyama A, Sukawa Y, Kashiwada T, et al. Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT Study). *J Clin Oncol* 2020;38:1919–1927. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32208960>.
352. Janjigian YY, Kawazoe A, Yanez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. *Nature* 2021;600:727–730. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34912120>.
353. Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. *Lancet* 2023;402:2197–2208. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37871604>.
354. Rha SY, Oh DY, Yanez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. *Lancet Oncol* 2023;24:1181–1195. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37875143>.
355. Maio M, Ascierto PA, Manzyuk L, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. *Ann Oncol* 2022;33:929–938. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35680043>.
356. Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial. *JAMA Oncol* 2018;4:e180013. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29543932>.
357. Shitara K, Ozguroglu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. *Lancet* 2018;392:123–133. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29880231>.
358. Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: The KEYNOTE-062 phase 3 randomized clinical trial. *JAMA Oncol* 2020;6:1571–1580. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32880601>.
359. Fuchs CS, Ozguroglu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. *Gastric Cancer* 2022;25:197–206. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34468869>.
360. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. *Lancet* 2021;398:27–40. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34102137>.



## NCCN Guidelines Version 3.2025

### Gastric Cancer

361. Janjigian YY, Ajani JA, Moehler M, et al. First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial. *J Clin Oncol* 2024;42:2012–2020. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/38382001>.
362. Janjigian YY, Moehler MH, Ajani JA, et al. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649. *Journal of Clinical Oncology* 2025;43:398–398. Available at: [https://doi.org/10.1200/JCO.2025.43.4\\_suppl.398](https://doi.org/10.1200/JCO.2025.43.4_suppl.398).
363. Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *Lancet Oncol* 2014;15:1224–1235. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25240821>.
364. Tabernero J, Ohtsu A, Muro K, et al. Exposure-response analyses of ramucirumab from two randomized, phase III trials of second-line treatment for advanced gastric or gastroesophageal junction cancer. *Mol Cancer Ther* 2017;16:2215–2222. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28716815>.
365. Fuchs CS, Shitara K, Di Bartolomeo M, et al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncol* 2019;20:420–435. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30718072>.
366. Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. *N Engl J Med* 2020;382:2419–2430. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32469182>.
367. Van Cutsem E, di Bartolomeo M, Smyth E, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. *Lancet Oncol* 2023;24:744–756. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37329891>.
368. Gatalica Z, Xiu J, Swensen J, Vranic S. Molecular characterization of cancers with NTRK gene fusions. *Mod Pathol* 2019;32:147–153. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30171197>.
369. Okamura R, Boichard A, Kato S, et al. Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: Implications for NTRK-targeted therapeutics. *JCO Precis Oncol* 2018;2018. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30637364>.
370. Arnold A, Daum S, von Winterfeld M, et al. Analysis of NTRK expression in gastric and esophageal adenocarcinoma (AGE) with pan-TRK immunohistochemistry. *Pathol Res Pract* 2019;215:152662. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31575452>.
371. Shinozaki-Ushiku A, Ishikawa S, Komura D, et al. The first case of gastric carcinoma with NTRK rearrangement: identification of a novel ATP1B-NTRK1 fusion. *Gastric Cancer* 2020;23:944–947. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32189226>.
372. Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. *Lancet Oncol* 2020;21:531–540. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32105622>.
373. Oaknin A, Tinker AV, Gilbert L, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. *JAMA Oncology* 2020;6:1766–1772. Available at: <https://doi.org/10.1001/jamaoncol.2020.4515>.
374. Andre T, Berton D, Curigliano G, et al. Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: A nonrandomized controlled trial. *JAMA Netw Open*



# NCCN Guidelines Version 3.2025

## Gastric Cancer

2023;6:e2341165. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/37917058>.

375. U.S. Food and Drug Administration. Current and resolved drug shortages and discontinuations reported to FDA. 2018. Available at: <https://www.accessdata.fda.gov/scripts/drugshortages/>. Accessed February 21, 2020.

376. QUASAR Collaborative Group. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 2000;355:1588–1596. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10821362>.

377. Reynolds J, Chamberland-Tremblay A, Herrington JD, et al. High-versus low-dose leucovorin in the modified FOLFOX6 regimen for first-line treatment of metastatic colorectal cancer. J Oncol Pharm Pract 2017;23:173–178. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26786027>.

378. Clarke S, Goldstein D, Mitchell P, et al. Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy. Clin Colorectal Cancer 2007;6:578–582. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17681104>.

379. Roberts G, Benusiglio PR, Bisseling T, et al. International Delphi consensus guidelines for follow-up after prophylactic total gastrectomy: the Life after Prophylactic Total Gastrectomy (LAP-TG) study. Gastric Cancer 2022;25:1094–1104. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35831514>.

380. Baiocchi GL, D'Ugo D, Coit D, et al. Follow-up after gastrectomy for cancer: the Charter Scagliero Consensus Conference. Gastric Cancer 2016;19:15–20. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26140915>.

381. Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update:

Cosponsored by American Association Of Clinical Endocrinologists/American College Of Endocrinology, The Obesity Society, American Society For Metabolic & Bariatric Surgery, Obesity Medicine Association, And American Society Of Anesthesiologists - executive summary. Endocr Pract 2019;25:1346–1359. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31682518>.

382. Nilsson M. Postgastrectomy follow-up in the West: evidence base, guidelines, and daily practice. Gastric Cancer 2017;20:135–140. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27718134>.

383. Suzuki Y, Ishibashi Y, Omura N, et al. Alendronate improves vitamin D-resistant osteopenia triggered by gastrectomy in patients with gastric cancer followed long term. J Gastrointest Surg 2005;9:955–960. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16137591>.

384. Lim JS, Lee JI. Prevalence, pathophysiology, screening and management of osteoporosis in gastric cancer patients. J Gastric Cancer 2011;11:7–15. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22076196>.

385. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 2014;25:2359–2381. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25182228>.

386. Rausei S, Mangano A, Galli F, et al. Quality of life after gastrectomy for cancer evaluated via the EORTC QLQ-C30 and QLQ-STO22 questionnaires: surgical considerations from the analysis of 103 patients. Int J Surg 2013;11 Suppl 1:S104–109. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24380539>.

387. Svedlund J, Sullivan M, Liedman B, Lundell L. Long term consequences of gastrectomy for patient's quality of life: the impact of reconstructive techniques. Am J Gastroenterol 1999;94:438–445. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/10022643>.

388. Bae JM, Kim S, Kim YW, et al. Health-related quality of life among disease-free stomach cancer survivors in Korea. Qual Life Res



## NCCN Guidelines Version 3.2025

### Gastric Cancer

2006;15:1587–1596. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/17036253>.

389. Yu W, Park KB, Chung HY, et al. Chronological changes of quality of life in long-term survivors after gastrectomy for gastric cancer. *Cancer Res Treat* 2016;48:1030–1036. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/27004956>.

390. Rosania R, Chiapponi C, Malfertheiner P, Venerito M. Nutrition in patients with gastric cancer: an update. *Gastrointest Tumors* 2016;2:178–187. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27403412>.

391. Lim CH, Kim SW, Kim WC, et al. Anemia after gastrectomy for early gastric cancer: long-term follow-up observational study. *World J Gastroenterol* 2012;18:6114–6119. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/23155340>.

392. Hu Y, Kim HI, Hyung WJ, et al. Vitamin B(12) deficiency after gastrectomy for gastric cancer: an analysis of clinical patterns and risk factors. *Ann Surg* 2013;258:970–975. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/24096753>.

393. Muszynski T, Polak K, Fratczak A, et al. Vitamin d—the nutritional status of post-gastrectomy gastric cancer patients—systematic review. *Nutrients* 2022;14. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/35807892>.

394. Blonk L, Gooszen JAH, Fakkert RA, et al. Micronutrient deficiencies and anemia in the follow-up after gastroesophageal cancer surgery. *Dis Esophagus* 2024;37. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/38912788>.

395. Kim HI, Hyung WJ, Song KJ, et al. Oral vitamin B12 replacement: an effective treatment for vitamin B12 deficiency after total gastrectomy in gastric cancer patients. *Ann Surg Oncol* 2011;18:3711–3717. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/21556950>.

396. Jeong O, Park YK. Effect of intravenous iron supplementation for acute postoperative anemia in patients undergoing gastrectomy for gastric

carcinoma: a pilot study. *Ann Surg Oncol* 2014;21:547–552. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/23996517>.

397. Mine S, Sano T, Tsutsumi K, et al. Large-scale investigation into dumping syndrome after gastrectomy for gastric cancer. *J Am Coll Surg* 2010;211:628–636. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/20829078>.

398. Maksimaityte V, Bausys A, Kryzauskas M, et al. Gastrectomy impact on the gut microbiome in patients with gastric cancer: A comprehensive review. *World J Gastrointest Surg* 2021;13:678–688. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/34354801>.

399. Sharabi E, Rezaie A. Small Intestinal Bacterial Overgrowth. *Current Infectious Disease Reports* 2024;26:227–233. Available at:

<https://doi.org/10.1007/s11908-024-00847-7>.

400. Bushyhead D, Quigley EMM. Small Intestinal Bacterial Overgrowth—Pathophysiology and Its Implications for Definition and Management. *Gastroenterology* 2022;163:593–607. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/35398346>.

401. Wang J, Zhang L, Hou X. Efficacy of rifaximin in treating with small intestine bacterial overgrowth: a systematic review and meta-analysis. *Expert Rev Gastroenterol Hepatol* 2021;15:1385–1399. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/34767484>.

402. Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. *Aliment Pharmacol Ther* 2017;45:604–616. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/28078798>.

403. Imbesi JJ, Kurtz RC. A multidisciplinary approach to gastrointestinal bleeding in cancer patients. *J Support Oncol* 2005;3:101–110. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15796441>.

404. Kim YI, Choi IJ. Endoscopic management of tumor bleeding from inoperable gastric cancer. *Clin Endosc* 2015;48:121–127. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25844339>.



## NCCN Guidelines Version 3.2025

### Gastric Cancer

405. Sheibani S, Kim JJ, Chen B, et al. Natural history of acute upper GI bleeding due to tumours: short-term success and long-term recurrence with or without endoscopic therapy. *Aliment Pharmacol Ther* 2013;38:144–150. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23710797>.
406. Poulsides GA, Kim CJ, Orlando R, 3rd, et al. Angiographic embolization for gastroduodenal hemorrhage: safety, efficacy, and predictors of outcome. *Arch Surg* 2008;143:457–461. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18490553>.
407. Kim MM, Rana V, Janjan NA, et al. Clinical benefit of palliative radiation therapy in advanced gastric cancer. *Acta Oncol* 2008;47:421–427. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17899453>.
408. Kondoh C, Shitara K, Nomura M, et al. Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study. *BMC Palliat Care* 2015;14:37. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26238344>.
409. Jeurink SM, van Eijck CHJ, Steyerberg EW, et al. Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review. *BMC Gastroenterol* 2007;7:18–27. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17559659>.
410. Holt AP, Patel M, Ahmed MM. Palliation of patients with malignant gastroduodenal obstruction with self-expanding metallic stents: the treatment of choice? *Gastrointest Endosc* 2004;60:1010–1017. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15605026>.
411. Lindsay JO, Andreyev HJN, Vlavianos P, Westaby D. Self-expanding metal stents for the palliation of malignant gastroduodenal obstruction in patients unsuitable for surgical bypass. *Aliment Pharmacol Ther* 2004;19:901–905. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15080851>.
412. Kim TO, Kang DH, Kim GH, et al. Self-expandable metallic stents for palliation of patients with malignant gastric outlet obstruction caused by stomach cancer. *World J Gastroenterol* 2007;13:916–920. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17352023>.
413. Endo S, Takiguchi S, Miyazaki Y, et al. Efficacy of endoscopic gastroduodenal stenting for gastric outlet obstruction due to unresectable advanced gastric cancer: a prospective multicenter study. *J Surg Oncol* 2014;109:208–212. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24464867>.
414. Ly J, O'Grady G, Mittal A, et al. A systematic review of methods to palliate malignant gastric outlet obstruction. *Surg Endosc* 2010;24:290–297. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19551436>.
415. Issaka RB, Shapiro DM, Parikh ND, et al. Palliative venting percutaneous endoscopic gastrostomy tube is safe and effective in patients with malignant obstruction. *Surg Endosc* 2014;28:1668–1673. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24366189>.
416. Wollman B, D'Agostino HB. Percutaneous radiologic and endoscopic gastrostomy: a 3-year institutional analysis of procedure performance. *AJR Am J Roentgenol* 1997;169:1551–1553. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9393163>.
417. Silas AM, Pearce LF, Lestina LS, et al. Percutaneous radiologic gastrostomy versus percutaneous endoscopic gastrostomy: a comparison of indications, complications and outcomes in 370 patients. *Eur J Radiol* 2005;56:84–90. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16168268>.
418. Lee MJ, Saini S, Brink JA, et al. Malignant small bowel obstruction and ascites: not a contraindication to percutaneous gastrostomy. *Clin Radiol* 1991;44:332–334. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1836988>.
419. Ryan JM, Hahn PF, Mueller PR. Performing radiologic gastrostomy or gastrojejunostomy in patients with malignant ascites. *AJR Am J Roentgenol* 1998;171:1003–1006. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9762985>.